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ABSTRACT
Note: Portions of this abstract have been previously published in the journal Blood,
Basiorka et al. Blood. 2016 Oct 13, and has been reproduced in this manuscript with
permission from the publisher.
Myelodysplastic syndromes (MDS) are genetically diverse hematopoietic stem
cell malignancies that share a common phenotype of cytological dysplasia, ineffective
hematopoiesis and aberrant myeloid lineage maturation. Apoptotic cell death
potentiated by inflammatory cytokines has been considered a fundamental feature of
MDS for over two decades. However, this non-inflammatory form of cell death cannot
account for the inflammatory nature of these disorders. We report that a hallmark of
lower-risk (LR) MDS is activation of the NLRP3 inflammasome, which drives clonal
expansion and pyroptosis, a caspase-1-dependent programmed cell death induced by
danger-associated molecular pattern (DAMP) signals. Independent of genotype, MDS
hematopoietic stem and progenitor cells (HSPC) overexpress pyroptosis-related
transcripts, inflammasome proteins and manifest activated NLRP3 inflammasome
complexes that direct caspase-1 activation, IL-1β and IL-18 maturation and pyroptotic
cell death. Using the S100A9 transgenic (S100A9Tg) mouse model that phenocopies
human MDS, we demonstrated that forced expression of S100A9 was sufficient to drive
pyroptosis in vivo, implicating pyroptosis as the principal mechanism of HSPC cell death
in S100A9Tg mice. The lytic cell death releases intraceullar contents that include
alarmins and catalytically active ASC specks, which can propagate bystander

x

inflammation. Notably, MDS mesenchymal stromal cells (MSC) and stromal-derived
linages were found to predominantly undergo pyroptosis, with marked activation of
caspase-1 and NLRP3 inflammasome complexes. These findings may account for the
clusters of both HSPC and stromal cell death previously described in the bone marrows
of patients with MDS.
Mechanistically, pyroptosis is triggered by the alarmin S100A9 that is found in
excess in MDS HSPC and bone marrow (BM) plasma. Further, both somatic gene
mutations and S100A9-induced signaling activate NADPH oxidase (NOX), generating
reactive oxygen species (ROS) that initiate cation influx, cell swelling and β-catenin
activation. Accordingly, ROS and active β-catenin were significantly increased in MDS
BM mononuclear cells (BM-MNC) and S100A9Tg mice compared to normal controls, as
well as in human cell lines harboring gene mutations and in murine models of gene
mutation knock-in or gene loss. ROS and β-catenin nuclear translocation were
significantly reduced by NLRP3 or NOX inhibition, indicating that S100A9 and somatic
gene mutations prime cells to undergo NOX1/4-dependent NLRP3 inflammasome
assembly, pyroptosis and β-catenin activation. Together, these data explain the
concurrent proliferation and inflammatory cell death characteristic of LR-MDS.
Given that loss of a gene-rich area in del(5q) disease results in derepression of
innate immune signaling, we hypothesized that this genetic deficit would trigger
assembly of the NLRP3 inflammasome complex, akin to the pathobiological mechanism
characteristic of non-del(5q) MDS. To this end, we utilized two distinct murine models of
del(5q) disease, namely in the context of Rps14 haploinsufficiency and concurrent loss
of mDia1 and microRNA (miR)-146a. In both models, pyroptosis was not evident in the

xi

HSPC compartment; however, early erythroid progenitors displayed high fractions of
pyroptotic cells. This was associated with significant increases in caspase-1 and NLRP3
inflammasome activation, ROS and nuclear localization of β-catenin, which was
extinguished by inflammasome or NOX complex inhibition. These data suggest that
early activation of the inflammasome drives cell death and prevents terminal maturation
of erythroid precursors, accounting for the progressive anemia characteristic of del(5q)
disease, whereby hematopoietic defects are primarily restricted to the erythroid
compartment. Importantly, these data implicate a similar pathobiological mechanism in
del(5q) MDS as is observed in non-del(5q) patients.
The identification of the NLRP3 inflammasome as a pathobiological driver of the
LR non-del(5q) and del(5q) MDS phenotype allows for novel therapeutic agent
development. Notably, knockdown of NLRP3 or caspase-1, neutralization of S100A9,
and pharmacologic inhibition of NLRP3 or NOX suppresses pyroptosis, ROS generation
and nuclear β-catenin in MDS, and are sufficient to restore effective hematopoiesis. In
del(5q) murine models, inhibition of the NLRP3 inflammasome significantly improved
erythroid colony forming capacity by a mechanism distinct from that of lenalidomide,
highlighting the translational potential for targeting this innate immune complex in this
subset of MDS. Thus, alarmins and founder gene mutations in MDS license a common
redox-sensitive inflammasome circuit, which suggests new avenues for therapeutic
intervention.
Furthermore, aggregated clusters of the NLRP3 adaptor protein ASC [apoptosisassociated speck-like protein containing a caspase activation and recruitment domain
(CARD)] are referred to as ASC specks. During pyroptosis, ASC specks are released

xii

from dying cells and function as DAMP signals that propagate inflammation. In this way,
specks are a surrogate marker for NLRP3 inflammasome activation and pyroptotic cell
death. Given that pyroptosis is the predominant mechanism of cell death in MDS and
ASC specks are readily quantified by flow cytometry, we hypothesized that BM or
peripheral blood (PB) plasma-derived ASC specks may be a biologically rational
biomarker for the diagnosis of MDS.
The percentage of ASC specks were significantly increased in MDS BM plasma
compared to normal, healthy donors, which was validated by confocal microscopy. PB
plasma-derived ASC specks were significantly greater in LR- versus HR-MDS,
consistent with the greater extent of cell death and myeloid-derived suppressor cell
(MDSC) expansion in LR disease. As hyperglycemia induces NLRP3 inflammasome
activation, plasma glucose levels were measured to adjust for this confounding variable.
Subsequently, the percentage of glucose-adjusted, PB plasma-derived ASC specks
was measured in a panel of specimens of varied hematologic malignancies. The
corrected percentage of ASC specks was significantly increased in MDS compared to
normal donors and to each other malignancy investigated, including other myeloid and
lymphoid leukemias, myeloproliferative neoplasms and overlap syndromes, like chronic
myelomonocytic leukemia (CMML). These data indicate that the glucose-adjusted ASC
speck percentage is MDS-specific and may be a valuable diagnostic biomarker. At a
cutoff of 0.039, the biomarker minimizes misclassification error and achieves 95%
sensitivity and 82% specificity in classifying MDS from normal donors, other
hematologic malignancies and T2D. Lastly, the biomarker declined with treatment
response to lenalidomide in LR-MDS patients, but not to erythropoietin stimulating agent

xiii

(ESA) or hypomethylating agent (HMA) therapy. As such, the percentage of ASC
specks represents the first biologically rational, diagnostic biomarker for MDS that can
be implemented with current diagnostic practices to reduce diagnostic error.
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CHAPTER 1
Background

Myelodysplastic Syndromes (MDS)

MDS Overview. Myelodysplastic syndromes (MDS) are hematopoietic stem cell
malignancies characterized by ineffective hematopoiesis with marked genetic
heterogeneity.1-3 These disorders are clonal in nature, with the affected precursor cell
restricted to the erythroid, myeloid and megakaryocytic lineage.2 Resultant peripheral
blood cytopenias demonstrate aberrant myeloid differentiation leading to dysplastic and
ineffective blood production.4,5 Though prevalence is likely under-reported, MDS occur
in approximately 3 or 4 individuals per 105, with a significant over-representation of
males.6-8 No significant differences are observed with respect to race, though individuals
of white decent are more frequently affected.6
Although MDS cases are largely sporadic, rare familial clusters have been
reported. To date, four familial syndromes predisposing to MDS have been described.9
Inherited germline mutations in the RUNX1 or CEBPA genes, as well as partial or
complete loss of chromosome 7 have been implicated in familial predisposition.10-14
Additionally, though incidence is quite rare, childhood cases of MDS are typically
associated

with

congenital

disorders

and

underlying

bone

marrow

failure

syndromes.15,16 Karyotypic abnormalities are found in approximately 55% of primary

1

childhood cases, with monosomy 7 most commonly detected.17
Etiology of MDS. To date, a holistic understanding of MDS etiology remains
problematic. This can be attributed to a number of factors, including the lack of true
MDS cell lines and inadequate animal models, slow growth of primary cells in culture
and conflict over disease classification.4,18,19 Nevertheless, a number of predisposing
factors are recognized. Incidence increases dramatically with age, suggesting that age
may be the greatest risk factor for MDS development.20 Individuals 80 years and older
have a five-fold greater likelihood for development of MDS than individuals ages 60-69,
with a median age of 77 years at diagnosis.6-8 Moreover, whereas 85-90% of cases
arise de novo, 10-15% of MDS cases occur in individuals who have received prior
radiation or chemotherapy.20-22 These secondary or treatment-related cases are
associated with poorer prognosis owing largely to the over-representation of
unfavorable karyotypes.
Additionally, MDS may arise secondary to prolonged environmental or
occupational exposures to organic solvents, including benzene or other petrochemicals
and genotoxic agents such as pesticides, fertilizer and others.20 In a meta-analysis of 10
case-control studies, cigarette smoking was significantly associated with MDS, with an
odds ratio of 1.45, or a 45% increase in risk.23 In a similar meta-analysis, when alcohol
consumption was assessed in 5 case-control studies, the overall association of 1.31
was not significant.23 Furthermore, in a prospective lifestyle study, obese individuals
were shown to have a 2.2-fold greater risk for MDS development, illustrating a positive
correlation between body mass index and MDS.24 These findings suggest that smoking
and obesity, but not alcohol consumption, play a role in MDS pathogenesis.
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Both MDS and AML occur with greater frequency in individuals with a history of
chronic infection and/or autoimmune disease, raising the notion that immune disruption
precedes MDS/AML development.25 As is true of childhood cases, individuals with
congenital diseases or bone marrow failure conditions are also at heightened risk for
MDS development.9,16
Moreover, clonal drifts in hematopoietic stem cell (HSC) lineage distribution,
namely myeloid skewing at the expense of lymphoid HSC, are associated with lymphoid
senescence and enriched myelopoiesis with normal aging.26-28 During aging, stem cell
functionality diminishes with respect to quiescence, self-renewal, differentiation and
immune function, as a result of inflammatory cytokines, oxidative stress, DNA damage
and telomere erosion.27 As MDS are characterized by a defect in the myeloid-HSC
compartment

leading

to

aberrant

myeloid

maturation,

senescence-dependent

accumulation of alternations in hematopoietic stem and progenitor cells (HSPC), as well
as cells of the surrounding microenvironment, may contribute to MDS pathogenesis and
stem cell dysfunction. For instance, telomeres are shorter in MDS compared to normal
donors, resulting in part from the high proliferative fraction of HSPC in MDS.29 Patients
who reported prior exposure to known etiologic environmental factors had significantly
reduced telomeres in myeloid cells than unexposed persons.29
MDS Classification. The vast degree of disease heterogeneity, both clinical and
molecular, has warranted categorization of MDS into distinct, recognizable subtypes.
Prior to the 1970s, what is now known as MDS was regarded as a preleukemic
condition.30 Patients with “preleukemia,” though at increased risk of leukemic
transformation, did not always develop myeloid leukemia, and so the term

3

“myelodysplastic disease” was suggested instead.31 In the early 1970s, the FrenchAmerican-British (FAB) Co-operative Group formed in an attempt to classify the acute
and chronic leukemias. The seven members of the FAB described two “dysmyelopoietic
syndromes,” refractory anemia with excess blasts (RAEB) and chronic myelomonocytic
leukemia (CMML) in their first publication in 1976.32 It became apparent that these
designations did not readily differentiate the dysmyelopoietic syndromes, or
myelodysplastic syndromes, from acute myeloid leukemia (AML), illustrating the need
for a new approach that would provide greater distinction between MDS subtypes.
In 1982, the FAB published a new proposal for MDS classification which was
largely based on morphology and the percentage of blasts within the bone marrow (BM)
and peripheral blood (PB). In total, five morphological subtypes of MDS were
recognized, including refractory anemia (RA), RA with ringed sideroblasts (RARS), RA
with excess blasts (RAEB), RAEB ‘in transformation’ and CMML.33 The addition of
RAEB in transformation prompted adjustment of AML diagnostic criterion from 50%
blasts to at least 30%. Though the FAB acknowledged that these classification criteria
did not precisely stratify MDS, it would serve as the precedent for nearly twenty years.
As understanding of the biological, molecular, immunophenotypical and clinical
features of MDS pathobiology increased, so did the need for a new classification
approach. In 2001, the World Health Organization (WHO) proposed an updated
classification system for myeloid neoplasms, including MDS.34 Definitions of RA and
RARS were refined. A new subtype was added, namely refractory cytopenia with
multilineage dysplasia (RCMD), which when combined with the presence of ringed
sideroblasts would be called RCMD-RS and offered prognostic refinement. RAEB was
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divided into two separate entities, RAEB-1 when bone marrow blast percentage was
between 5-9% and RAEB-2 with blasts between 10-19%. RAEB in transformation was
removed, and the AML diagnostic criterion was again lowered to 20% or more
peripheral

blood

or

bone

marrow

blasts.

CMML

was

reclassified

as

a

myelodysplastic/myeloproliferative disease (MDS/MPN), or a condition with overlapping
features of both hematologic malignancy types. Lastly, the 5q- syndrome was
recognized as the first and only cytogenetically defined MDS subtype, characterized by
an interstitial deletion between q21 and q32 of chromosome 5.34,35
In 2008, the WHO published a revision of its MDS classification system.36 The
previously separated RCMD-RS subtype was now captured under RCMD because of
overlapping outcomes. Perhaps the greatest change was the creation of a new, overarching subtype called refractory cytopenia with unilineage dysplasia (RCUD). This
includes patients with RA, and those with refractory neutropenia (RN) and refractory
thrombocytopenia (RT). Finally, the WHO recently revised this classification early in
2016.37 While focus in the 2016 revision remains on the percentage of blasts and the
extent of dysplasia, changes in subtype nomenclature reflect that identifying the specific
cytopenic lineage is not central to accurate classification.37 Furthermore, cytogenetic
abnormalities deemed MDS-defining remain unchanged from the previous revision.
While identification of the MDS mutanome has expanded dramatically in the last
decade, this updated version does not incorporate mutational information into
classification with the sole exception of SF3B1, perhaps foreshadowing what can be
expected in the next WHO revision.37 A summary of the FAB and WHO classification
systems is outlined in Table 1. As understanding of MDS pathobiology continues to
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expand with novel findings and accumulating molecular insight, our understanding of
these complex disorders will continue to be refined.
MDS Prognostication. Inasmuch as patients exhibit clinical and molecular
heterogeneity, they too exhibit vast prognostic variation. Therefore, it became
imperative to establish a consensus prognostic scoring system that could stratify
patients into distinct risk groups and ultimately guide therapy selection. In 1997, the
International Prognostic Scoring System (IPSS) was established.38 The IPSS is based
on three independent variables that significantly impact disease outcome with respect to
risk of leukemic transformation and survival in patients with de novo MDS, namely
cytogenetic anomalies, BM blast percentage and number of cytopenias.38 Each variable
is given a particular weighted score, whose sum yields a cumulative score
representative of risk. The IPSS stratifies patients into four distinct risk groups: low,
intermediate-1, intermediate-2 and high risk. Patients of low and intermediate-1 risk
collectively represent lower-risk disease, and intermediate-2 and high risk patients
collectively represent higher-risk MDS. Though the IPSS served as the fundamental
scoring system for over two decades, it was not without limitations.
The revised IPSS (IPSS-R), published in 2012, aimed to address the
shortcomings of the initial system while incorporating the potential prognostic impact of
novel clinical and cytogenetic findings.39 Although the core variables remained the
same, refinements were made. Less common cytogenetic abnormalities were now
included and the BM blast category was further repartitioned. Whereas less weight was
given to the number of cytopenias in the IPSS, the IPSS-R recognizes the severity of
cytopenias by establishing clinically relevant cutpoints. Taken together, the IPSS-R
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Table 1. Overview of the FAB and WHO classification systems for MDS.
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recognizes five distinct risk groups, specifically very good, good, intermediate, poor and
very poor. As history has demonstrated with respect to both classification and prognosis
of MDS, improved understanding of MDS biology will likely necessitate further
refinement of the IPSS-R. A summary of the IPSS and IPSS-R can be found in Table 2.
Notably, both the IPSS and IPSS-R models stratify MDS patients at the time of
diagnosis, illustrating a key limitation. In order to account for excluded patient
populations, including patients with secondary MDS and those who have previously
been treated, the MD Anderson Global Prognostic Scoring System (MDGPSS) was
created.40 This model, applicable to patients at any time during the course of their
disease, was shown to add prognostic value to the IPSS. The MDGPSS includes
variables not considered in the IPSS or IPSS-R, including age, performance status and
prior transfusion requirement.40 Like the IPSS, the MDGPSS stratifies patients into low,
intermediate-1, intermediate-2 and high risk.
In solid tumors, the presence of a comorbidity significantly impacts therapeutic
selection as well as overall survival.41 Comorbid conditions are strikingly common
amongst individuals with MDS,8 though none of the aforementioned prognostic systems
consider the impact of comorbidities on prognosis. Use of the Adult Comorbidity
Evaluation-27 (ACE-27) index, demonstrated that overall survival decreased with
increasing severity of comorbid conditions, prompting the creation of a novel prognostic
model.42 Three variables, namely age, IPSS and baseline comorbidities, segregate
patients into low, intermediate or high risk disease.42 In a similar analysis, the
consideration of comorbid conditions at the time of diagnosis was shown to add to the
prognostic value of the IPSS-R.43
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Table 2. IPSS and IPSS-R scoring systems for MDS risk stratification.

At the present time, the IPSS-R is the most commonly employed model in the
hematology clinic at the H. Lee Moffitt Cancer Center and Research Institute.
Nevertheless, the majority of research investigations utilize the IPSS. Typically patients
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will be grouped into lower-risk (low and intermediate-1) versus higher-risk (intermediate2 and high) disease for therapeutic trials.
MDS Treatment. Historically, treatment for MDS has largely been empirical.
Unfortunately, response rates and durations of response are often limited. While three
therapies have been FDA-approved for MDS to date,44-46 regrettably no novel therapies
have been approved in over ten years. As the age of the American population is
increasing, there is a projected increase in burden of all age-related disorders, including
MDS, and consequently a heightened necessity for novel treatment approaches.47 The
lack of effective therapeutic strategies in MDS can be attributed to deficiencies in our
understanding of the underlying molecular mechanisms that contribute to disease
initiation and progression, underscoring the importance of developing biologically
rational therapies aimed at targets relevant to disease pathobiology that will surpass the
standards of care available today. Presently, clinicians use a risk-adapted approach to
therapy, whereby therapy selection is made following IPSS-R-guided determination of
disease prognosis.5 Generally, the treatment goal for lower-risk disease is to improve
quality of life by managing cytopenias and symptoms. A more aggressive approach is
used in higher-risk patients, whereby efforts are made to reduce risk of AML
transformation and increase survival. A summary of therapeutic approaches in MDS can
be found in Table 3.
Notably, the only curative treatment for patients with MDS, irrespective of risk
group,

is

allogeneic

stem

cell

transplantation

(alloSCT).48,49

Unfortunately,

transplantation is associated with high morbidity and mortality, and few patients are
suitable candidates given their late age and the frequent presence of comorbidities.
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Nevertheless, transplantation approaches are being refined to expand patient eligibility,
improve survival and reduce the risk of relapse following alloSCT.48-50
Treatment of lower-risk patients. With respect to clinical manifestations,
treatment of anemia remains a principal challenge. The majority of patients present with
anemia, and 80-90% will require frequent red blood cell transfusions at some point
during the course of the disease.51 Transfusion-dependence does have negative
implications, including poorer overall survival, increased risk of AML transformation and
iron overload, which results in significant morbidity and mortality.51 As an alternative to
frequent transfusions, growth factor support like erythroid stimulating agents (ESAs) has
been employed. Recombinant human erythropoietin (Epo) has proven effective in
improving red cell production in a subset of patients with low serum erythropoietin level
and transfusion-burden. Response rates range from approximately 25% to 60%
depending on the study population.52-55 Though Epo has been the standard of care
since the early 1990s, it has yet to gain FDA approval.56 Additionally, in an attempt to
augment response to Epo, others have combined Epo treatment with granulocyte- or
granulocyte-macrophage colony stimulating factors (G-CSF/GM-CSF).57 However, a
meta-analysis revealed no significant response benefit of either combination therapy
over Epo therapy alone.58
Moreover, increasing evidence suggesting that immune dysfunction contributes
causally to aberrant hematopoiesis in MDS has encouraged use of immunosuppressive
therapies (IST), including cyclosporine A and antithymocyte globulin (ATG).59,60
Lenalidomide,

an

immune

modulating

but

not

IST,

is

a

second-generation

immunomodulatory drug (IMiD). In 2005, the FDA approved lenalidomide for the
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Table 3. Standard and investigational therapeutic approaches for the treatment of MDS.

treatment of transfusion-dependent, lower IPSS risk patients with a chromosome 5q
deletion [del(5q)].45 This subset of patients, who typically responds poorly to Epo
treatment, has remarkable response rates to lenalidomide. Approximately 76% of
patients respond to therapy, 67% become transfusion-independent and 45% achieve a
complete cytogenetic remission, illustrating that lenalidomide suppresses the del(5q)
clone.45 In a phase 2 study of lenalidomide in non-del(5q) MDS, approximately 46% of
patients responded with 26% becoming transfusion-independent.61 These findings
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suggest lenalidomide may benefit a subset of non-del(5q) patients who fail ESA
therapy.61
To date, the landscape of novel therapeutic strategies is enriched with
approaches aimed at inhibiting dysregulated innate immune pathways. For a number of
novel agents, promising pre-clinical data has warranted further investigation in clinical
trials. The selective inhibition of IDO1, an enzyme involved in tryptophan catabolism and
immune modulation, with INCB024360 can reduce regulatory T cell expansion and
myeloid-derived suppressor cell (MDSC) activity while concurrently increasing T cell
proliferation.62 A phase II study of this agent has recently completed. Aberrant
overactivation of the SMAD/TGF-β axis has led to a number of phase II clinical trials,
including the use of a TGF-β ligand trap receptor and a TGF-β receptor 1 kinase
inhibitor.63-65 A humanized Toll-like receptor (TLR2) antibody is currently in a phase II
study. Expression of TLR2 is up-regulated 37-fold in CD34+ BM mononuclear cells (BMMNC).66,67 Lastly, a dual p38 MAPK/Tie2 inhibitor has completed phase I testing, with
approximately 32% of patients responding.68 Undoubtedly, the innate immune era
affords great promise for improved therapeutic strategies that may lead to durable
responses and ideally cures.
Treatment of higher-risk patients. Prior to the mid-2000s, conventional care for
higher-risk patients included supportive therapy, like transfusions or growth factor
support, low-dose cytarabine or intensive chemotherapeutic regimens that mirrored
those employed in de novo AML. Though complete responses to intensive
chemotherapy range from 40-60%, they are neither durable nor curative.69,70 Moreover,
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elderly patients, who represent the majority of MDS cases, poorly tolerate these
aggressive regimens, evidenced by relatively high toxicity-related mortalities.70
A major advancement in higher-risk therapy came with the understanding that
DNA in MDS is largely hypermethylated, encouraging preclinical studies of
hypomethylating agents (HMAs), or azanucleosides.71 In 2004 and 2006, the FDA
approved the use of 5'-azacytidine and its analog decitabine, respectively, for the
treatment of MDS.46,72 Patients treated with these therapies demonstrate more durable
responses, increased median time to AML transformation, and most importantly in the
case of azacitadine, increased overall survival.46,72-74 Given the survival benefit of
azanucleoside therapy, these agents represent the standard of care for higher-risk
patients, but interestingly impart no survival advantage to patients of lower-risk disease.
For higher-risk patients, novel therapeutic strategies are largely aimed at
imparting benefit to patients who have failed azanucleoside therapy, or identifying
therapies that may be used in combination with hypomethylating agents. Nucleoside
analogues, including clofarabine and sapacitabine, have completed phase I clinical
testing.75-77 These cytotoxic agents demonstrated efficacy in refractory patients,
warranting further investigation as single agents or in combination therapy. As an
alternative to HMAs, and also in conjunction with HMA treatment, histone deacetylase
(HDAC) inhibitors have been investigated as a means of modulating aberrant epigenetic
alterations in MDS. The phase I and II data have yielded encouraging response rates,
whereas randomized phase II and III trials have been disappointing.78-80 Rigosertib, a
kinase inhibitor with multiple targets, including polo-like kinase 1 (PLK1), also has
clinical activity in HMA resistant patients.81 Moreover, molecular alterations in the FLT3
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and RAS genes are associated with poor overall survival, increased risk of AML
transformation and poor response to standard therapies.82 As these mutations are
readily targetable, investigations into FLT3-specific and MAPK pathway inhibitors in
higher-risk patients are warranted and underway. Lastly, immune checkpoint receptors
and ligands CTLA4, PD-1, PD-L1 and PD-L2, which function to attenuate the immune
response, have been shown to be overexpressed in MDS, possibly contributing to the
suppressive bone marrow milieu observed in these disorders.83 Notably, treatment with
hypomethylating agents increases expression of these checkpoint receptors, suggesting
use of blocking antibodies not only as single-agent therapies, but in combination with
standard therapeutic approaches.83
Molecular and Cytogenetic Alterations. In the last decade, understanding of
the breadth and type of genetic lesions present in MDS has rapidly expanded, due in
part to advances in sequencing technology and computational approaches aimed at
managing large data sets. These data have illustrated that molecular and cytogenetic
alterations are common and often complex, owing to chromosomal abnormalities,
somatic gene mutations and epigenetic alterations. The vast molecular heterogeneity
evident in MDS imparts biological and clinical heterogeneity in these disorders, both
illustrating that genotype directly affects phenotype and contributing to the premise that
multiple mechanisms of pathogenesis culminate in the MDS phenotype.84
Cytogenetic alterations are critical in guiding diagnosis, prognosis and treatment
selection in MDS, as the IPSS and IPSS-R both consider the type and clinical impact of
specific karyotypic abnormalities.38,39 Frequently observed genetic lesions include
inversions, deletions, gains or losses of whole chromosomes and copy number
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alterations. Approximately 50% of de novo patients and up to 80% of secondary or
treatment-related MDS patients present with a karyotypic anomaly.85 With the exception
of isolated 5q and 20q deletions, the presence of cytogenetic alterations negatively
impacts survival, as overall survival drops dramatically from 53 months in individuals
with a normal karyotype, to 17 months in those with 3 distinct lesions and just 9 months
in those with 4 or more changes.85
Moreover, somatic mutations have been discovered in a wide range of genes
and gene classes, including splicing factors, epigenetic regulators, transcription factors,
growth factor signaling kinases and others, illustrating profound diversity. In the last five
years, three groups sought to determine the impact of mutations on disease outcome in
an effort to further improve prognostic discrimination.86-88 The presence of one or more
somatic mutations was observed in 78-89.5% of patients, with a median of three per
patient.87,88 Genes most frequently found mutated included SF3B1, TET2, SRSF2,
ASXL1, DNMT3A, RUNX1 and U2AF1.87,88 Notably, a trend was observed in the
temporal order of acquisition of somatic mutations, namely mutations in splicing factors
and epigenetic regulators occurring earlier and those in transcription factors and
signaling kinases occurring later with disease progression.87,88 The temporal order and
approximate frequency of common MDS somatic mutations is summarized in Figure 1.
Of interest, significant correlations were observed between specific mutations,
demonstrating not only that the presence of a mutation matters, but that the specific
combination

imparts

functional

differences

that

can

uniquely

affect

disease

pathobiology.88 Moreover, analysis of variant allele frequencies (VAFs) showed that
while 62% of patients had clonal mutations, as much as 34-48% had subclonal
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Figure 1. Temporal order and frequency of recurrent somatic gene mutations in MDS.
Somatic mutations in splicing factor genes and epigenetic regulator genes are
commonly observed earlier in MDS disease progression, whereas mutations in
transcription factor and signaling kinase genes typically occur later. The percentage
next to each gene designates the mutation frequency observed in MDS.
mutations indicative of intratumoral heterogeneity.87,88 In patients with higher-risk
disease, the mean number of mutations per patient is typically increased, and these
individuals display greater mutational diversity, increasingly complex clonal architecture
and worse overall survival.88 These findings support the notion that transformation of
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MDS to AML is associated with clonal evolution, marked by the acquisition of additional,
advantage-conferring mutations and clonal selection in favor of survival.89
These studies demonstrated that the presence of a mutation in select genes
independently added prognostic value to the IPSS and IPSS-R, illustrating potential
clinical utility.86-88 However, recent reports have indicated that the frequency of premalignant, clonal hematopoiesis in the normal population can be quite high and clearly
senescence-dependent.90 This age-related clonal expansion results predominantly from
the acquisition of somatic gene mutations commonly detected as founder mutations in
MDS and AML, including DNMT3A, TET2 and ASXL1.90 Whereas mutations were
nearly undetectable in younger patients (ages 40 years or below), 5.6% of persons 6069 years of age, 11.7% of persons 80-89 years of age, and 18.4% of persons 90 years
or older carried mutations by next-generation gene sequencing (NGS).90 This
phenomena, namely clonal hematopoiesis resulting from a myeloid malignancyassociated somatic gene mutation, occurs in otherwise hematologically normal
individuals, and has since been named clonal hematopoiesis of indeterminate potential
(CHIP).91 Persons with CHIP have 11.1-fold increased risk of developing a hematologic
malignancy, as well as increased risk of type 2 diabetes, cardiovascular disease and allcause mortality.90 Only a small percentage of persons with CHIP progress to a
hematologic neoplasm, like MDS or AML.90,91 Until additional studies are performed to
understand the longitudinal effects of CHIP on outcome, the inclusion of mutation-based
criteria into the IPSS or IPSS-R is unlikely.92 Nevertheless, evaluation of somatic gene
mutations can help guide prognostication and offer insight into otherwise challenging
diagnoses.

18

Aberrant Immune Activation in MDS

Autoimmune Disease and Infection. Sustained immune activation is
recognized to increase the risk of hematologic malignancy. Accordingly, the literature
supports a link between MDS and a number of inflammatory conditions.93 For one, the
presence of an autoimmune disorder significantly increases the risk of developing both
MDS and AML.94 As many as 30% of MDS cases occur concomitantly with autoimmune
disorders.95 MDS-associated rheumatoid arthritis and inflammatory bowel disease have
been reported and precede development of MDS in approximately 55% of cases.94,96
Moreover, history of a board range of infections, including pneumonia, upper respiratory
tract infection and sinusitis, significantly increases MDS and AML risk.25 When a latency
analysis was performed to assess the contribution of infection three years prior to MDS
or AML diagnosis, many infections retained significance.25 Together, these data suggest
that selective pressures associated with chronic inflammation related to infection and
autoimmune conditions favor emergence of somatic mutations in HSPC, creating a
fertile milieu for leukemogenesis and the development of MDS and AML. It is therefore
likely that immune perturbations antecede the emergence of MDS.
Cytokine, Chemokine and Growth Factor Profile. MDS peripheral blood and
bone marrow are marked by aberrant expression of inflammatory cytokines,
chemokines and growth factors. Generally, lower-risk patients demonstrate marked upregulation of pro-inflammatory mediators whereas immunosuppressive signals dominant
higher-risk disease.97 Increased interferon gamma (IFN-γ) gene expression is
detectable in approximately 42% of MDS cases, with a significant overabundance of
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cytokine expression within sera.97,98 Additionally, cytokines essential for T cell
activation, differentiation and proliferation, including IL-12 and IL-7, are significantly
increased in lower-risk sera, as well as the chemokine CCL5 important for lymphocyte
chemotaxis.97 Approximately 40% of early-stage MDS patients evidence significantly
greater secretion of the pro-inflammatory cytokine IL-1β within the bone marrow, which
correlates positively with the degree of cell death.99 MDS stromal cells not only express
increased levels of IL-1β, IL-6 and G-CSF mRNA, but produce mature IL-1β and IL-6
basally without exogenous stimulation,100 illustrating a pathobiologic contribution of the
bone marrow microenvironment. Notably, expression of pro-angiogenic factors in solid
tumors is often associated with advance stage disease and poor prognosis. In MDS,
increased plasma levels of vascular endothelial growth factor (VEGF) and angiogenin
(ANG) positively correlate with disease risk, suggesting a role in disease progression.101
Moreover, TNFα gene expression is increased in approximately 79% of cases, with a
corresponding increase in the cytokine within the bone marrow.98 Not only are TNFα
levels increased in higher-risk patients, but this up-regulation correlates with lower
complete response rates and reduced survival.102 Other inhibitory cytokines, including
IL-10 and the soluble IL-2 receptor, are also increased in the sera of higher-risk
patients,97 and the myelosuppressive cytokine TGF-β1 is increased in both PB plasma
and the BM milieu.103
Overview of TLR Signaling. Pattern recognition receptors (PRRs) represent a
class of germline-encoded receptors recognizing both microorganism- and host-derived
danger signals, or pathogen-associated molecular patterns (PAMPs) and dangerassociated molecular patterns (DAMPs), respectively.104,105 The PRR family can
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generally be divided into four receptor subfamilies. Two subfamilies, the Toll-like
receptors (TLRs) and C-type lectin receptors (CLRs), are transmembrane, whereas the
other two reside cytoplasmically, namely the NOD-like receptors (NLRs) and the
Retinoic acid-inducible gene (RIG)-I-like receptors (RLRs).104 Activation of PRRs results
in activation of the innate immune response via a coordinated and fine-tuned
inflammatory signal.
Undoubtedly, the TLRs are among the best-characterized PRR family, with ten
members identified in humans.104,105 Cellular localization of the TLRs is divided between
the plasma membrane (TLR-1, 2 and 4-6) and endosomal compartments (TLR-3 and 710), and DAMP and PAMP recognition varies between receptors.106 Signaling originates
at the cytoplasmic Toll/IL-1R homology (TIR) domain of the TLR following receptor
engagement. Subsequently, recruitment of specific adaptor proteins allows for modified
and specific responses. In total, five adaptor proteins are recognized, namely myeloid
differentiation primary response gene 88 (MyD88), TIR domain containing adaptor
protein (TIRAP), TIR domain-containing adaptor-inducing interferon-β (TRIF), TRIFrelated adaptor molecular (TRAM) and Sterile-alpha and Armadillo motif containing
protein (SARM).104,105
Generally, TLR signaling can be divided into MyD88-dependent and TRIFdependent pathways, with the majority of TLRs utilizing the former mechanism, with the
exception of TLR3.104,105 Notably, TLR4 signaling results in activation of both
pathways.104 To start, MyD88 recruitment to the TIR domain results in a chain of events
beginning with activation of interleukin-1 receptor-associated kinase 1 (IRAK1), then
IRAK2.104 Following dissociation from MyD88, the IRAK members associate with TNFR-
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associated factor 6 (TRAF6), an E3 ubiquitin ligase.104 Downstream signaling from
TRAF6 ensues, resulting in the activation and nuclear localization of nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB).104 Conversely, the TRIFdependent signaling pathway begins with recruitment of TRAF3 and TRAF6.104 While
NF-κB will become activated downstream, this pathway also results in phosphorylation
of interferon regulatory factor 3 (IRF3) and IRF7. Following dimerization, IRF3 and IRF7
translocate into the nucleus and induce expression of type I interferons (IFNs).104
Ultimately, activation of TLR signaling culminates in activation of NF-κB, the generation
of pro-inflammatory cytokines, interferons and an organized immune response (Figure
2).105
TLR Signaling Dysregulation in MDS. The evidence supporting up-regulation
and activation of TLR signaling in MDS is extensive and growing. Interestingly, chronic
TLR4 signaling results in functional damage to long-term HSC.107 The impaired
repopulating potential of these HSC reflects the stem cell exhaustion observed with
aging and characterized by loss of quiescence and increased cycling causing HSC
depletion, accompanied by expansion of the myeloid compartment at the expense of the
lymphoid.107-109 Similar findings are evident with chronic IL-1β stimulation as well.110
Such a phenotype is evident in MDS, suggesting TLR-driven aberrancies in
hematopoiesis. Interestingly, normal BM-derived, CD34+ HSPC constitutively express
TLR4 and TLR7-9, and stimulation of TLR7-8 actually skews differentiation of these
cells along the myeloid lineage.111 Moreover, gene expression of TLR1, TLR2, TLR4
and TLR6 is significantly increased in MDS BM-MNC, as well as protein expression of
TLR2 and TLR4.67,112 Activation of TLR2 in CD34+ HSPC decreases erythropoietic
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Figure 2. Overview of MyD88-dependent and TRIF-dependent TLR signaling
pathways. With the exception of TLR3, all of the TLRs utilize MyD88-dependent
signaling. (A) The TLRs located at the plasma membrane vary in the specific PAMPs
and DAMPs they detect, as well as the adaptor proteins that are recruited to mediate
23

downstream signaling. (B) In MyD88-dependent signaling, MyD88 recruits and activates
IRAK1 and IRAK2. (C) Following activation, IRAK1/IRAK2 dissociate and associate with
TRAF6, an E3 ubiquitin ligase. (D) Once autoubiquitinated, TRAF6 recruits the IKK
complex, consisting of IKKα, IKKβ and IKKγ. TAK1 will phosphorylate IKKβ, leading to
phosphorylation and liberation of NF-κB from the IKK complex members. NF-κB
translocates into the nucleus and induces transcription. (E) Activation of TAK1 results in
MAPK signaling and the activation of a variety of transcription factors (TF), including
AP-1, p38 MAPK and JNK. Subsequently, these TFs translocate into the nucleus and
direct transcription. (F) TLR3, located within endosomal compartments, utilizes TRIFdependent signaling whereby TRAF3 and TRAF6 are recruited for activation. (G)
Activation of TBK1 results in the activation of the IRF3 transcription factor and
transcription.
potential, as measured by colony forming capacity.67 Additionally, approximately 11% of
MDS patients harbor a single nucleotide polymorphism (SNP) encoding a phenylalanine
to serine amino acid substitution at position 217 of TLR2, resulting in enhanced NF-κB
activation and signaling.67 Notably, protein membrane expression of TLR4 is
significantly increased on MDS CD34+ cells, overall 92% greater than normal HSPC,
and expression on BM-MNC correlates with the extent of apoptosis as measured by
annexin-V positivity.112
Comparative gene expression analyses of 84 TLR-related genes in BM-derived,
CD14+ monocytes demonstrated that approximately 63% of these genes were
significantly over-expressed in MDS compared to normal controls.113 Subsequent gene
set enrichment analysis elucidated that up-regulated genes belonged to both the
MyD88-dependent and -independent pathways, as well as TLR signaling adaptors and
downstream pathway mediators, illustrating widespread network dysregulation.113 In
accordance with these findings, while no mutations in MyD88 are demonstrable in MDS,
increased gene expression has been shown in both BM-MNC and CD34+ HSPC.114
Lower-risk patients have greater over-expression than those with higher-risk disease,
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and this up-regulation directly correlates with reduced survival and diminished erythroid
colony forming capacity.114 Additionally, the genomic regions harboring TIRAP and
TRAF6, the downstream target of the IRAK1 kinase, are amplified in a subset of
patients.115 Furthermore, approximately 10-30% of MDS cases manifest over-expressed
and hyperactive IRAK1 adaptor protein.116 Silencing of IRAK1 by RNA interference or
pharmacologic inhibition of the kinase resulted in reduced proliferation and colony
forming capacity in MDS, illustrating the importance of this target in these disorders.116
Notably, deletion of the long arm of chromosome 5 in patients with del(5q) MDS results
in haploinsufficiency for a number of genes, including two microRNAs (miRNAs) within
the commonly deleted region (CDR), namely miR-145 and miR-146a.117,118 These
miRNA, which target TIRAP and TRAF6, respectively, are normally expressed in CD34+
HSPC and function to fine-tune the innate immune response.117 Loss of miR-145 and
miR-146a recapitulates the del(5q) phenotype, elegantly demonstrating that aberrant
activation of TLR- and innate immune-driven signaling has pathobiological effects in
MDS.117
Bone Marrow Microenvironment Abnormalities. Like hematopoietic stem
cells, mesenchymal stromal cells (MSC) reside within the bone marrow whose stem cell
component is characterized by multipotency, self-renewal and the ability to differentiate
into cells of the adiopocytic, chondrocytic and osteocytic lineages (Figure 3).119
Together, these cells constitute the BM microenvironment and fulfill the crucial function
of supporting normal hematopoiesis.
Undoubtedly, complex and dynamic interactions exist between cells of the
hematopoietic and stromal lineages. Dysfunction in either dichotomy, namely the
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Figure 3. Hierarchy of the mesenchymal lineage. Mesenchymal stem cells (MSC)
propagate cells of the mesenchymal lineage through a number of differentiation
pathways, like osteogenesis, stromagenesis, etc. The precursor cells of these pathways
will terminally differentiate into mesenchymal cells, including osteocytes, stromal cells,
chondrocytes, adipocytes, fibroblasts, myocytes and astrocytes.
hematopoietic cells or the surrounding stroma, has implications for disease
pathogenesis, as an abnormality in either typically translates to abnormalities in the
other.84,120 For one, co-culture studies of the F-36P AML cell line with MDS-derived
stromal layers illustrated the defective ability of the stroma to support hematopoiesis, as
evidenced by increased cell death of the cell line.121 In a sophisticated animal model,
disruption of the microenvironment was sufficient to initiate neoplastic change in a cell
type of non-mesenchymal origin.122 Specifically, osteoprogenitor-specific deletion of
Dicer1, an RNase III family endonuclease, resulted in myelodysplastic features with
dysplasia, increased rate of transformation to AML and clonal genetic events in the
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hematopoietic compartment.122 The role of the BM microenvironment in initiating
disease was further supported by studies using the NUP98-HOXD13 (NDH13) animal
model, which phenocopies MDS and is generated by hematopoietic cell-specific
expression of the NUP98-HOXD13 transgene.123 Not only was the NDH13 stroma
defective in supporting hematopoiesis, but transplantation of NDH13 BM-MNC into WT
recipients resulted in increased survival and reduced leukemic transformation compared
to transplantation into NDH13 transgenic recipients.123 These findings illustrate that
normalizing the diseased BM microenvironment improves general hematopoietic
function.123 Conversely, the instructive reprogramming of the microenvironment by
MDS-derived BM-MNC has also been demonstrated.120 In the presence of MDS BMMNC, normal MSC actually acquire an abnormal phenotype, with features similar to
MDS-derived MSC.120
Not only are BM-derived MSC phenotypically and functionally abnormal in MDS,
they are also genetically unstable.124 Germline genetic alterations in MSC have been
described in MDS.125 Moreover, clonal chromosomal abnormalities in MSC have also
been reported and confirmed in approximately 34% of MDS patients, and these are of
distinct origin from the MDS clone.124 Patients harboring a clonal MSC abnormality have
significantly reduced overall survival compared to those without MSC-specific genomic
changes.126 Although the precise biological consequence of these genetic alterations is
largely unknown, they confer neither a proliferative nor a survival benefit.124
Overview

of

Hematopoiesis.

Though

largely

regarded

today

as

an

oversimplification, hematopoiesis, or the process resulting in the formation of all types of
blood cells, is typically depicted as a hierarchy (Figure 4). Hematopoietic stem cells
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(HSC), found atop of the hematopoietic pyramid, reside within the bone marrow as a
rare, and largely quiescent, multipotent cell population.127 HSC are characterized
according to two unique attributes, namely the ability to self-renew, or generate
additional HSC through cell division, and secondly, the ability to propagate all cells of
the hematopoietic system.128 In a simplistic view, HSC give rise to slightly more
differentiated

progenitor

cells,

which

then

differentiate

further

along

specific

hematopoietic lineages into fully mature and terminally differentiated cells.128 In this
way, self-renewal potential dramatically decreases as cell maturation increases. Two
populations of HSC have been recognized, the long-term (LT-HSC) and short-term (STHSC) hematopoietic-initiating cells which differ in their self-renewal ability. Perhaps selfevident from their designation, LT-HSC retain life-long ability to reconstitute the
hematopoietic system, whereas ST-HSC are more limited and can only do so shortterm.129 Therefore, LT-HSC give rise to ST-HSC, which then continue on to differentiate
into multipotent progenitor cells (MPP).129 MPP differentiate either into common myeloid
progenitor (CMP) or common lymphoid progenitor (CLP) cells, which then produce cells
of the entire myeloid and lymphoid lineages, respectively.128,129 In this way, MPP serve
as the divergence point for the two main branches of hematopoiesis.129 The CMP is also
referred

to

as

the

colony

forming

unit

(CFU)-granulocyte,

erythrocyte,

monocyte/macrophage, megakaryocyte (CFU-GEMM), as it gives rise to these myeloid
cell populations.129 Red blood cells are formed following maturation of the CFU-GEMM
into burst forming unit-erythroid (BFU-E) and then CFU-erythroid (CFU-E).129
Differentiation of CFU-GEMM into CFU-granulocyte-macrophage (CFU-GM) results in
the production of mature neutrophils and macrophages.129 The myeloid lineage also
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includes megakaryocytes, which form platelets, mast cells, and the granulocytic
basophil and eosinophil populations. Conversely, the CLP generates mature T and B
lymphocytes, as well as natural killer (NK) cells.129 A basic representation of
hematopoiesis is illustrated in Figure 4. In MDS, aberrant hematopoiesis typically results
in peripheral blood cytopenias, or the loss of cells of a particular lineage from premature
cell death. Although loss of mature red blood cells, or anemia, is the most frequently
observed cytopenia in MDS, other forms include neutropenia, loss of neutrophils,
thrombocytopenia, loss of platelets, and leukopenia, general loss of white blood cells.4
Lymphoid Cell Lineage Involvement. Aberrant expression, activation and
function of specific lymphocytic lineage cells is well documented in MDS, linking this
branch of hematopoiesis to immune-mediated pathobiology. For one, natural killer (NK)
cell cytolytic activity is globally impaired, with reduced expression of activating receptors
resulting in impaired and deficient immunosurveillance.130 Importantly, reduced function
significantly correlated with disease progression, as the greatest functional defects were
observed in higher-risk patients, those with increased BM blast count and abnormal
karyotype.130 These findings suggest that NK cells may function to eliminate aberrant
hematopoietic cells in lower-risk disease, and that the progressive loss of cytotoxic
ability results in expansion and escape of the leukemic clone.130 Alternatively, biological
events associated with genetic evolution of the clone may further impair NK cell
function. Moreover, genes associated with the B cell lineage are significantly reduced in
MDS CD34+ BM-MNC compared to normal controls, potentially contributing to the
apparent myeloid lineage bias in MDS.131 Accordingly, B cell precursors are markedly
reduced in MDS compared to normal.131
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Figure 4. Overview of hematopoiesis. Long-term (LT) hematopoietic stem cells (HSC)
differentiate into short-term (ST)-HSC, which have reduced self-renewal capacity. STHSC differentiate into multipotent progenitor cells (MPP), which can either differentiate
into precursor cells of the myeloid or lymphoid lineages, namely common myeloid
progenitors (CMP) or common lymphoid progenitors (CLP). The CMP will propagate all
cells of the myeloid lineage, including red blood cells (RBC), megakaryocytes and
platelets, monocytes and macrophages, and the granulocytes, including eosinophils,
neutrophils and basophils. The CLP will generate B cells, T cells and natural killer (NK)
cells through lymphopoiesis.
Conversely, cytotoxic T lymphocytes are expanded in MDS, retain potent
cytolytic activity and appear to be reduced upon response to treatment.132 Depletion of
CD8+CD57+ effector T cells from long-term cultures of BM-MNC resulted in a marked
increase in colony forming capacity, albeit to a lesser extent than that observed in
normal controls.133 While MDS-derived CD8+ cell add-back had no effect on normal
control colonies, no colonies formed in all 33 MDS samples where autologous CD8+

30

cells were added back into culture, illustrating an antigen-specific autologous
response.133 In support of this observation, in patients with an abnormal karyotype,
depletion of this effector lymphocyte population increased the proportion of genetically
abnormal cells by approximately 12.5%, indicating that the biological effects of the
CD8+ cells is largely surveillant and involved in direct clonal suppression.133
Accordingly, isolated CD8+ cells are typically oligoclonal, likely a result of selective
expansion in response to self-recognition of an abnormal hematopoietic progenitor.134
While CD4+ helper T cells are also aberrantly expanded in MDS, isolated
populations are typically polyclonal.134 Expansion of regulatory T cells (Tregs), defined
as CD4+CD25+FOXP3+, is evident in the PB and BM of MDS patients with higher-risk
disease.135,136 In lower-risk patients, autoimmune reactions targeting dysplastic
hematopoietic cells may be the result of diminished Treg function and localization to the
BM in this subset of patients.135,136 On the contrary, in higher-risk patients, Treg
expansion aids in immunologic escape of the MDS clone, permitting disease
progression.135,136 Indeed, PB Treg expression is associated with reduced survival and
poor prognosis.137 Lastly, IL-17 producing CD4+ T cells, or Th17 cells, have known
pathobiological roles in autoimmune conditions and other inflammatory responses
whereby they function as potent inducers of cytokine production.97 Th17 cells are
markedly expanded in lower-risk MDS, which is likely indicative of an inflammatory
reaction.97 Moreover, Th17 and Treg cells have an inverse relationship in lower- versus
higher-risk MDS and this pattern reflects that observed in autoimmune conditions.97
These findings may indicate why autoimmune diseases are significantly associated with
MDS, particularly in lower-risk patients.

31

The Role of Myeloid-Derived Suppressor Cells (MDSC) and S100A9. Named
appropriately, myeloid-derived suppressor cells (MDSC) represent a phenotypically
distinct, immature myeloid cell population that remains in an activated and highly
immunosuppressive state.138 A block in myeloid lineage differentiation results in the
accumulation of MDSC, which are often expanded in pathological conditions, including
cancer, autoimmunity, inflammation and infection, as well as in the normal process of
aging.138 MDSC modulate both the innate and adaptive immune responses through two
general modes of action, namely cell-to-cell, contact-based interactions and also the
release of soluble mediators.138 MDSC produce a number of factors that contribute to
immune suppression, including substantial amounts of reactive oxygen species (ROS),
nitrous oxide (NO), arginase and inducible nitric oxide synthase (iNOS), as well as
direct release of granzyme granules.138 These factors are highly suppressive of NK and
T cell responses, which in conjunction with the known role of MDSC in promoting Treg
expression, demonstrates clearly the role of MDSC in fostering immune tolerance.138,139
To date, two populations of MDSC have been identified and differ in morphology, with
one appearing more granulocytic and the other more monocytic.138 These subsets
display inversed expression of ROS and NO, with low levels of ROS and high NO
evident in the monocytic subset and high ROS and low NO in the granulocytic.138
Understanding of the distinct functions of these subsets is presently under investigation.
While MDSC regulation is complex, a number of mediators have key roles in
MDSC activation and expansion, including pro-inflammatory cytokines like IFN-γ and
TGF-β, and signaling through TLRs.138 Recently, the danger-associated molecular
pattern (DAMP) proteins S100A8 and S100A9, or migration inhibitory factor-related
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protein 8 (MRP8) and MRP14, respectively, have been implicated in MDSC activation
and expansion.140,141 S100A8 and S100A9 are just two of the twenty-five members of
the S100 calcium-binding protein family with known roles in tumorigenesis, infection and
inflammation.142 These proteins are highly expressed by neutrophils and monocytes,
and secretion of S100A8/A9 into the extracellular milieu represents a pro-inflammatory
signal of cell damage.143 Generally, S100A8 and S100A9 function as a heterodimer that
is also known as calprotectin, expression of which is significantly increased in a number
of cancer types, including breast, prostate, lung and stomach cancers.142 Both
intracellular and extracellular roles have been described for S100 family members.
Extracellular S100A8/A9 functions akin to cytokine signaling, whereby engagement of
specific cell surface receptors results in signal transduction and an inflammatory
response.142 To date, S100A8/A9 has been shown to serve as a ligand for TLR4, RAGE
and surface receptors with carboxylated N-glycan moieties.144-146 S100A9-induced
activation of TLR4 results in a similar signaling cascade as is observed with
lipopolysaccharide (LPS) stimulation, namely through IκBa- and MAPK-mediated
pathways resulting in robust activation of NF-κB and generation of inflammatory
cytokines.147 In a murine model of human breast cancer, ligation of S100A8/A9 with
surface receptors on MDSC was shown to induce NF-κB-dependent peripheral blood
MDSC expansion.141 S100A8/A9 is actively produced by MDSC, which upon secretion,
functions in an autocrine circuit to further sustain MDSC expansion.141 In an alternative
murine model, the constitutive secretion of IL-1β by fibrosarcoma cells results in highly
metastatic and aggressive tumors through IL-1β-directed immune suppression.148
Interestingly, the IL-1β receptor, a member of the IL-1/TLR family, directs the
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accumulation of murine MDSC, defined as CD11b+/Gr-1+ cells, resulting not only in T
cell inactivity but also hematopoietic abnormalities, such as anemia.148
Importantly, we reported that MDSC are significantly expanded in the BM of
lower-risk, but not higher-risk MDS patients compared with normal, age-matched
controls as well as patients with solid tumors.140 Subsequent fluorescence in situ
hybridization (FISH) analyses and targeted quantitative PCR (qPCR) for commonly
observed MDS somatic gene mutations confirmed that the expanded MDSC population
was distinct from the MDS clone.140 MDSC depletion from BM-MNC cultures resulted in
increased T cell proliferation and improved progenitor colony forming capacity,
illustrating the pathobiological role of MDSC in the aberrant hematopoiesis of MDS.
Furthermore, MDSC highly express the surface receptor glycoprotein CD33, which
belongs to the sialic acid-binding immunoglobulin-type lectin (Siglec) family of receptors
with known roles in inflammation.149 Surface receptor density of CD33 is significantly
greater in MDSC from MDS compared to those from normal donors, suggesting an
aberrant role of CD33-driven signaling in MDS.140 We found that the primary MDSspecific ligand for CD33 is the DAMP protein S100A9, which is actively produced and
secreted by MDSC.140 Engagement of S100A9 with CD33 results in CD33-dependent
signaling, culminating in MDSC activation and expansion.140 Notably, S100A9
transgenic (S100A9Tg) mice phenocopy human MDS, evidenced by progressive
multilineage cytopenias and cytological dysplasia, hypercellular marrows and agedependent expansion and accumulation of MDSC.140 Treatment of the transgenic mice
with all-trans retinoic acid (ATRA) resulted in the forced differentiation of MDSC to
mature myeloid cells with corresponding improvement in blood counts and
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hematopoiesis.140 Together, these data illustrate that aberrant inflammation driven by
S100A9 and the expansion of MDSC together create a suppressive and inflammatory
microenvironment that is sufficient to direct the development of MDS. A summary of
general MDSC immunosuppressive mechanisms and our findings related to MDSC and
S100A9 in MDS can be found in Figure 5.

The 5q- Syndrome.

Overview. Though the 5q- syndrome was initially described in 1974 in the
seminal publication by Van den Berghe et al., it was not acknowledged as a distinct
subset of Myelodysplastic Syndromes until 2001 with the release of the first WHO
classification system.34,35 To date, it represents the sole MDS subtype characterized by
the presence of a cytogenetic abnormality, namely the isolated, interstitial deletion of
the long arm of chromosome 5 (del(5q) MDS).37 With respect to the clinical phenotype,
patients with del(5q) MDS present with a progressive, macrocytic, hypoplastic anemia
despite the presence of a normo- or hypercellular bone marrow (BM).150 Conversely,
platelet and megakaryocyte counts are generally normal or increased, illustrating that
only the erythroid compartment suffers from worsening blood counts.150 Both BM and
peripheral blood (PB) blast percentages are below 5%.37 Of interest, the 5q- syndrome
is more common in females, with a 7:3 prevalence versus males.151 Overall, patients
with del(5q) MDS have a favorable prognosis, with a median survival of 63 months and
a lower chance for leukemic transformation.151
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Figure 5. General mechanisms of hematopoietic inhibition by MDSC and the role
of the MDSC/S100A9 axis in MDS. (A) MDSC mediate the suppression of a number of
immune cells, including NK and T cells, and also promote the expansion of regulatory T
cells (Treg). (B) Through the release of soluble factors, MDSC are highly suppressive
and have a number of mechanisms of inhibition. These include release of reactive
oxygen species (ROS) and nitrous oxide (NO), arginase and inducible nitric oxide
synthase (iNOS), and inflammatory cytokines, like TGF-β, IFN-α, IL-10 and others. (C)
MDSC robustly express the surface receptor glycoprotein CD33. (D) The DAMP protein
S100A9 is a native ligand for CD33 and is actively produced by MDSC. Upon secretion,
S100A9 functions (E) in a paracrine manner to mediate progenitor cell death.
Additionally, S100A9 (F) reinforces MDSC activation and expansion through autocrine
signaling and binding to CD33.
Moreover, this particular clonal abnormality is restricted to the myeloid lineage,
as both myeloid and erythroid progenitors harbor the chromosomal deletion but
generally not cells of the lymphoid compartment.152 Both proximal (5q12-14) and distal
(5q31-33) deletions are typically reported, with breakpoints having been recognized at
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each band between 5q11 and 5q35.153 Unmistakably, this particular genetic loss is large
and substantial. The majority of the long arm of chromosome 5 is lost, and with it a
gene-rich area.153 In the early 2000s, considerable efforts in molecular mapping
identified the del(5q) commonly deleted region (CDR), or the smallest region lost in
patients with the 5q- syndrome.154 Specifically, the CDR spans a genomic region of 1.5megabases and 40 genes, bordered by marker D5S413 and the gene GLRA1.154
Comprehensive array-based transcriptome analyses of CD34+ HSPC illustrated that
536 genes are differentially expressed in del(5q) patients compared to normal
donors.155 Of interest, mutations in the CDR genes are rare, implicating gene dosage
effects in the pathobiology of the 5q deletion.155 Accordingly, expression levels of the
CDR genes are approximately 60-80% of normal.155 This range is not characteristic of a
two-hit model of gene loss, and is reminiscent instead of haploinsufficiency stemming
from loss of a single allele.155 Indeed, Boultwood et al. suggested that casein kinase 1
alpha 1 (CSNK1A1) or ribosomal protein S14 (RPS14) may be candidate
haploinsufficient genes implicated in del(5q) MDS pathobiology.155
Treatment of Del(5q) MDS. Anemia is the major therapeutic challenge for
patients with del(5q) MDS. Approximately 80% of patients are transfusion-dependent
proximate to the time of diagnosis, and 93% of patients will be at some point during their
disease.151 Historically, patients with del(5q) MDS received supportive therapy, as other
treatment approaches were largely disappointing. While lenalidomide, a secondgeneration immunomodulatory drug (IMiD), is currently FDA approved for the treatment
of del(5q) MDS, the path to this designation is rather unique. Thalidomide, the parent
compound of lenalidomide, is a known teratogenic agent responsible for widespread
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birth defects or phycomelia in the 1950s.156 Despite this, thalidomide has unique
biological effects including the enhancement of antigen-induced T cell proliferation and
activity and inhibition of angiogenesis, illustrating the ability of this agent to modulate the
immune response.156,157 In a study performed in lower- and higher-risk MDS,
approximately 19% of patients responded to thalidomide.158 Though no cytogenetic or
complete responses were observed, the drug did improve blood counts and reduce
cytopenias in a subset of lower-risk patients.158 The negative connotation of the IMiDs
was lessened with the identification of lenalidomide, a 4-amino-glutarimide analogue of
thalidomide.156 Lenalidomide has greater potency than its parent compound with less
toxic effects.156 Seminal work by List et al. demonstrated the therapeutic efficacy of
lenalidomide in del(5q) MDS.45 Approximately 83% of del(5q) patients had a fast
hematologic response associated with transfusion-independence.45,159 Additionally,
lenalidomide was cytotoxic to the del(5q) clone as evidenced by frequent cytogenetic
responses.159 Lenalidomide received FDA approval in 2005 and still remains the
standard of care in patients with deletion of chromosome 5q MDS.
Pathobiology of the 5q- Syndrome.
Ribosomal protein S14 (RPS14). Major advances in the understanding of 5qsyndrome biology were made by Ebert and colleges in 2008, with the identification of
ribosomal protein S14 (RPS14) haploinsufficiency in the pathobiology of del(5q) MDS
anemia.160 In an elaborate set of knockdown experiments, normal CD34+ HSPC were
lentivirally transduced with shRNAs targeting each of the 40 genes in the CDR.161
Knockdown of one gene, namely RPS14, to haploinsufficient levels (~60% expression)
recapitulated the 5q- phenotype, namely erythroid-specific proliferative arrest and cell
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death.160 The group additionally demonstrated that no mutations were detectable in the
remaining RPS14 allele in del(5q) patients, confirming the pathological effects of RPS14
loss in MDS were attributable to a RPS14 gene dosage effect.160 Moreover, a murine
model of the 5q- syndrome was generated by the syntenic deletion of the del(5q) CDR,
which translates to the Cd74-Nid67 interval in mice.162 Mice harboring the deletion
phenocopy human del(5q) MDS, with severe anemia, erythroid dysplasia and reduced
red blood cell counts.162 Notably, Cd74-Nid67 BM erythroid cells demonstrated
significantly increased expression of p53.162 Crossing of the Cd74-Nid67 mice with p53
deficient mice rescued the hematologic phenotype and improved erythropoiesis,
illustrating that the molecular pathobiology of the 5q- syndrome is p53-dependent.162
In support of these findings, RPS14 gene haploinsufficiency in del(5q) MDS was
shown to result in the erythroid lineage-specific activation and accumulation of p53.163
RPS14, a central component of the 40S ribosome, has essential roles in RNA
processing and maturation.160 Mechanistically, decreased RPS14 expression disrupts
ribosome assembly, triggering the degradation of MDM2, an E3 ubiquitin ligase and the
central negative regulator of p53 activation.160,163 Indeed, BM biopsies from del(5q)
patients confirm increased nuclear expression of p53 and reduced expression of MDM2
in erythroid progenitors.164 Stabilized and activated p53 triggers p21-dependent cell
cycle arrest, erythroid progenitor-specific cell death and anemia.163 Abnormal activation
of the p53 pathway in MDS can additionally be attributed to the role of p53 in monitoring
ribosome function, as ribosomal stress can directly activate p53.165 Interestingly, in a
recent investigation, reduced expression of RPS14 was identified in 83 of 156 non-
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del(5q) MDS patient specimens, and was associated with increased apoptosis of
erythroid precursors.166
Perhaps the findings demonstrating a key role for the RPS14/MDM2/p53
pathway in driving ineffective erythropoiesis in del(5q) MDS are best corroborated by
studies performed in the Rps14 haploinsufficient mouse model.167 Inactivation of Rps14
results in p53-dependent defects in erythropoiesis, age-dependent, progressive anemia
and other defining features of human disease.167 Using a quantitative proteomics-based
approach, 26 proteins were identified as differentially expressed in the Rps14
haploinsufficient versus wild-type littermates.167 As expected, many of these were
ribosomal-related proteins, which functioned as a positive control for the experiment.
Most important, though, S100A8 and S100A9 were the highest differentially expressed
proteins in the context of Rps14 haploinsufficiency.167 Wild-type HSPC, defined as LSK
(Lin-Sca-1+c-Kit+) positive, treated with recombinant murine S100A8 failed to
differentiate properly along the erythroid lineage, which was rescued by CRISPR-Cas9mediated knockdown of S100a8.167 Furthermore, S100A8 and S100A9 can signal to
increase p53 activation, and multiple p53 binding sites have been identified within the
S100A9 gene promoter, linking these proteins in a positive feedback loop.167,168 Indeed,
p53 activation was increased in the context of Rps14 haploinsufficiency, impairing
differentiation and increasing erythroid progenitor cell death.167 These data link innate
immune

mediators

in

the

pathobiology

of

del(5q)

MDS

though

an

S100A8/A9/Rps14/p53 pathway.
Casein kinase 1A1 (CSNK1A1). In addition to RPS14, Boultwood et al. hinted at
a potential pathobiologic role for haploinsufficiency of casein kinase 1A1 (CSNK1A1) in
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del(5q) MDS, as expression levels of CSNK1A1 were reduced to approximately 50% in
this cohort of patients.155 Indeed, this hypothesis was recently confirmed using a murine
model of CSNK1A1 haploinsufficiency.169 CK1α, which is encoded by CSNK1A1, is a
key regulator of β-catenin given its membership in the β-catenin destruction complex.
Haploinsufficiency of CSNK1A1 increased β-catenin activation in HSPC, resulting in
enhanced survival and proliferation of the stem cell population.169 These data suggest
that loss of CSNK1A1 expression provides a proliferative advantage to the del(5q)
clone, and highlight an additional mechanism of pathobiology conferred by the
chromosome 5q deletion.
TLR4/TRAF6/NF-κB-dependent

signaling

axis.

Intriguing

work

by

Starczynowski and colleagues implicated, for the first time, microRNAs in the
pathobiology of the 5q- syndrome.117 MicroRNAs (miRNAs), highly conserved, ~22nucleotide-long, small non-coding RNAs, mediate post-transcriptional gene regulation to
exert widespread repressive changes in gene expression.170 Following parallel
sequencing and qPCR validation, miR-145 and miR-146a were shown to be significantly
reduced in del(5q) patients compared to normal controls.117 miR-145 lies within the CDR
whereas miR-146a is just outside this region.117 In lethal irradiation and transplantation
experiments, overexpression of miR-145 and miR-146a recapitulated the del(5q)
phenotype, confirming a role for the miRNA in disease biology.117 Moreover, tollinterleukin 1 receptor (TIR) domain containing adaptor protein (TIRAP) and TNF
receptor-associated factor 6 (TRAF6) were identified as the targets of miR-145 and
miR-146a, respectively.117 Loss of miR-145 and miR-146a derepressed expression of
these downstream targets which aberrantly drives innate immune activation, as both
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TIRAP and TRAF6 have central roles in TLR4 and NF-κB signaling.117 As proof of
concept, forced expression of TRAF6 significantly reduced blood cell counts, impaired
myeloid lineage differentiation and induced bone marrow failure and risk of AML
progression.117
Notably, these data are strongly supported by recent findings related to TRAFinteracting protein with forkhead-associated domain B (TIFAB), a gene located at
5q31.1 that is also haploinsufficient in del(5q) MDS.171 Transplantation experiments of
germline Tifab knockout BM cells into wild-type recipients showed that loss of Tifab
confers hematopoietic defects.171 Recipient mice developed bone marrow failure and
cytopenias with impaired myeloid differentiation.171 Mechanistically, TIFAB complexes
with TRAF6 to promote its degradation, which in turn inhibits NF-κB.171 Therefore,
haploinsufficient loss of TIFAB in del(5q) MDS increases TRAF6 activity, enhancing
TLR4-mediated signaling and activation of NF-κB.117,171
Finally, the aberrant TLR4/TRAF6/NF-κB pathway in del(5q) MDS is additionally
dysregulated by p62, also known as sequestosome 1 (SQSTM1), a mitochondrial
adapter indispensable for autophagy.172 Paradoxically, despite the presence of p62
within the 5q chromosome deletion in MDS, expression levels of p62 are often normal
or even increased.172 Normally, p62 helps activate NF-κB by recruitment and activation
of TRAF6. This allows for TRAF6-mediated signaling and activation of NF-κB.172 In
del(5q), where expression of miR-145 and miR-146a are reduced, overexpression of
p62 exacerbates signaling along this pathway.172 Additionally, p62 is a transcriptional
target of NF-κB, illustrating a feedforward mechanism of expression.
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Diaphanous related formin 1 (DIAPH1). Located at 5q31.3, DIAPH1 flanks the
CDR of chromosome 5 in del(5q) MDS.173 DIAPH1 encodes the mDia1 protein with
known roles in actin polymerization and Rho GTPase signaling.173 Importantly, mDia1
has been shown to facilitate activation of a number of innate immune cells, including T
cells, macrophages and neutrophils, linking mDia directly to innate immunity.174-176
Gene expression of mDia1 was reduced approximately 50% in del(5q) MDS patients
compared to normal controls, which is consistent with the degree of knockdown of other
CDR genes.173 In mice, the Drf1 gene encodes for mDia1, and mice heterozygous and
homozygous for Drf1 loss evidence dramatic hematologic defects.173,174 Specifically, the
mice phenocopy human MDS and share features of murine models from other CDR
genes, including Rps14.173,174 In mechanistic murine model studies, loss of mDia
correlated with a significant increase in expression of the TLR4 co-receptor CD14 on
granulocytes.174 These findings were corroborated by flow-based measurements of
CD14 expression, whereby expression was significantly increased in del(5q) patients
compared

to

both

normal

donors

and

patients

with

non-del(5q)

MDS.174

Understandably, overexpression of CD14 results in hypersensitive activation of TLR4 to
agonists, driving aberrant innate immune activation.

Programmed Cell Death

Caspases. Programmed cell death (PCD) describes tightly-regulated, intrinsic
suicide mechanisms utilized by cells during processes related to normal development,
tissue maintenance and even aberrantly in the context of disease, including cancer and
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autoimmune disorders. Apoptosis, described in a later section of this manuscript, is the
best-characterized mechanism of PCD, mainly because it was among the first forms of
PCD identified. As a consequence, substantial work performed in model organisms as
well as in mammalian cells has elegantly deconvoluted the pathway culminating in
apoptotic cell death.177 Nonetheless, other distinct forms of PCD are now recognized,
including autophagy, necroptosis and pyroptosis. Each mechanism has unique
morphological and biological hallmarks, as well as general attributes common to many
PCD pathways. Mechanisms of PCD, as well as a number of inflammatory processes,
are largely mediated by cysteine proteases, called caspases.178
Expansion of the caspase (cysteine-dependent aspartate-specific protease)
family name highlights two key catalytic functions that each member of this enzymatic
family possesses: first, a cysteine-histidine catalytic mechanism and second, specificity
for substrate cleavage after an aspartic acid residue.179,180 Caspases vary in the four
amino acid sequence that dictates substrate recognition, and synthetic peptide inhibitors
to particular caspases are typically created with activity against the respective
recognition motif.181 To date, twelve human caspases have been identified.182,183 The
human genome contains eleven or twelve caspases, the variability a consequence of a
single nucleotide polymorphism in caspase-12, resulting either in a truncated protein or
full-length enzyme. Full-length caspase-12, however, appears confined to populations of
African descent.182
Generally, pro-caspases share a similar structure, each composed of an Nterminal prodomain of variable length and a C-terminal protease domain. Within the
protease domain, a large, p20 subunit is joined to a smaller, p10 subunit by means of a
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short linker region. The p20 subunit has been implicated in catalytic activity, while the
p10 confers substrate specificity.181 Despite this basic organization, caspases can be
categorized into distinct subsets, and historically a number of criteria have been applied
to do so. Notably, and overlooking a few exceptions, caspases segregate into the same
subfamilies, regardless of what factor is used in categorization (Figure 6).
By simpler means, caspases can be classified according to the length of their
prodomains. Contrary to shorter domains, longer prodomains house homotypic proteinprotein interaction motifs of the death domain (DD) superfamily, with caspase activation
and recruitment domain (CARD), death effector domain (DED), and pyrin domain (PYD)
subfamilies.184 These interaction motifs aid in caspase activation by allowing for the
recruitment of pro-caspases to signaling platforms where they undergo proximityinduced auto-activation.181,184 Furthermore, phylogenetic analysis of the complete
mRNA sequence of each caspase establishes three main clusters, which perhaps not
surprisingly, coincide with the general function that each performs. Cluster I contains
caspases with known roles in inflammation, whereas clusters II and III relate to
apoptosis, with the initiator caspases comprising the former group, and the effectors the
latter.
Apoptosis. Apoptotic cell death can be triggered by two distinct pathways, the
intrinsic and extrinsic, both of which converge on a similar signaling event, namely
activation of caspase-3 (Figure 7).105,185 The intrinsic pathway is predominantly
governed by mitochondrial integrity and specifically, the balance between pro- and antiapoptotic Bcl-2 family members. Beyond a particular threshold, cytochrome c is
released from the mitochondria, triggering activation of the initiator caspase-9 which
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Figure 6. Classification of human caspases. A number of classification approaches
exist for classifying the twelve human caspases that have been identified. Generally, the
caspases group into the same sub-families irrespective of the classification approach
employed. The main approaches used to date include general function (inflammation,
initiator, effector), phylogenetic (cluster I, II or III), death domain (DD) interaction motif
(no motif, DED, CARD) and prodomain length (short, long).
subsequently cleaves and activates caspase-3, culminating in apoptosis.186 Conversely,
the extrinsic pathway is dependent on cell extrinsic ligand interaction with plasma
membrane-bound death receptors of the tumor necrosis factor (TNF) superfamily.105,185
Ligation of TNF to TNF receptor (TNFR), TNF-related apoptosis-inducing ligand
(TRAIL) to TRAIL receptor (TRAIL-R) and Fas to Fas receptor (FasR) results in
activation of the initiator caspase-8 and activation of caspase-3.187 Ultimately, apoptosis
is a non-immunogenic mechanism of cell death. Following nuclear condensation and
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Figure 7. Simplistic overview of the intrinsic and extrinsic apoptotic pathways.
The intrinsic apoptotic pathway is largely governed by mitochondrial integrity. (A)
Cellular stresses alter the balance between pro- and anti-apoptotic Bcl-2 family
members, resulting in (B) the release of cytochrome c from the mitochondria. This in
turn triggers activation of caspase-9, an initiator caspase. Caspase-9 will activate
caspase-3, and subsequent signaling events will result in apoptotic death. (C) The
extrinsic apoptotic pathway initiates with external ligation of TNF superfamily surface
receptors, specifically TNFR, TRAIL-R and FasR. (D) Caspase-8 will be cleaved and
activated, resulting in downstream activation of caspase-3 and apoptosis.
DNA fragmentation, cellular contents are packaged into apoptotic bodies which result
from blebbing of the plasma membrane. During this process, cytosolic phosphatidyl
serine is exposed extracellularly, marking the apoptotic bodies for phagocytosis by
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neighboring cells.185 The cell shrinks and is removed without generation of inflammatory
signals.
Autophagy. As an evolutionarily conserved and tightly-regulated process,
autophagy represents a cytoprotective mechanism to maintain cellular energy
homeostasis through the catabolism of long-lived, damaged or excessive proteins or
organelles.188 A conserved set of thirty or more core proteins, the autophagy-related
proteins (Atg), mediate the formation of a double-membrane vacuole, called the
autophagosome, which sequesters cytosolic material to provide energy and recycle
nutrients.188,189 The autophagosome fuses with the lysosome, whereby its contents are
degraded by lysosomal hydrolases, or cathepsins (Figure 8). Autophagy can occur nonselectively as a stress-adaptation mechanism so that the cell can avoid death.
Alternatively, selective or cargo-specific autophagy results in the removal of select
proteins or organelles to control number and ensure quality.189 Mitophagy, for instance,
the autophagic removal of mitochondria, occurs normally during red blood cell
maturation but also occurs upon detection of damaged or noxious mitochondria (Figure
8).189 While autophagy is driven in response to stress, over stimulation can trigger
autophagic, or type II cell death.188
Moreover, interplay exists between autophagy and apoptosis as a means of
regulating cell death. In some contexts, autophagy suppresses apoptotic cell death
providing the cell an opportunity to survive. Conversely, autophagy can also promote
apoptosis. For instance, caspase-mediated cleavage of beclin 1, an essential
autophagic protein, results in its mitochondrial accumulation and accelerated cell
death.190,191 Additionally, the autophagosomal membrane can act as a platform for the
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Figure 8. Autophagy and mitophagy maintain cellular homeostasis through
catabolism. (A) Long-lived, damaged or unnecessary proteins or organelles will be
degraded and recycled through the process of autophagy. (B) Mitophagy, or the
recycling of damaged mitochondria, is a specialized form of autophagy. Both autophagy
and mitophagy initiate with the formation of the (C) autophagosome, a double
membrane vacuole. The autophagosome sequesters the unwanted cellular material,
allowing for (D) lysosomal hydrolases to fuse with the autophagosome and (E) degrade
the contents.
formation of an intracellular death-inducing signaling complex (iDISC), resulting in the
recruitment and activation of caspase-8 to initiate apoptosis.192 Similar to apoptosis, a
complex interaction exists between autophagy and pyroptosis, discussed in a later
section of this manuscript. Under basal conditions, autophagy and pyroptosis are
antagonistic. Reduced autophagic activity and the accumulation of damaged
mitochondria result in release of mitochondrial DNA (mtDNA), thereby activating the
NLRP3 inflammasome to mature caspase-1 and interleukin (IL)-1β.193 In contrast,
formation

of

NLRP3

inflammasome

complexes

triggers

formation

of

autophagosomes.194 In this context, both pro-IL-1β and active NLRP3 inflammasome
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complexes can undergo degradation, illustrating autophagy-mediated dampening of the
inflammatory response.194,195
Historic View of Cell Death in MDS. For over two decades, apoptotic cell death
potentiated by inflammatory cytokines has long been considered a fundamental feature
of MDS. Despite the presence of normo- or hypercellular marrows, MDS patients
typically present with peripheral blood cytopenias involving one or more lineages, an
apparent paradox that in retrospect was reconciled incorrectly by apoptosis. In lowerrisk disease, BM-MNC and CD34+ stem and progenitor cells were shown to exhibit a
heighted rate of proliferation, which occurred concurrently with apoptosis.196,197
Apoptosis was demonstrable in the erythroid, myeloid and megakaryocytic lineages, as
well as in cells of the surrounding stroma by a number of methodologies, including in
situ end labeling of fragmented DNA and annexin-V and PI staining.196-198 Even though
the marrow is highly engaged in DNA synthesis, the rapid turnover of precursor cells
prohibits their maturation and differentiation, thereby accounting for the presence of
cytopenias and the hematopoietic deficiency observed in MDS. Though unknown at the
time, these markers are not faithful and specific indicators of apoptotic cell death and as
a consequence, the principal mechanism of cell death in MDS has been incorrectly
labeled. This was demonstrated by our group in 2016, over twenty years later,
effectively changing the paradigm for these disorders.199 These data are described in
detail in Chapter 2.
Though it is not the predominant programmed cell death pathway, apoptosis
does play a role in MDS, as dysregulation of both the intrinsic and extrinsic pathways
have been reported.105 In early-stage disease, pathobiology favors a pro-apoptotic
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phenotype. Death-inducing ligands TNF-α and Fas are up-regulated, as well as death
receptors and the signaling adaptor Fas-associated death domain (FADD), required for
caspase-8 activation.98,200-202 Additionally, spontaneous mitochondrial release of
cytochrome c into the cytosol is observed in MDS, which is hypothesized to not only
drive activation of caspase-9 and caspase-3 but also to sensitize cells to extrinsicallyinduced apoptosis.203 In late-stage disease, a shift to an anti-apoptotic phenotype is
observed with reduced cell death and increased survival signals. Whereas pro-apoptotic
Bcl-2 family members, like Bad and Bax, are over-expressed in lower-risk patients,
higher-risk patients over-express anti-apoptotic members, including Bcl-2 and BclxL.197,204 NF-κB-dependent up-regulation of FLICE-inhibitory protein (FLIP), a negative
regulator of death receptor signaling, also occurs with disease progression.200,205
Anemia, a consequence of ineffective erythropoiesis, is evident in approximately
90% of MDS patients at some point in the course of their disease.206 Given the role of
mitophagy in normal erythroid maturation and the aberrances observed in the erythroid
compartment in MDS, dysregulated mitophagy has been implicated in MDS
pathobiology.105 Though loss of autophagic pathway genes has not been reported in
MDS to date, a number of genes are lost in AML, suggesting a possible role in disease
progression.207 Cytochrome c oxidase, encoded by mtDNA, is enzymatically involved in
the electron transport chain and iron metabolism in the mitochondria.208 Approximately
75% of MDS patients harbor mutations in cytochrome c oxidase, resulting in the
accumulation of iron in the mitochondrial matrix.208 Accordingly, MDS mitochondria are
characteristically enlarged and iron-laden, and the presence of abnormalities increases
with prognostic risk.209 Pathologic iron accumulation not only increases oxidative stress,

51

leading to increased mutations of both mtDNA and nuclear DNA, but exacerbates
impaired mitochondrial integrity and homeostasis.209 Indeed, enhanced mitophagy is
manifest in early-stage disease.210 MDS-derived erythroblasts undergo mitophagy
earlier than normal erythroid progenitors, evidenced by five-time greater formation of
iron-positive autophagosomes.210 Though mitophagy may be a protective mechanism in
lower-risk disease to clear iron-laden mitochondria and safeguard against further
genetic damage, activation of this mechanism occurs at the expense of the normal
erythroid program.

Pyroptotic Cell Death

History and Hallmarks of Pyroptosis. First identified nearly two decades ago,
pyroptosis was described as a caspase-1-dependent necrosis.211 At the time, Brennan
and Cookson had classified the death of macrophages post Salmonella typhimurium
infection as a more specialized, albeit unusual, form of necrosis.211 However, the
inherent dependence upon caspase-1 warranted a distinct cell death designation, one
that encompassed the inflammatory, but more importantly, the programmed nature of
this pathway. Just a year after their initial discovery, the pair amended their conclusion
and coined the term pyroptosis, whose roots stem from the Greek word ‘pyro,’ meaning
fire, and ‘ptosis,’ a falling.212 Today, pyroptosis is regarded as a pro-inflammatory
programmed cell death mechanism mediated by the formation of cytosolic
inflammasome complexes which function to catalyze maturation of caspase-1, resulting
in caspase-1-dependent signaling events that culminate in cytolysis (Figure 9).
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Figure 9. The hallmarks of pyroptosis. While some hallmarks of pyroptosis are
shared with apoptotic cell death, most are uniquely specific, including activation of
NLRP3 inflammasome complexes, caspase-1-dependency and cell lysis.

Of note, pyroptosis does share features characteristic of apoptosis, which may
be attributable to the fact that in additional to cleavage of other pro-caspases, including
caspase-4, -5 and -7, caspase-1 can activate caspase-3, the canonical apoptotic
caspase.213 While also common to apoptosis, nuclear condensation and DNA
fragmentation occur but through a distinct mechanism, namely by means of a caspase1-activated nuclease.214 Furthermore, poly(ADP-ribose) polymerase 1 (PARP1)
cleavage is similarly observed in both cell death mechanisms. During pyroptosis,
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caspase-1 cleaves caspase-7, which translocates into the nucleus to cleave PARP1.215
PARP1, which serves to negatively regulate certain NF-κB-specific gene targets, is
subsequently released, leading to transcription induction.215
Generally, spillage of intracellular content into the extracellular environment,
membrane pore formation, release of activated pro-inflammatory cytokines and cell lysis
speak to the many distinct facets of pyroptosis that contribute to its inflammatory
nature.213,214 At earlier time points, caspase-1 mediates formation of plasma membrane
pores, which measure approximately 15-20 nanometers in diameter.214 These pores
compromise membrane integrity, resulting in the dissipation of cellular ionic gradients, a
net increase in osmotic pressure, intake of water and cell swelling.214,216 Additionally,
activation of the cell surface cation channel transient receptor potential melastatin 2
(TRPM2) may contribute to cell swelling during pyroptosis. TRPM2 is a calcium
permeable channel expressed by a number of cell types, but most importantly,
hematopoietic cells including CD34+ HSPC and immature erythroid and myeloid
cells.217 Activation of TRPM2 by TNF-α or oxidative stress results in a significant
increase in the intracellular concentration of Ca2+, leading to cell volume expansion and
increased cell death.218 Reduced viability was attributed to cleavage of both extrinsic
and intrinsic apoptotic caspases, like caspase-7 and caspase-3, both of which are
known to be cleaved and activated by caspase-1.213,218 These findings suggest that in
the context of oxidative stress or excess inflammatory cytokines, cell death of
hematopoietic cells may be regulated in part by activation of TRPM2.218 Accordingly,
mice deficient in both alleles of Trpm2 demonstrate not only reduced calcium influx and
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signaling, but significant reductions in caspase-1 activation and IL-1β production.217
TRPM2

activation

and

subsequent

calcium

mobilization

may

contribute

to

inflammasome activation, leading to maturation of caspase-1. Irrespective of the
mechanism resulting in cell swelling, both apoptosis and pyroptosis are marked by
compromised membrane integrity. Historically, annexin-V and 7-AAD positivity have
labeled cells as apoptotic. However, cells undergoing pyroptosis additionally stain
positive for these same markers,211 illustrating that caution should be exercised when
identifying and characterizing a particular cell death mechanism.
In accordance with one of its central roles in pyroptosis, specifically the
maturation of pro-inflammatory cytokines, caspase-1 was initially identified for its ability
to convert pro-interleukin-1β (pro-IL-1β) to its mature, active form.219,220 Actually, until a
system of caspase nomenclature was implemented, caspase-1 was known as ICE, or
interleukin-1β-converting enzyme, highlighting the importance of this particular role.
Furthermore, caspase-1 catalyzes maturation of pro-IL-18, and together IL-1β and IL-18
represent the prototypical cytokines that are activated during pyroptosis.221 These proinflammatory cytokines are released following cell lysis, or execution of the pyroptotic
program. However, secretion also occurs prior to cell lysis, specifically through nonconventional secretory mechanisms.214 As both IL-1β and IL-18 are leaderless
cytokines, their release does not follow the conventional endoplasmic reticulum (ER)Golgi apparatus pathway.222 Though the mechanism is not entirely understood, these
pro-inflammatory targets, in addition to seventy-five other proteins, are targeted for nonconventional secretion by active caspase-1.214,223 As potent inflammatory mediators,
expression of IL-1β and IL-18 is tightly regulated to prevent unwarranted and damaging
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inflammation. Foremost, expression of pro-IL-1β and pro-IL-18 is dependent on NF-κB
activation for transcriptional priming.213 Next, maturation occurs only following cleavage
of the cytokine prodomain by active caspase-1.213
Indeed, many of the hallmarks of pyroptosis can be attributed to processes that
occur as a result of caspase-1 activation (Figure 9). Inasmuch as pyroptosis is
dependent on caspase-1, it remains as dependent on inflammasome complexes, the
functional complex that matures pro-caspase-1 to drive cell demise.
NLR Proteins. The nomenclature of the nucleotide-binding oligomerization
domain (NOD)-like receptors (NLRs) has since been reformed for unity and clarity.224
Named for the presence of two receptor family-defining domains, the NLRs are now
more accurately known as the nucleotide-binding domain and leucine-rich repeat
containing receptors (NLRs).224 These germline-encoded receptors belong to the
pattern recognition receptor family (PRR) with central roles in innate immunity.
Specifically the NLRs function to recognition both microorganism and host-derived
danger signals, or pathogen-associated molecular patterns (PAMPs) and dangerassociated molecular patterns (DAMPs), respectively.225 Subsequent signaling results in
activation of both the innate and adaptive immune responses. The twenty-two known
members of the NLR family share structural similarities and can generally be divided
into three main parts.226 First, the N-terminal domain is variable and mediates proteinprotein interactions.226 In total, four different domains exist, namely the acidic
transactivating domain, the Baculovirus inhibitor of apoptosis repeat (BIR) domain, the
caspase activation and recruitment domain (CARD) and the pyrin domain (PYD).226
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Downstream signaling is largely dependent on the N-terminus, as the domains
participate in key homotypic protein-protein interactions.226 Following activation,
receptor oligomerization occurs through the NACHT domain located centrally on the
NLR.225 Lastly, the C-terminus contains a leucine-rich repeat (LRR) domain responsible
for PAMP and DAMP detection.225 The new system of nomenclature divides the NLR
family into five main subfamilies according to each receptor’s variable N-terminal
domain, specifically, (1) NLRA, acidic transactivating domain containing, (2) NLRB, BIR
domain containing, (3) NLRC, CARD domain containing, (4) NLRP, PYD domain
containing and (5) NLRX, unclassifiable N-terminal domain (Figure 10).224 Activation of
NLR signaling is highly interactive with and complementary to TLR signaling, and
certain signaling intermediates overlap between the two pathways.226 Typically three
targets may become activated following NLR pathway activation, including NF-κB,
MAPKs and caspase-1.226 Only five NLR family members function to mature procaspase-1 to its active form, and these do so through self-oligomerization into large,
multi-protein complexes called inflammasomes.226
Inflammasome Complexes and Canonical Activation and Signaling. Critical
to innate immunity and the generation of an immune reaction is the efficient detection of
pathogens that have gained entry into the cytosol, as well as the recognition of hostderived signals of danger or damage. Five specific NLR family members mediate these
detection events, namely NLRC4, pyrin (also known as marenostrin or TRIM20), absent
in melanoma 2 (AIM2), NLRP1 and NLRP3.227 Upon detection of an activating signal
within the cytosol, these NLR members self-oligomerize into wheel-like macromolecular
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complexes called inflammasomes, which are named for the NLR protein by which they
form (Figure 11A).227

Figure 10. Domain organization of the nucleotide-binding oligomerization domain
(NOD)-like receptors (NLRs). The NLRs are classified into five distinct families
according to the variable N-terminal domain possessed by each receptor. Four distinct
N-terminal domains exist, namely CARD (caspase activation and recruitment domain),
AD (acidic transactivating), BIR (Baculovirus inhibitor of apoptosis repeat) and PYD
(pyrin domain). Other abbreviations include NACHT (NAIP, CIITA, HET-E, and TP-1),
NAD (NACHT-associated domain), LRR (leucine-rich repeat), FIIND (function to find)
and X (unknown).

In 2002, Martinon et al. identified a multi-protein complex responsible for
activating caspase-1, producing mature pro-inflammatory cytokines and mediating a
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cytolytic, inflammatory cell death, called pyroptosis.228 This complex was coined the
inflammasome, and the group specifically identified NLRP1.228 While mice have three
paralogs of Nlrp1, namely Nlrp1a-1c, the human genome encodes a single NLRP1
gene.229 A variety of PAMPs activate NLRP1, including anthrax lethal toxin, muramyl
dipeptide, and even metabolic changes like reductions in intracellular ATP levels.229
Perhaps most relevant for this manuscript, NLRP1 expression is high within the
hematopoietic compartment, in both the myeloid and lymphoid lineages.230 Masters et
al. demonstrated that a point mutation in Nlrp1a (Q593P), resulting in a constitutively
active inflammasome complex, leads to aberrant activation of caspase-1.231
Homozygous Nlrp1Q593P/Q593P mice succumb to a highly lethal inflammatory phenotype,
with death ensuing at approximately 4 months of age.231 Prolonged activation of Nlrp1
resulted in severe cytopenias, aberrant myeloid lineage maturation, immune
suppression and HSPC death.231 Notably, this phenotype was also evidenced in mice
subjected to sustained hematopoietic stress.231 Together, these data suggest that the
NLRP1 inflammasome may play an important role in aberrant hematopoiesis.
Since the discovery of NLRP1, four additional inflammasome complexes have
been identified. Not only do the activating signals vary between inflammasome
complexes, but so too does expression, suggesting that particular complexes are most
pertinent in certain tissues.230 The absent in melanoma 2 (AIM2) inflammasome binds
cytoplasmic double stranded DNA (dsDNA) and some dsDNA viruses through its
oligonucleotide/oligosaccharide-binding domain.232,233 This HIN-200 domain is unique to
the AIM2 inflammasome as compared to other inflammasome-forming NLR family
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members. Activation of caspase-1 follows AIM2PYD-dependent recruitment of ASC.232,233
Moreover, the NLRC4 inflammasome responds to a variety of bacterial components,
including flagellin, Gram-negative bacteria-derived needle proteins and type III secretion
system (TTSS) rod components.234 NLRC4 inflammasome assembly requires a physical
association with NAIP in humans, and NAIP2 and NAIP5 in mice, which function as the
sensor of these cytoplasmic bacterial products.234 The binding of NAIP members to
NLRC4 results in inflammasome assembly, caspase-1 activation and the generation of
an immune response.234 Furthermore, pyrin, also known as TRIM20, is the most
recently discovered inflammasome complex.235 Caspase-1 is generated in response to
the pyrin-dependent detection of bacterially-mediated modifications of Rho GTPase
family members.235 More specifically, monoglycosylation of Rho family members on a
particular threonine residue prevents GTP binding, resulting in Rho inactivation.235
Interestingly, the PRY/SPRY domain of pyrin that is located at its N-terminus, interacts
directly with NLRP1, NLRP3 and pro-caspase-1.236 This interaction mediates the
autophagy-specific degradation of these inflammasome components, illustrating direct
regulation of one inflammasome complex over another.236 Lastly, the best characterized
inflammasome-forming protein is undoubtedly NLRP3, which will be discussed in more
detail in another portion of this manuscript.
Inflammasome complexes function to drive the maturation of caspase-1 and the
generation of pro-inflammatory cytokines IL-1β and IL-18.227,237 Pro-caspase-1, which
contains a caspase recruitment domain (CARD), will be recruited to the site of the
assembled inflammasome complex through homotypic death domain fold motif
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interactions. Specifically, the CARD and pyrin domain (PYD) motifs are important for
caspase-1 activation.238 NLR proteins that contain a CARD domain, specifically NLRC4
and NLRP1, can directly recruit pro-caspase-1 through NLRCARD and pro-caspase-1CARD
interactions

(Figure

11B).239

Interesting,

pro-caspase-1

polymerization

in

the

inflammasome was shown to occur through the interaction of CARD domains, leading to
enhanced cleavage and proteolytic activity.239
Alternatively, the other inflammasome forming proteins, specifically pyrin, AIM2
and NLRP3, lack a CARD domain and instead express a PYD motif.239 These receptors
rely on the adaptor protein apoptosis-associated speck-like protein containing a CARD
(ASC) (Figure 11C).238 Specifically, the PYD-only receptors and NLRP1, which contains
both a CARD and a PYD domain, use an ASC-dependent mechanism for
inflammasome oligomerization and caspase-1 activation.238 In support, mice deficient in
ASC mature significantly less active caspase-1 and IL-1β than both wild-type and
heterozygous counterparts.240 Murine ASC is highly homologous to human ASC, both in
structure and function, suggesting evolutionary conservation.241 ASC has a bipartite
domain structure, with an N-terminal PYD domain and a C-terminal CARD domain.238
The active NLR receptors recruit ASC through NLRPYD and ASCPYD interactions,
resulting in the nucleation and polymerization of ASC at the site of the inflammasome
complex (Figure 11D).239 The PYD-PYD interactions are rather rigid in nature, allowing
for the subsequent nucleation and polymerization of pro-caspase-1 (Figure 11D).241
Specifically, ASC will recruit pro-caspase-1 to the inflammasome complex, whereby
ASCCARD

and

pro-caspase-1CARD domain

interactions
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allow

for

pro-caspase-1

nucleation.239 The CARD-CARD interactions do maintain more flexibility than the rather
inflexible PYD cores, which helps regulate the density of pro-caspase-1 at the site of
activation.241 Once in appropriate proximity, pro-caspase-1 will auto-cleave and activate,
resulting in downstream signaling. Both the ASC-dependent and ASC-independent
mechanisms of caspase-1 activation fall under canonical inflammasome signaling.

Figure 11. Activation of pro-caspase-1 by inflammasome complexes requires
ASC-dependent or ASC-independent nucleation and polymerization. (A) Depicted
in the schematic is the NLRP3 inflammasome. Once an activating PAMP/DAMP signal
is detected, the inflammasome will oligomerize into a cytosolic, wheel-like complex
called the inflammasome. (B) Inflammasome-forming NLRs that contain a CARD
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CARD

CARD

domain can directly recruit pro-caspase-1 through NLR
and pro-caspase-1
interactions. The domain structure of NLRP1 is depicted. As NLRP1 additionally
contains a PYD motif, it can also recruit pro-caspase-1 via the adaptor protein ASC. (C)
The other inflammasome forming proteins, namely pyrin, AIM2 and NLRP3, which is
depicted in the schematic, contain a PYD domain motif only. These receptors recruit
pro-caspase-1 indirectly through ASC, which subsequently recruits pro-caspase-1
CARD
CARD
through ASC
and pro-caspase-1
homotypic interactions. (D) NLRP3-mediated
activation of pro-caspase-1 is detailed here. Activated NLRP3 recruits ASC through
PYD
PYD
NLRP3
and ASC
domain interactions. ASC will nucleate and polymerize into a
filamentous structure that is rather rigid in nature. Next, ASC will recruit pro-caspase-1
through CARD-CARD domain interactions, leading to nucleation of pro-caspase-1. As
the homotypic CARD interactions are more flexible, they help regulate the density of
pro-caspase-1, leading to facilitated and enhanced auto-cleavage and activation of the
caspase.
Non-Canonical Inflammasome Signaling. Most basically, the processing of
pro-caspase-1

and

the

generation

of

pro-inflammatory

cytokines

through

inflammasome-dependent mechanisms defines canonical inflammasome signaling.
Approximately five years ago, the non-canonical inflammasome was identified in mice
through a series of experiments using caspase-11-/- BM-derived macrophages
(BMDM).242 Caspase-11 activation drives two central signaling events that together
characterize the non-canonical inflammasome.242 Specifically, activation of caspase-11
results in (i) NLRP3-independent pyroptotic cell death and (ii) concurrent NLRP3dependent activation of caspase-1, which is necessary to generate the mature forms of
IL-1β and IL-18 (Figure 12).242 Murine caspase-11-directed signaling is matched in
humans by its pro-inflammatory caspase orthologs, namely caspase-4 and caspase5.243 Furthermore, in myeloid cells, caspase-4, -5 and -11 were shown to be activated in
response to gram-negative bacteria whereby they detect the presence of cytoplasmic
LPS.243,244 Detection of LPS is mediated by the caspase CARD domain, leading to auto-
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activation and dimerization of the caspase into its mature, proteolytically active
form.243,244 Alternative activators of caspase-4, -5 or -11 are still under investigation.
In canonical inflammasome signaling, activation of caspase-1, the initiator
caspase, stems from NLR-dependent PAMP/DAMP detection, leading to inflammasome
complex assembly and activation. Contrary to this mechanism, in non-canonical
inflammasome signaling, caspase-4, -5, or -11 function as both the PAMP/DAMP
detection ‘receptor’ as well as the initiating caspase.243,245 Although these caspases are
capable of directly triggering pyroptosis, they are unable to mature pro-IL-1β and IL-18
independently. Instead, using potent NLRP3 activators, like nigericin, as well as small
molecule inhibitors of NLRP3, specifically compound MCC950, Baker et al. reported that
cytokine maturation occurs downstream of caspase-4, -5 or -11 activation through an
NLRP3-dependent mechanism that results in activation of caspase-1 followed by
cytokine processing.245 More specifically, the dramatic drop of intracellular potassium
concentration triggers NLRP3 inflammasome assembly and activation (Figure 12).246,247
Whether capase-4, -5 or -11 directly or indirectly trigger changes in potassium
concentration remains to be determined.246,247
In non-canonical inflammasome signaling, caspase-4-, -5- or -11-dependent
induction of pyroptotic cell death occurs through gasdermin D (GSDMD) cleavage and
activation (Figure 12).244,248 GSDMD belongs to the gasdermin family of proteins whose
physiological roles are still poorly understood.248 Murine and human GSDMD maintain
approximately 72% sequence homology, which results in similar functionality.248 Murine
GSDMD is cleaved by active inflammatory caspases after amino acid 276 and human
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GSDMD after 275.248 This results in two GSDMD cleavage products, namely the
inactive C-terminal (~22 kDa) and the active N-terminal (~31 kDa) fragments.244
Whereas full-length (~53 kDa) GSDMD and the C-terminal fragment cannot induce
pyroptosis, the N-terminal fragment drives cell death.244 Intramolecular interactions
between the C-terminal and N-terminal portion of pro-GSDMD maintain the protein in an
inactive state.248 Cleavage relieves this suppressive mechanism, releasing the Nterminal fragment.248 The N-terminal p30 fragment serves as the executioner
responsible for membrane pore formation. Recent investigations have shown that the
GSDMD N-terminal p30 fragment oligomerizes before binding to phosphatidylinositol
phosphates and phosphatidyl serines restricted to the cell membrane inner leaflet to
create non-selective membrane pores with an inner diameter of 10-20 nanometers in
size.249-252 Interestingly, GSDMD has been identified as a substrate of caspase-1,
suggesting that the physiological functioning of GSDMD overlaps between canonical
and

non-canonical

inflammasome

signaling.244

A

summary

of

non-canonical

inflammasome signaling is found in Figure 12.

The NLRP3 Inflammasome

NLRP3 Agonists. Undoubtedly, NLRP3 is the best characterized and most
highly understood inflammasome-forming protein. Expression of NLRP3 largely
overlaps with NLRP1 and may be found in numerous cell types.230 Most importantly,
NLRP3 is readily expressed in the myeloid and lymphoid lineages of the hematopoietic
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system.230 Over a decade ago, murine BM-derived macrophages deficient in Nlrp3 were
shown to lack caspase-1 activation.253 These data elegantly illustrate, from the most
basic of viewpoints, that NLRP3 functions to activate caspase-1, elaborate inflammatory
cytokines and generate an effective and potent innate immune response.253
Nevertheless, many questions remain regarding the complete biology governing the
functionality of this receptor, including its mechanism of activation, mode of agonist
sensing, regulation and therapeutic targeting, among others.

Figure 12. The non-canonical inflammasome signaling pathway. (A) Non-canonical
signaling begins with the PAMP/DAMP-specific detection by pro-caspase-4, -5 or -11.
Detection is mediated by direct interaction of the PAMP/DAMP with the CARD domain
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of the caspase, leading to caspase dimerization and activation. (B) Through a direct or
indirect mechanism, active (a)-caspase-4, -5 or -11 mediate a dramatic reduction in
intracellular potassium concentration. This serves as a trigger for (C) NLRP3
inflammasome activation. The inflammasome mediates activation of pro-caspase-1,
which subsequently matures pro-IL-1β and pro-IL-18, leading to cytokine release. (D)
Concurrently, a-caspase-4, -5 or -11 cleave gasdermin D (GSDMD), which releases the
active N-terminal fragment. This fragment is necessary to signal pyroptotic cell death.

With respect to activation signals, NLRP3 is unique from other inflammasomeforming

proteins.

Whereas

other

complexes

mainly

detect

PAMPs,

NLRP3

predominantly detects DAMP signals.254 Furthermore, NLRP3 detects a very extensive
set of both physically and structurally diverse and dissimilar agonists, which is highly
unusual compared to the activators detected by other complexes.254,255 Generally,
NLRP3 is activated by three types of agonists, including extracellular microbial products
or toxins (LPS, nucleic acids, muramyl dipeptide, nigericin), environmental irritants and
inorganic crystals (asbestos, silica, alum), and DAMPs (ROS, ATP, hyaluronan,
S100A9).254,255 The mechanism by which such diverse proteins and products activate
NLRP3 is still largely unknown and represents one of the most important unanswered
questions in the field to date.
NLRP3 Inflammasome Activation: Signal 1. It is generally accepted that
NLRP3 inflammasome activation requires two steps, namely an initiating, priming signal
followed by a secondary, activation signal.255,256 This two-step mechanism is conserved
between mice and humans, and represents just one of many regulatory mechanisms
that prevent unwarranted and damaging inflammasome activation.256 Surface and
cytoplasmic

receptor

signaling

culminating

in

NF-κB

activation

primes

the

inflammasome and functions to provide signal 1.255 In the absence of transcriptional
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priming, NLRP3 will generate an inadequate or simply no inflammatory response, even
in the presence of an appropriate signal 2.255 IL-1R, CD33, various TLRs and NLRs
represent just a few receptors that can prime the inflammasome.255 As basal cellular
concentrations of both NLRP3 and pro-IL-1β are insufficient for the generation of an
inflammasome-mediated immune response, NF-κB-dependent transcriptional priming
must occur prior to the detection of signal 2.256 Conversely, levels of pro-caspase-1, IL18 and ASC are basally sufficient, and therefore do not require priming.255 Notably, NFκB-dependent

priming

of

NLRP3

occurs

upstream

of

ASC

recruitment,

as

inflammasome activation fails to occur in the context of ASC overexpression.256
Once primed, NLRP3 is maintained in an ubiquitinated, auto-repressed and
inactive configuration within the cytosol.254,255 This additional regulation of NLRP3 at the
post-transcriptional level prevents exposure of the nucleotide-binding domain (NBD) of
NLRP3, effectively preventing oligomerization into mature inflammasome complexes.254
Upon detection of an appropriate activating signal, the leucine-rich repeat (LRR) domain
of NLRP3 is deubiquitinated by BRCA1-BRCA2-containing complex 3 (BRCC3) in mice,
and BRCC36 (also known as BRCC3) in humans.257 Subsequently, NLRP3 opens its
configuration permissive to oligomerization. While transcriptional priming, or signal 1,
occurs independently of BRCC3, it is indispensable for NLRP3 inflammasome activation
following detection of signal 2.257
NLRP3 Inflammasome Activation: Signal 2. Given that NLRP3 is activated by
such a diverse set of agonists, it is unlikely that direct binding is responsible for
inflammasome activation.254 Generally, three hypotheses exist for signal 2, or the signal
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that induces NLRP3 activation and oligomerization into the inflammasome complex.254
Foremost, reactive oxygen species (ROS) have been shown to induce both priming and
activation of the NLRP3 inflammasome.258 This can occur through an NADPH oxidase
(NOX)-dependent mechanism.258 The NOX proteins, of which there are six homologs in
humans, are ubiquitously expressed and function to generate superoxide and ROS by
the transfer of electrons across the plasma membrane.259 Both siRNA-directed silencing
as well as pharmacologic inhibition of NOX using diphenyleneiodonium (DPI) results in
a significant reduction in NLRP3 priming, caspase-1 activation and IL-1β production.258
Using a yeast two-hybrid approach, thioredoxin-interacting protein (TXNIP) was
shown to bind to and negatively regulate thioredoxin (TRX), a protein with roles in
multiple biological processes.260 Binding of TXNIP to TRX is redox-dependent, as TRX
is oxidized in the presence of high ROS concentration, liberating TXNIP from TRX.261
Subsequently, TXNIP was shown to bind to the LRR of NLRP3, resulting in
inflammasome assembly and activation.261 Suppression of TXNIP in the THP-1 cell line
using siRNAs resulted in a significant reduction in caspase-1 activation and IL-1β
secretion.261 Additionally, BMDM from Txnip-/- mice corroborate these findings,
illustrating that the TXNIP/NLRP3 axis is significant in vivo and functionally activates
NLRP3 downstream of ROS.261 Interestingly, in a model of type 2 diabetes, Masters et
al. was unable to demonstrate neither binding of TXNIP to NLRP3, nor a role of TXNIP
in the maturation of IL-1β.262 Perhaps these conflicting data may be reconciled by the
possibility of cell- or context-specific mechanisms leading to NLRP3 activation
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downstream of secondary activating signals. To date, the precise mechanism leading to
NLRP3 inflammasome activation downstream of ROS production is still unknown.
Notably, in the context of MDS, genomic alterations increase ROS in a NOXdependent manner.263 The extent of ROS production increases with the number of
mutations, as well as with disease progression.263 Moreover, the DAMP proteins
S100A8 and S100A9, which have been shown to be increased in lower-risk MDS,140 are
scaffold proteins for the assembly and activation of the NOX complex within
neutrophils.264,265 S100A8/A9 physically interact with cytosolic NOX complex members,
resulting in enhanced oxidase activity and enzyme kinetics.265 Studies in PB
mononuclear cells (PB-MNC) demonstrated that S100A8/A9 induce NF-κB-mediated
transcriptional priming of NLRP3 and pro-IL-1β via NOX-dependent generation of
ROS.266 Additionally, treatment of PB-MNC with S100A8/A9 increased NLRP3
inflammasome activation, with subsequent caspase-1 activation and IL-1β secretion.266
Lastly, mitochondria-derived ROS also activate NLRP3, resulting in caspase-1
activation and cell death.267,268
Within the cytosol, ROS can trigger permeabilization of the mitochondrial
membrane as well as of the lysosomal membrane, which both trigger NLRP3
inflammasome activation.267 Indeed, NLRP3 appears to be a sensor of organelle
dysfunction.267,269 A lysosome/cathepsin B-dependent mechanism represents the
second hypothesis allowing for NLRP3 inflammasome activation. In PB-MNCs,
phagocytosis of crystalline substances, like silica and alum, results in lysosomal
swelling, damage and spillage of lysosomally-contained material into the cytosol.269 This
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results in the release of the lysosomal protease cathepsin B, which by a direct or
indirect mechanism activates the NLRP3 inflammasome, triggering caspase-1 activation
with IL-1β secretion.269 A conserved mechanism is evident in Alzheimer’s disease,
contributing to disease pathobiology.270 Phagocytosis of amyloid β, an endogenous
DAMP peptide, by microglial cells damages lysosomes, resulting in cathepsin B release
and activation of the NLRP3 inflammasome complex.270 Undoubtedly, phagocytosis of
other DAMPs capable of triggering lysosomal membrane permeabilization and spillage
of lysosomal contents into the cytosol would also activate NLRP3.
Lastly, the final hypothesis for NLRP3 inflammasome activation is characterized
by upstream changes in intracellular cation concentrations.254 Potassium efflux may be
elicited by a variety of NLRP3 agonists, resulting in NLRP3 inflammasome formation,
caspase-1 activation and IL-1β generation.271 The opening of ion channels or
alternatively, the formation of pores by bacterial or pathogenic toxins likely mediates K+
efflux.254,271 Conversely, increased cytoplasmic concentration of Ca2+ modulates NLRP3
inflammasome activation.272 ER stress frequently results in rapid increases in Ca2+,
recently identified to trigger inflammasome formation.272 Moreover, lysosomal
membrane permeabilization as well as overt rupture function to mobilize Ca2+, which
can mediate subsequent plasma membrane pore permeability and the efflux of K+.271,272
In this way, both K+ and Ca2+ activate NLRP3 inflammasome complexes at the level of
signal 2.
Endogenous Regulation of the NLRP3 Inflammasome. In addition to the
requisite two signals necessary for NLRP3 inflammasome assembly and activation, a
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number of decoy proteins have originated from gene duplication events that further
regulate NLRP3 activation.273-277 To start, three genes have originated adjacent to one
another on chromosome 11q22, near caspase-1, and serve as negative regulators of
caspase-1-dependent activation of IL-1β.273-275 Specifically, ICEBERG, inhibitory CARD
(INCA) and CARD only protein (COP) share 52%, 81% and 97% sequence identity to
the CARD domain, located within the prodomain of pro-caspase-1.274,275 These proteins
are induced by pro-inflammatory stimuli, resulting in their expression and the
subsequent extinction of caspase-1-dependent responses.273-275 Through directly
binding to the prodomain of pro-caspase-1, ICEBERG, INCA and COP inhibit the
activation of caspase-1 by blocking dimerization, which is required for conversion of the
zymogen to its active form.273-275 In this way, these endogenous inhibitors prevent
unwarranted, exacerbated and accidental caspase-1 activation and limit IL-1β-induced
inflammation.273-275
Additionally, pyrin-domain (PYD) only protein 1 (POP1) represents an alternative
negative regulator of NF-κB, ASC and NLRP3.276,277 POP1 is thought to have generated
from gene duplication events, as it shares approximately 88% sequence identity to the
PYD of the NLRP3 adaptor protein ASC. Foremost, POP1 directly interacts with the IKK
complex responsible for activating NF-κB in response to cytokine stimulation.276 This
results in the inhibition of NF-κB activation, as well as the repression of NF-κB-inducible
target genes.276 Moreover, POP1 directly binds to ASCPYD, which blocks ASCPYD and
NLRP3PYD domain interactions, effectively preventing NLRP3 assembly, ASC nucleation
and polymerization, caspase-1 activation and the release of mature IL-1β and IL-18.277
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While these negative regulatory mechanisms function to limit and fine-tune
inflammasome-dependent responses, excessive and prolonged activation of the NLRP3
inflammasome has been pathobiologically implicated in a wide range of autoimmune
diseases and inflammatory conditions.254
Evidence of Pyroptosis in the MDS Literature. Over two decades ago, Mundle
et al. demonstrated that approximately 40% of lower-risk MDS cases demonstrate
significantly increased IL-1β secretion within the bone marrow, which positively
correlated with the amount of DNA fragmentation.99 More importantly, treatment of BMMNC with a caspase-1-specific inhibitor reduced DNA fragmentation and IL-1β
secretion, implicating caspase-1 activation in the cell death observed in MDS.99 In
corroboration of these findings, caspase-3 activation was shown to occur downstream
of caspase-1 activation in MDS, illustrating a sequence of caspase activation consistent
with pyroptosis rather than apoptosis.278 More recently, a non-canonical role for NLRP3
was described in regulating receptor-mediated apoptosis in epithelial cells. In response
to TNF-α/TNFR signaling, NLRP3, ASC and pro-caspase-8 are recruited to the
mitochondria where NLRP3-dependent processing of pro-caspase-8 occurs.279 As TNFα is overexpressed in MDS and the extrinsic apoptotic pathway is activated, it is likely
that such a mechanism additionally occurs within this context.
Beyond basal activation, in overstimulated or overstressed conditions, autophagy
synergizes with inflammasome activation to augment the inflammatory response.280
Accordingly, non-canonical roles of autophagy-related proteins are continually being
described, including atypical roles in antigen presentation and non-conventional
secretion.188 Stimulation of autophagy in the context of NLRP3 inflammasome activation
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results in co-localization of autophagosomes with IL-1β and HMGB1. Subsequently,
through non-conventional secretion, the autophagic machinery mediates secretion of
inflammasome substrates, like IL-1β and IL-18, as well as potent DAMPs into the
extracellular milieu.281 As a consequence of mitochondrial damage, mitochondrialderived ROS are increased, which can enhance NLRP3 inflammasome activation and
thereby activation of caspase-1 and generation of IL-1β.268 These findings help
vindicate why mitochondrial dysfunction is often linked to inflammatory disease, both of
which are manifest in MDS. Furthermore, in the context of oxidative stress, caspase-1
augments mitophagic flux by promoting up-regulation of beclin 1.282 A recent publication
illustrated that both mRNA and protein expression of beclin 1 are increased in lower-risk
MDS.283 Although the findings in this manuscript are the first to link NLRP3
inflammasome activation and pyroptotic cell death to the pathobiology of MDS, the
literature supports, both directly and indirectly, the role of caspase-1 and NLRP3
activation in these disorders.

β-Catenin

Canonical Wnt/β-Catenin Signaling. The canonical Wnt/β-catenin signaling
pathway, which was first identified in Drosophila, is implicated in supporting selfrenewal, proliferation and cell survival.284 This is accomplished through the activation of
β-catenin, which will translocate into the nucleus and bind transcriptional activators,
resulting in gene transcription.284 Understandably so, mutations in this signaling
pathway are commonly observed in human cancer.284
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In the basal state, β-catenin activation is repressed by the β-catenin destruction
complex. The complex consists of two tumor suppressors, Axin and adenomatous
polyposis coli (APC), as well as two constitutively active serine/threonine kinases, or
casein kinase 1 (CK1) and glycogen synthase kinase 3 (GSK3).284 Axin, the main
scaffold for the destruction complex, directly interacts with β-catenin. CK1 and GSK3
will deliver phosphorylation marks on β-catenin, resulting in its recognition by the E3
ubiquitin ligase, beta-transducin repeat containing protein (β-TrCP).284 Ubiquitination of
β-catenin by β-TrCP targets it for proteasomal degradation, effectively eliminating βcatenin-mediated transcription effects in the absence of appropriate pathway activation.
Wnt/β-catenin pathway inactivation is summarized in Figure 13A-D.
Conversely, canonical Wnt/β-catenin signaling initiates with the binding of a Wnt
ligand to a transmembrane receptor complex consisting of Frizzled (Fz) and low-density
lipoprotein receptor-related protein 5 (LRP5) or 6 (LRP6).284 Next, Dishevelled (Dvl) will
bind the cytoplasmic part of Fz, allowing for recruitment of Axin to the LRP5/6 tail.284
These recruitment events sequester Axin, preventing the formation of the destruction
complex and subsequently allow for the accumulation of cytoplasmic β-catenin.284
Ultimately, β-catenin translocates into the nucleus and binds transcriptional activators,
like T cell factor (TCF) and lymphoid enhancing factor (LEF), resulting in gene
transcription.284 The signaling cascade resulting from Wnt/β-catenin pathway activation
is summarized in Figure 13E-G. Though β-catenin activation vastly alters gene
expression, cyclin D1 and c-myc are among the best characterized downstream targets.
Notably, in a cohort of sixteen MDS patients, approximately 90% of all CD34+ BM-MNC
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Figure 13. Canonical Wnt/β-catenin signaling depicted in the context of pathway
inactivation and activation. The signaling events resulting from the lack of a pathway
activating signal are shown in A-D. (A) Without ligand binding to the transmembrane
Frizzled (Fz) or LRP5/6 receptors, the (B) β-catenin destruction complex, consisting of
Axin, APC, CK1 and GSK3, will initiate degradation of β-catenin. The serine/threonine
kinases CK1 and GSK3 phosphorylate β-catenin, which is recognized by (C) β-TrCP, an
E3 ubiquitin ligase. Ubiquitination of β-catenin targets it for proteasomal degradation.
(D) β-catenin-mediated transcriptional activation of TCF/LEF controlled genes is
repressed. The signaling events resulting from pathway activation are shown in E-G. (E)
Binding of a Wnt ligand to Frizzled/LRP5/6 allows for recruitment of Dishevelled (Dvl)
and Axin to the cytoplasmic tails of Fz and LRP5/6, respectively. (F) The destruction
complex will not form, allowing for the cytoplasmic accumulation of β-catenin. (G)
Translocation of β-catenin into the nucleus results in activation of TCF/LEF controlled
genes, leading to gene transcription.
were c-myc+, as measured by flow cytometry.198 Expression of c-myc was greater in
MDS compared to normal controls, and increased with disease risk.198 These findings
suggest a role for aberrant β-catenin activation in MDS, likely contributing to survival of
the MDS clone during disease progression.
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Activation of β-Catenin is Regulated by Oxidative Stress. Extensive evidence
indicates that oxidative stress enhances activation of β-catenin, resulting in increased
expression of its downstream target genes, including c-myc. Notably, Rac proteins,
members of the Rho family of small GTPases, associate with NADPH oxidase (NOX)
complexes and enhance NOX activation.285 Rac1 activation was shown to be a requisite
for the nuclear translocation of β-catenin.285 NOX members, who function to generate
ROS through the transfer of electrons across membranes, are central producers of
ROS.259 Therefore, NOX activation and NOX-dependent production of ROS would be
expected to promote β-catenin activation. Accordingly, not only are β-catenin gene
targets markedly suppressed in NOX1KO mice, activity of the β-catenin destruction
complex member GSK3 is significantly increased.286 These data are particularly
interesting, given that S100A8/A9, the DAMP signals increased in lower-risk MDS,140
function as a scaffold for the membrane assembly and activation of the NOX complex,
and additionally increase NOX function.265
Moreover, an unbiased, mass spectrometry pull-down approach to identify
additional binding partners of dishevelled (Dvl) identified nucleoredoxin (NRX) as a
novel interaction partner.287 NRX, related to thioredoxin (TRX), was confirmed through
immunoprecipitation experiments to bind Dvl directly.287 Binding of NRX-Dvl is Wnt
ligand-independent, but rather redox-dependent. In the absence of oxidative stress,
NRX specifically binds Dvl, illustrating a mechanism whereby NRX negatively regulates
β-catenin activation.287 In contrast, oxidation of NRX liberates Dvl, allowing Dvl to inhibit
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the β-catenin destruction complex and enhance β-catenin nuclear translocation.287
These effects of oxidative stress on β-catenin activation are summarized in Figure 14.

Figure 14. Oxidative stress positively regulates β-catenin activation and
signaling. (A) Activation of the NADPH oxidase (NOX) complex is enhanced by the
DAMP proteins S100A8/A9 as well as Rac proteins. NOX generates reactive oxygen
species (ROS) by the transfer of electrons across the plasma membrane. (B) NOXderived ROS can oxidize nucleoredoxin (NRX), a binding partner and negative regulator
of dishevelled (Dvl) and β-catenin signaling. Once oxidized, NRX dissociates from Dvl,
allowing Dvl to (C) bind to Axin and prevent the formation of the β-catenin destruction
complex. As a result, β-catenin accumulates within the cytoplasm and can translocate
into the nucleus and alter gene transcription.
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CHAPTER 2
The NLRP3 Inflammasome Functions as a Driver of the Myelodysplastic
Syndromes (MDS) Phenotype
Note: This chapter has been previously published in the journal Blood, Basiorka et al.
Blood. 2016 Oct 13, and has been reproduced in this manuscript with permission from
the publisher.
Introduction
Myelodysplastic syndromes (MDS) are hematopoietic stem cell malignancies
characterized by dysplastic and ineffective hematopoiesis. MDS bone marrow
precursors typically display larger cell size, deregulated proliferation and maturation,
and accelerated attrition by programmed cell death.45,288,289 Despite these shared
phenotypes, MDS harbor a spectrum of clonal chromosome abnormalities and somatic
gene mutations, the latter most commonly involving genes encoding RNA splicing and
epigenetic regulatory proteins.84,290 How such diverse genetic alterations initiate a
common MDS phenotype is unexplained. Apoptosis, a non-inflammatory form of
programmed cell death, has been implicated in the ineffective hematopoiesis in MDS
based

upon

membrane

externalization

of

phosphatidylserine,

mitochondrial

depolarization and DNA fragmentation.196,197,203 However, the cytokine profile and
cellular milieu in MDS instead support aberrant innate immune activation.291 Indeed,
inflammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor-α,
transforming growth factor-β, IL-6 and others are generated in excess in MDS,

79

accompanied by bone marrow expansion of hematopoietic-inhibitory, myeloid derived
suppressor cells (MDSC) activated by the danger associated molecular pattern (DAMP)
S100A9, a Toll-like receptor (TLR)-4 and CD33 ligand.99,140,144,292 Furthermore, MDS
hematopoietic stem and progenitor cells (HSPC) overexpress TLRs accompanied by
activation of respective signaling intermediates, which have been implicated in the
aberrant proliferation of MDS HSPC and in the pathogenesis of peripheral blood
cytopenias.112,116,293
Recent studies have shown that activation of TLRs by select DAMPs can trigger
pyroptosis, a novel caspase-1-dependent pro-inflammatory cell death that involves the
activation of ion gradients, cell swelling, the release of IL-1β and IL-18, intracellular
DAMPs and other pro-inflammatory cytokines.211,212,292,294 Pyroptosis is mediated by the
formation of inflammasome complexes, which are cytosolic heptameric oligomers
composed of nucleotide-binding domain and leucine-rich repeat containing pattern
recognition receptors (NLRs). The best characterized NLR, NLRP3, is a redox-sensitive
cytosolic sensor that undergoes a conformational change in response to DAMP
interaction to recruit the ASC (apoptosis-associated speck-like protein containing a
caspase-recruitment domain) adaptor protein. This interaction in turn triggers ASC
polymerization and nucleation of large cytoplasmic aggregates referred to as ASC
specks.239 ASC specks serve as a platform recruiting pro-caspase-1 monomers that are
activated by proximity-induced autocatalysis to initiate proteolytic processing of pro-IL1β and pro-IL-18 to their mature, active forms.211 Inflammasome activation involves two
steps beginning with NFκB-induced transcriptional priming of inflammasome proteins,
followed by cation channel activation, cell volume expansion and inflammasome
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component assembly.211,212,294 NLRP3 is activated by diverse DAMP signals, including
S100A9 homodimers and S100A8/9 heterodimers that function as alarmins to induce
NADPH oxidase and generate reactive oxygen species (ROS).266,295,296
Here we show that S100A9 and ROS, generated in response to NLRP3
inflammasome activation or somatic gene mutations, serve as DAMP signaling
intermediates responsible for inflammasome-mediated pyroptosis and β-catenin
activation in MDS. Remarkably, disabling this inflammasome circuit restores effective
hematopoiesis in MDS. Collectively, these findings define key biological effectors of the
MDS phenotype and suggest novel strategies for therapeutic intervention.

Results

MDS HSPC manifest inflammasome activation and pyroptosis. To determine
if pyroptosis was primed in MDS, expression of genes encoding inflammasome proteins
was evaluated in BM-MNC isolated from MDS patients (n=10) compared to agematched normal controls (n=5). MDS specimens displayed marked up-regulation of
inflammasome transcripts (Figure 15A) where caspase-1 (CASP1) mRNA levels were
increased 209-fold and NLRP3 48.1-fold in MDS; in contrast, levels of caspase-3
(CASP3) mRNA, the canonical apoptotic caspase, were similar in MDS and normal BMMNC. Further, mRNAs encoding the inflammatory cytokines IL-1β and IL-18 were
increased 3.7-fold and 29.6-fold in lower-risk MDS (n=5) versus normal BM-MNC (n=5),
whereas expression was only increased 1.1-fold and 9.2-fold in higher-risk MDS
specimens (n=5). Confocal fluorescence microscopy confirmed selective activation of
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Figure 15. Fulminant pyroptosis is manifest in HSPC and progeny in MDS. (A)
qPCR analyses of expression of pyroptosis-associated genes in BM-MNC isolated from
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MDS patient specimens (n=10 total; n=5 lower- and n=5 higher-risk disease) compared
to normal BM-MNC (n=5). (B) Representative confocal fluorescence micrograph (2520x
magnification, 7.5 µm scale) of (active) a-caspase-1 and NLRP3 expression in MDS
versus normal BM-MNC. DAPI (blue), a-caspase-1 (green), NLRP3 (red); merged
images show inflammasome formation. (C) Quantitative analysis of confocal images of
BM-MNC isolated from MDS patients [lower-risk (n=7), higher-risk (n=3)] and normal
donors (n=6). (D) Binding of ASC to NLRP3 in lower-risk MDS BM-MNC compared to
normal donors (IP: NLRP3, IB: NLRP3, ASC). Data are representative of three
independent experiments. (E) Immunoblot following chemical crosslinking of BM-MNC
cell lysates derived from normal donors (n=3) and LR-MDS patients (n=3). (F)
Quantitation of inflammasome activation based on ASC oligomerization in BM-MNC
from lower-risk MDS (n=5) versus normal BM-MNC (n=3). (G) Mean percentage of ASC
specks and speck MFI in the BM plasma of lower-risk MDS specimens (n=6) compared
to normal BM plasma (n=3). (H) The mean percentage of pyroptotic cells by
hematopoietic lineage in lower-risk MDS (n=8) versus normal donors (n=8). (I-J) Mean
+
+
percentage of (I) total a-caspase-1 and (J) a-caspase-3/7 cells assessed by
hematopoietic lineage in lower-risk MDS (n=8) and normal donors (n=5). (K)
Comparison of the mean percentage of pyroptotic versus apoptotic cells by
hematopoietic lineage in lower-risk MDS specimens (n=8). (L) Comparison of the mean
+
+
percentage of a-caspase-1 versus a-caspase-3/7 cells in the same lower-risk MDS
patients (n=8). (M) Mean percentage of pyroptotic cells following knockdown of NLRP3,
CASP1 and CASP3 by shRNA-directed silencing of lower-risk MDS BM-MNC (NLRP3,
n=4; CASP1 and CASP3, n=3). Error bars: SE, *p<0.05, **p<0.01 and ***p<0.001.
NLRP3 inflammasome complexes in MDS specimens versus age-matched normal BMMNC, evidenced by co-localization and increased active (a)-caspase-1 (MFI 3.7-fold
increase in lower-risk [p=7.1x10-3] versus 4.1-fold in higher-risk MDS [p=6.0x10-3]) and
NLRP3 (MFI 69.1-fold increase in lower-risk [p=0.013] and 68.2-fold in higher-risk
disease [p=5.1x10-3]) (Figure 15B and 15C). NLRP3 oligomerization and activation was
confirmed by increased binding of NLRP3 to ASC in MDS compared to normal donors
(Figure 15D), and by robust formation of ASC monomers and higher-order oligomer
complexes, which are indispensable for inflammasome activity and evident following
DSS-crosslinking (Figure 15E). MDS BM-MNC also displayed increased levels of proand a-caspase-1, pro-IL-1β and a-IL-1β compared to normal BM-MNC (n=3) (Figure
15E). Finally, inflammasome formation was confirmed by alternate methods of
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assessment of ASC oligomerization, where ASC incorporation into inflammasome
complexes is detected by flow cytometric changes in fluorescence pulse height and
area

(Figure

15F).297

MDS

specimens

also

displayed

significantly

greater

inflammasome assembly compared to controls, irrespective of IPSS risk group (Figure
15C). Specifically, NLRP3 inflammasome assembly was increased 2.9-fold in lower-risk
(p=3.9x10-5) and 3.1-fold in higher-risk (p=7.1x10-5) MDS patients. Active ASC specks
are released into the extracellular space following cytolysis and specifically following
execution of pyroptotic pore formation and cytolysis.298 Notably, analysis of ASC specks
in BM plasma from lower-risk MDS specimens (n=6) confirmed a profound increase in
the percentage and MFI of ASC specks in MDS compared to normal BM plasma (n=3)
(mean, MDS 36.2+1.4 vs. 6.0+8.4, Figure 15G). Finally, immunofluorescence and flow
cytometry analyses of other hematologic malignancies suggest that inflammasome
activation is specific for MDS (Figure 16).
Caspase-1 activation by the inflammasome is followed by mitochondrial
depolarization and caspase-3 activation, a secondary cleavage target of caspase-1, as
late events in pyroptosis. To specifically assess pyroptosis versus apoptosis in MDS,
the percentage of pyroptotic cells, defined as the percentage of a-caspase-1+/acaspase-3/7+/annexin-V+ cells, was determined in phenotypically distinct hematopoietic
lineages by flow cytometry. Normal (n=5) and lower-risk MDS BM-MNC (n=8) were
incubated with autologous BM plasma for 24 hours prior to flow cytometry analysis.
MDS HSPC demonstrated profound increases in pyroptosis, where the fraction of
pyroptotic cells was increased 4.1-fold in CD34+CD38- stem cells (p=0.035), 4.9-fold in
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Figure 16. NLRP3 inflammasome assembly may be MDS-specific. (A)
Representative confocal fluorescence micrograph (2520x magnification, 7.5 µm scale)
of a-caspase-1 and NLRP3 expression in MDS (n=10), de novo AML (n=5), secondary
AML (n=8), chronic lymphocytic leukemia (CLL, n=5), multiple myeloma (MM, n=5),
chronic myeloid leukemia (CML, n=3), acute B lymphoblastic leukemia (B-ALL, n=3)
and T cell lymphoma (TCL, n=3) BM-MNC. DAPI (blue), a-caspase-1 (green), NLRP3
(red); merged images show inflammasome formation. (B-C) Quantitative analysis of (B)
a-Caspase-1 MFI and (C) NLRP3 MFI. Error bars: SE, *p<0.05, **p<0.01 and
***p<0.001.
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progenitor cells (CD34+CD38+, p=6.8x10-3), 6.6-fold in immature myeloid cells (CD33+,
p=1.5x10-3), and 7.3-fold in erythroid cells (CD71+, p=2.8x10-3) compared to normal
controls (Figure 15H). Additionally, the percentage of a-caspase-1+ cells was increased
14.2-fold in the stem cell fraction (p=8.0x10-3), 13.2-fold in progenitors, 12.9-fold in
immature myeloid cells (p=1.3x10-4), and 13.0-fold in CD71+ erythroid precursors
(p=7.7x10-3) (Figure 15I). A-caspase-1 MFI directly correlated with NLRP3 MFI,
inflammasome assembly and the percentage of pyroptotic stem cells. Notably, the latter
was directly associated with the percentage of a-caspase-1+ CD33+ myeloid progenitors
(Figure 17). In contrast, there were no significant differences in the apoptotic indices
(i.e., a-caspase-3/7+/a-caspase-1-/annexin-V+) in lower-risk MDS specimens (n=8)
versus normal progenitors in any of the four hematopoietic cell subsets investigated
(Figure 15J). Indeed, the pyroptotic cell fraction was 14.4-fold (p=9.7x10-3), 9.7-fold
(p=2.3x10-3), 21.9-fold (p=9.5x10-4), and 12.1-fold (p=1.6x10-3) increased in stem cells,
progenitor cells, immature myeloid and erythroid cells when compared to the apoptotic
cell fraction (Figure 15K). Finally, the fraction of a-caspase-1+ cells was significantly
greater than the corresponding a-caspase-3/7+ cell fraction, confirming that caspase-1
activation (pyroptosis) exceeds caspase-3 activation (apoptosis) in MDS (Figure 15L).
To confirm that NLRP3 inflammasome activation and caspase-1 are essential for
hematopoietic cell death in MDS, shRNA-directed knockdown of NLRP3, CASP1 and
CASP3 was performed by lentivirus transfection of lower-risk BM-MNC (NLRP3, n=4;
CASP1 and CASP3, n=3) (Figure 15M). Protein levels of NLRP3 were reduced 54%,
whereas expression of CASP1 and CASP3 were reduced 34% and 40%, respectively.
Knockdown of NLRP3 and caspase-1 significantly decreased the fraction of pyroptotic

86

Figure 17. Caspase-1 activation significantly correlates with the extent of
pyroptosis detected in MDS BM-MNC. (A-B) A-caspase-1 MFI, NLRP3 MFI and
NLRP3 inflammasome formation measured by co-localization of a-caspase-1/NLRP3,
were determined by analysis of confocal immunofluorescence images. (C-D) The
+
percentage of pyroptotic stem cells and MFI of a-caspase-1 in the stem cell and CD33
population were determined by flow cytometry.
cells versus scrambled transfected controls (p=5.7x10-3 and 0.038, respectively) (Figure
15M). In contrast, knockdown of caspase-3 had no discernible effect (Figure 15M),
confirming selective NLRP3- and caspase-1-dependence.

87

The alarmin S100A9 initiates pyroptosis. As we previously reported,140 BM
plasma concentration of S100A9 was significantly higher in lower-risk MDS patient
specimens (n=33) compared to normal controls (n=12; p=1.5x10-4) (Figure 18A).
Analysis of S100A9 BM plasma concentration by International Prognostic Scoring
System (IPSS) risk category showed a 2.3- and 2.2-fold increase in low risk (n=10,
p=2.3x10-5) and intermediate-I risk MDS (n=23, p=1.0x10-3), compared to normal
controls (n=12), whereas there were no significant differences among controls and
intermediate-II (n=17) or high risk (n=10) disease (Figure 18B). Notably, BM S100A9
concentrations were significantly higher in lower-risk versus higher-risk MDS (p=0.013)
(Figure 18A), consistent with the reduced fraction of MDSC and acquisition of survival
signals in higher-risk MDS that mitigates cell death and DAMP elaboration.84,197
In addition, the BM plasma concentration of HMGB1, a nuclear DAMP and TLR4
ligand, was significantly increased in MDS (n=55) versus normal controls (n=11)
(p=2.6x10-3)

(Figure

18C),

consistent

with

intracellular

DAMP

release

upon

cytolysis.113,299 Moreover, S100A9 and HMGB1 transcripts were up-regulated 104.5-fold
and 1.5-fold in MDS, respectively, compared to normal controls (Figure 18D and 18E).
Further, flow cytometry analyses of phenotypically distinct hematopoietic lineages
confirmed a corresponding increase in the intracellular levels of S100A9 protein in MDS
stem cells and progeny (Figure 18F and 18G).
As TLRs and NLRs are sensors of DAMP signals, we tested if S100A9 would
directly trigger pyroptosis in HSPC. Normal BM-MNCs were treated with 1 µg/mL
rhS100A9 and changes in gene expression were assessed by qPCR. The expression of
pyroptosis-associated genes was significantly induced by rhS100A9, and indeed
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Figure 18. S100A9 initiates pyroptosis in MDS. (A) ELISA assessment of BM plasma
concentration of S100A9 in normal donors (n=12) versus MDS [lower-risk (n=33),
higher-risk (n=27)]. (B) S100A9 BM plasma concentration analyzed according to IPSS
risk score. (C) HMGB1 BM plasma concentration assessed by ELISA in normal donors
(n=11) and MDS (n=55). (D) qPCR analysis of S100A9 mRNA levels in normal (n=2)
versus lower-risk MDS BM-MNC (n=8). (E) HMGB1 mRNA levels in normal (n=6)
versus MDS BM-MNC (n=10). (F) Representative histograms of intracellular levels of
S100A9 by hematopoietic lineage in BM-MNC isolated from MDS patients (n=6) and
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+

from normal donors (n=5). (G) Mean percentage of S100A9 cells by hematopoietic
lineage. (H) qPCR analysis of untreated normal BM-MNC (n=3), normal BM-MNC
treated with 1 µg/mL rhS100A9 for 24 hours (n=2) and MDS patient specimens (n=5). (I)
Representative micrograph (2520x magnification, 7.5 µm scale) depicting
inflammasome formation in normal, untreated BM-MNC or normal BM-MNC treated with
5 µg/mL rhS100A9 for 24 hours. DAPI (blue) a-caspase-1 (green), and NLRP3 (red);
merged images show inflammasome formation. (J) Quantitative analysis of confocal
images of BM-MNC from normal donors (n=6), normal BM-MNC treated with 5 µg/mL
rhS100A9 (n=2), and MDS patients (n=10). Error bars: SE, *p<0.05, **p<0.01 and
***p<0.001.
exceeded those found in MDS (Figure 18H). Accordingly, treatment of normal BM-MNC
with 5 µg/mL rhS100A9 was sufficient to induce a-caspase-1 and NLRP3 (Figure 18I)
by 2.5-fold and 47.1-fold (p=0.064), respectively, as well as NLRP3 inflammasome
assembly

(2.9-fold,

p=3.1x10-4)

(Figure

18J).

Although

rhS100A9

induced

inflammasome assembly and caspase-1 activation in normal BM-MNC, MDS patient
BM-MNC displayed greater activation of these effectors. Notably, treatment of normal
BM-MNC with MDS-derived bone marrow plasma did not induce pyroptosis, as
measured by the mean percentage of pyroptotic cells, a-caspase-1+ cells or a-caspase1 MFI (data not shown), indicating that MDS HSPCs are selectively primed for the
pyroptotic response.
Inflammasome-activated cation channels increase the size of MDS
progenitors. Cell swelling is a hallmark of pyroptosis following activation of plasma
membrane cation channels, which compromise membrane integrity and trigger
mitochondrial membrane depolarization.214 Confocal image analyses of MDS BM-MNC
cells revealed a significantly larger mean cell area compared to normal BM-MNC
(Figure 19A). Further, this phenotype was accentuated in lower-risk MDS patients
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Figure 19. MDS precursors evidence cell swelling, a pyroptotic hallmark. (A) Mean
cell area was quantified from confocal images of BM-MNC from normal donors (n=6)
versus MDS patient specimens [lower-risk (n=7), higher-risk (n=3)]. (B) Flow cytometric
analysis of mean SSC-A intensity of BM-MNC isolated from normal donors (n=6) or
lower-risk MDS patients (n=7). MDS BM-MNC have 2.0-fold greater mean cell area of
+
live, ungated BM-MNC (p=0.017), 2.2-fold of stem cells (CD34 CD38 , p=0.019), 1.5+
+
+
fold of progenitor cells (CD34 CD38 ), 1.6-fold of immature myeloid progenitors (CD33 )
and 2.0-fold of erythroid progenitors (CD71+, p=0.038). (C) NLRP3 MFI correlates with
BM-MNC area in lower-risk MDS patients (r=0.49, n=7). (D) Ethidium bromide dye
incorporation in BM-MNC from normal donors (n=3) and MDS patients (n=3) was
measured at 5 minute intervals by flow cytometry. (E) Left to right, photomicrograph
images from normal donors illustrating normal red blood cell (RBC, 7.0 µm) followed by
normal erythroid lineage maturation of nucleated BM precursors with corresponding cell
diameter. (F) Corresponding images from MDS BM aspirates, demonstrating an oval
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macrocyte (RBC, 9.1 µm) followed by dysplastic and megaloblastic erythroid lineage
maturation. (G) Normal myelocyte. (H) Enlarged dysplastic myelocyte with mild
hypogranulation in MDS. (I-J) (I) Erythroid and (J) myeloid lineage maturation
comparison of mean cell diameter in normal donor (n=4) versus MDS patient (n=4) BM.
Maturation is depicted as most to least mature cell populations from left to right. Error
bars: SE, *p<0.05, **p<0.01 and ***p<0.001.
versus normal controls (p=6.0x10-5), whereas there were no significant differences in
higher-risk patients. These findings were corroborated using SSC-A flow cytometric
measurements, a validated reference for cell size,300 in ungated BM-MNC derived from
lower-risk MDS patients (n=7) and normal donors (n=6), as well as in antigenically
distinct hematopoietic cell subsets (Figure 19B). Finally, mean NLRP3 MFI correlated
with mean cell area in lower-risk but not higher-risk MDS patients (r=0.49) (p=7.8x10-3)
(Figure 19C).
To assess ion channel activation, influx of the membrane-impermeable, cationic
dye ethidium bromide (EtBr) was assessed by flow cytometry. MDS specimens
incubated with autologous bone marrow plasma displayed rapid and sustained EtBr
influx compared to that of normal BM-MNC (Figure 19D). This was detected as early as
20 minutes in MDS specimens (p=0.041), and was sustained through 1 hour of dye
exposure (p=0.014). Finally, analysis of normal and MDS BM morphology confirmed the
larger cell size by maturation stage and lineage in MDS (Figure 19E-J).
Inhibition of pyroptosis promotes effective hematopoiesis in MDS. To
assess the role of S100A9 in pyroptosis in MDS, we tested if S100A9 neutralization in
autologous BM plasma using a high-affinity chimeric (CD33-IgG1) decoy receptor could
ameliorate the phenotypes manifest in MDS BM-MNC. Notably, treatment with the
CD33-IgG1 chimera markedly reduced the fraction of pyroptotic cells without altering the
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fraction of apoptotic cells (Figure 20A and 20B). Overall, short-term incubation with the
chimera was sufficient to reduce the fraction of pyroptotic cells across lineages, with an
81% reduction in stem cells, 57% in progenitor cells, 90% in CD33+ and 42% in CD71+
erythroid progenitors. Short-term treatment with CD33-IgG1 also significantly reduced
the MDSC fraction, confirming that blocking S100A9 function impairs survival of MDSC
(data not shown). Consistent with this, the CD33-IgG1 chimera reduced S100A9
transcriptional priming, evidenced by a concentration-dependent reduction in the
expression of CASP1, IL-1β, IL-18, and NLRP3 transcripts in MDS BM-MNC versus
treatment with autologous BM plasma alone (n=5) (Figure 20C). CASP3 expression was
also markedly reduced, consistent with late, secondary caspase-3 activation.278 Note
that as a result of the IgG1-Fc conjugation, high concentrations of the chimera led to
cross-linking of the Fc domains and aggregation that masked dose-dependent
transcriptional effects of S100A9 neutralization.
To test if S100A9 neutralization could improve hematopoiesis in MDS, colony
forming capacity was assessed after plating MDS BM-MNC in autologous BM plasma
and increasing concentrations of CD33-IgG1 (Figure 20D) or of MCC950 (Figure 20E), a
small molecule inhibitor of the NLRP3 inflammasome.301 Notably, neutralization of
S100A9 or inhibition of the NLRP3 inflammasome markedly improved colony forming
capacity of MDS progenitors (up to 6.6-fold greater than controls). Thus, pyroptotic
pathway inhibition abrogates MDS hematopoietic cell death and promotes effective
hematopoiesis.
S100A9 is sufficient to provoke HSPC pyroptosis in vivo. To test if forced
expression of S100A9 is sufficient to induce pyroptosis in vivo, we assessed

93

Figure 20. Inhibition of pyroptosis abrogates MDS HSPC death and augments
colony forming capacity. (A-B) Fold change in the mean percentage of (A) pyroptotic
or (B) apoptotic cells in each respective lineage in lower-risk MDS BM-MNC (n=6)
incubated with autologous BM plasma and 0.5 µg CD33-IgG1 chimera for 24 hours.
Values are normalized to autologous BM plasma-incubated MDS BM-MNC. (C) qPCR
analysis of BM-MNC isolated from lower-risk MDS patients (n=5) treated for 24 hours
with CD33-IgG1. (D) Colony forming capacity was assessed in BM-MNC from lower-risk
MDS patient specimens (n=3) treated with increasing concentrations of CD33-IgG1 or
(E) the inflammasome inhibitor MCC950. Error bars: SE, *p<0.05.
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phenotypes manifest in an S100A9 transgenic (S100A9Tg) mouse model that
phenocopies human MDS.140 Confocal fluorescence microscopy analyses of BM cells
from the tibia and femurs of S100A9Tg versus wild type (WT) mice at 2 (n=4), 6 (n=4),
and 11 (n=5) months of age showed that caspase-1 activation increased with age in the
BM cells of S100A9 transgenics, with a 2.1-fold up-regulation at 2 months, 2.4-fold at 6
months (p=3.3x10-3), and 2.5-fold at 11 months (p=0.010). Similarly, NLRP3 levels were
increased in S100A9Tg mice, with a 21.1-fold up-regulation at 2 months (p=0.059),
25.6-fold at 6 months (p=2.2x10-4), and 12.1-fold at 11 months (p=0.018) (Figure 21A).
Accordingly, formation of NLRP3 inflammasome complexes also significantly increased
with age, with 2.6-fold greater co-localization in the 2-month-old S100A9Tg transgenic
mice (p=0.017), 3.3-fold in 6 month (p=1.0x10-6), and 3.2-fold in 11-month-old mice
(p=1.2x10-3) (Figure 21A).
To determine if S100A9 was sufficient to trigger pyroptosis in mouse
hematopoietic cells, BM cells isolated from WT mice were treated with 5 µg/mL
recombinant murine S100A9 and inflammasome formation was assessed by confocal
microscopy (Figure 21B and 21C). As predicted, MFI of a-caspase-1 and NLRP3
significantly increased after rmS100A9 treatment (n=2) versus controls (n=2) (p=7.5x103

and 0.017, respectively). Notably, MFI values from rmS100A9-treated WT BM cells

were comparable to those manifest in the BM cells of S100A9 transgenic mice (n=13),
and rmS100A9 treatment of WT BM cells markedly induced assembly of inflammasome
complexes (p=0.023) (Figure 21C).
To assess the extent of pyroptosis versus apoptosis in vivo, BM cells were
isolated from 7-month-old WT (n=6) and 9-month-old S100A9Tg (n=6) mice and active
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Figure 21. Pyroptosis is the principal mechanism of HSPC death in S100A9
transgenic mice. (A) Confocal image analysis of BM cells isolated from WT (n=2), 2
month (n=4), 6 month (n=5) and 11 month (n=4) old S100A9Tg mice. (B)
Representative micrograph (2520x magnification, 7.5 µm scale) depicting
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inflammasome formation in BM cells from WT, WT cells treated for 24 hours with 5
µg/mL S100A9 and BM cells from S100A9Tg mice. DAPI (blue), a-caspase-1 (green)
and NLRP3 (red); merged images show inflammasome formation. (C) Quantitative
analysis of confocal images of BM cells isolated from WT (n=2) mice, from WT BM cells
treated for 24 hours with 5 µg/mL rmS100A9 (n=2) or BM cells from S100A9Tg mice
+
(n=13). (D) Representative scatter plots of pyroptotic and apoptotic LSK (Lin Sca-1 c+
Kit ) cells isolated from WT and transgenic mice. (E) Mean percentage of pyroptotic
versus apoptotic LSK cells in WT (n=6) and S100A9Tg mice (n=6). (F) Mean
+
+
percentage of total a-caspase-1 and a-caspase-3/7 LSK cells isolated from WT (n=6)
and S100A9Tg mice (n=6). (G) Flow cytometric analysis of mean SSC-A intensity of BM
-2
cells isolated from WT (n=6) and S100A9Tg mice (n=6) (p=1.0x10 ). (H) At six months
of age, S100A9Tg mice were treated with 50 mg/kg of ICTA. Shown are changes in
hemoglobin, white blood cell (WBC), RBC and platelet counts in WT (n=4), S100A9Tg
(n=5) and ICTA-treated S100A9Tg mice (n=5). (I) Mean percentage of LSK+ HSPC in
untreated versus ICTA-treated S100A9Tg mice. (J) Representative micrograph (2520x
magnification, 7.5 µm scale) depicting inflammasome formation in BM cells harvested
from untreated S100A9Tg mice or mice treated with ICTA by oral gavage for a total of
eight weeks. DAPI (blue), a-caspase-1 (green), and NLRP3 (red); merged images show
inflammasome formation. Error bars: SE, *p<0.05, **p<0.01 and ***p<0.001.
caspase-1 and a-caspases-3/7 were assessed by flow cytometry in the LSK (Lin-Sca-1+
c-Kit+) HSPC population. The mean percentage of pyroptotic LSK cells was significantly
increased in the S100A9Tg versus WT mice (p=0.052), whereas WT BM cells had a
higher apoptotic index (p=7.1x10-3) (Figure 21D and 21E). Additionally, the percentage
of a-caspase-1+ LSK cells was increased 2.6-fold in the S100A9Tg mice compared to
WT mice (p=4.2x10-3), while there was no significant difference in the a-caspase-3/7+
LSK cells in the two cohorts (Figure 21F). S100A9Tg BM cells also had a significant
increase in mean cell area, as assessed by SSC-A intensity measurements (Figure
21G). Finally, to test if in vivo inflammasome inhibition also improves hematopoiesis in
S100A9Tg mice, aged S100A9Tg mice (n=5) were treated with ICTA, an icariin
derivative that inhibits NLRP3 inflammasome activation, every other day for eight weeks
(Figure 22). ICTA treatment markedly improved peripheral blood counts, and increased
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Figure 22. ICTA inhibits inflammasome activation. (A) Representative micrograph
(1890x magnification, 10 µm scale) depicting inflammasome formation in U937 cells
following 24 hr treatment with vehicle or 5 µg/mL rhS100A9 alone or with ICTA (20
µg/mL). DAPI (blue), a-caspase-1 (green), NLRP3 (red); merged image shows
formation of inflammasome complexes. (B) Quantitative analysis of confocal images.
Error bars: SE, *p<0.05, **p<0.01 and ***p<0.001.
hemoglobin, leukocyte count, red blood cells and platelet counts in the transgenic mice
(Figure 21H), accompanied by a significant increase in the percentage of LSK+ HSPC
(p=0.047) (Figure 21I), consistent with restored effective hematopoiesis. Finally, NLRP3
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activation was dramatically reduced in BM cells from ICTA-treated S100A9Tg mice
(Figure 21J). Thus, pyroptosis is the principal mechanism driving HSPC cell death in
MDS and S100A9Tg mice.
S100A9 and MDS somatic gene mutations trigger pyroptosis and β-catenin
activation via ROS. ROS act as DAMP intermediates that activate the Wnt/β-catenin
axis, which is known to be activated in MDS.302-306 Thus, we hypothesized that ROS
generated by either S100A9 or somatic gene mutations would direct activation of βcatenin in MDS. In accord with this notion, the mean percentage of ROS positive cells
was increased in MDS BM-MNC (n=5) 16.5-fold compared to normal BM-MNC (n=2)
(p=0.011) (Figure 23A), with corresponding significant increases in ROS MFI (p=0.028)
(Figure 23B). Further, MDS BM-MNC displayed increased nuclear β-catenin (n=6)
compared to normal donors (n=3), as well as in normal BM-MNC treated with 5 µg/mL
rhS100A9 versus untreated BM-MNC (p=0.043 and p=6.38x10-7, respectively) (Figure
23C and 23D). Finally, β-catenin mRNA levels were increased 9.5-fold in the BM cells of
S100A9Tg mice versus WT BM cells, with corresponding up-regulation of Wnt/β-catenin
target genes (Figure 23E). As expected, this phenotype was associated with significant
increases in nuclear β-catenin in S100A9Tg-derived BM cells versus WT BM cells, and
levels of nuclear β-catenin were reduced following in vivo treatment with ICTA (Figure
23F), which led to corresponding reductions in the expression of Wnt/β-catenin target
genes (Figure 23E). Similarly, treatment of MDS BM-MNC with ICTA suppressed
nuclear β-catenin as well as Wnt/β-catenin target gene expression (Figure 23G). Thus,
the S100A9-to-NLRP3 inflammasome circuit is necessary and sufficient to drive
activation of β-catenin in MDS.
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Figure 23. S100A9 induces ROS through NADPH oxidase to activate β-catenin. (AB) The percentage of (A) ROS positive cells and (B) ROS MFI assessed by flow
cytometry in BM-MNC isolated from MDS patients (n=5) and normal donors (n=2). (C)
Representative micrograph (2520x magnification, 7.5 µm scale) of β-catenin expression
in normal BM-MNC (n=3), normal BM-MNC treated with 5 µg/mL rhS100A9 (n=3) and
MDS BM-MNC (n=6). DAPI (blue), β-catenin (red); merged images show nuclear βcatenin localization. (D) Quantitation and scoring of confocal images based on the
presence of no, low, medium or high nuclear β-catenin. (E) Wnt/β-catenin target gene
expression in WT and S100A9Tg BM cells. (F) Representative micrograph (2520x
magnification, 7.5 µm scale) of β-catenin expression in WT (n=5), S100A9Tg (n=5) and
S100A9Tg that were treated with ICTA (n=5) by oral gavage for a total of eight weeks.
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DAPI (blue), β-catenin (red); merged images show nuclear β-catenin localization. (G)
Wnt/β-catenin target gene expression in MDS BM-MNC (n=4) treated for 48 hours with
ICTA. Error bars: SE, *p<0.05 and ***p<0.001.
To determine if somatic gene mutations in MDS also trigger activation of the
NLRP3 inflammasome, increased ROS, pyroptosis and β-catenin activation, we first
investigated these phenotypes in TF-1 myeloid leukemia cells engineered to express
GFP-labeled wild type or mutants of the U2AF1 splicing factor gene.290 The percentage
of pyroptotic cells was increased 4.6-fold in U2AF1-S34F mutant versus U2AF1-WTexpressing cells, which was associated with increased levels of a-caspase-1 (p=0.044)
and annexin-V (p=0.021) (Figure 24A-24H). Further, there was increased ASC
oligomerization and NLRP3 inflammasome activation in the S34F-expressing cells, as
evidenced by increased binding of NLRP3:ASC (Figure 24I), maturation of caspase-1
and IL-1β (Figure 24J) and the generation of ASC monomers and higher-order ASC
complexes (Figure 24K).
ROS generation by NADPH oxidase-1 (NOX1) has been linked to Wnt/β-catenin
activation.302,303 Treatment of the S34F-expressing cells with the NOX1/4-specific
inhibitor GKT137831 or with the pan-NOX inhibitor DPI profoundly reduced ASC
oligomerization and thereby NLRP3 inflammasome assembly; thus, NLRP3 activation in
response to somatic gene mutation is NOX1/4-dependent (Figure 24B). Moreover,
elevated levels of ROS in U2AF1-S34F-expressing cells were abrogated by
GKT137831 or DPI treatment (Figure 24N and 24O). U2AF1-S34F-expressing cells also
displayed significant increases in mean cell area (p=0.035), ethidium bromide influx
(Figure 24L and 24M), mean percentage of ROS+ cells (p=1.5x10-3) and ROS MFI
(p=0.032) (Figure 24N and 24O), accompanied by nuclear localization of β-catenin
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Figure 24. U2AF1 mutations manifest in MDS provoke pyroptosis and induce
NOX-dependent activation of β-catenin. (A) Representative density plot of
inflammasome formation based on ASC oligomerization. (B) Quantitation of ASC in WT,
S34F and S34F cells treated with DPI for 24 hours. (C) Representative scatter plots of
pyroptotic cells by flow cytometry. (D) Mean percentage of pyroptotic cells in mutant and
+
+
WT cells. (E-H) Mean percentage of total (E) a-caspase-1 and (F) annexin-V cells, as
well as the MFI of (G) a-caspase-1 and (H) annexin-V assessed by flow cytometry. (I)
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Binding of ASC to NLRP3 (IP: NLRP3, IB: NLRP3, ASC). (J) Western blot of cleaved
caspase-1 and IL-1β maturation. (K) Immunoblot of ASC monomers and higher-order
ASC complexes following chemical crosslinking of cell lysates. (L) Mean cell area
quantitated from confocal images. (M) Incorporation of ethidium bromide measured by
flow cytometry at 5 minute intervals. (N-O) Mean percentage of (N) ROS positive cells
and (O) ROS MFI assessed by flow cytometry. (P) Representative micrograph (1890x
magnification, 10 µm scale) of β-catenin expression in U2AF1 WT cells, S34F or S34Fexpressing cells treated with NAC or DPI for 24 hours prior to staining. DAPI (blue), βcatenin (red); merged images show nuclear β-catenin localization. (Q) Quantitation and
scoring of confocal images based on the presence of no, low, medium or high nuclear βcatenin. (R) Representative density plot of inflammasome formation based on ASC
oligomerization in S34F cells treated with 10 µM ICTA. (S) Colony forming capacity
assessed in WT, S34F and S34F cells treated with increasing concentrations of ICTA
(0.01-10 µM). The mean number of colonies is representative of four replicates per
condition. Error bars: SE, *p<0.05, **p<0.01, and ***p<0.001. Data are representative of
three independent experiments.
(Figure 24P and 24Q). Notably, treatment of U2AF1-S34F mutant cells with the antioxidant N-acetylcysteine (NAC) or the NOX inhibitor DPI effectively reduced β-catenin
activation in U2AF1-S34F-expressing cells (p=3.8x10-3 and p=2.5x10-6, respectively)
(Figure 24P and 24Q); thus, β-catenin activation is initiated by NOX-derived ROS
generation. Finally, treatment of the U2AF1-S34F-expressing mutant cells with the
NLRP3 inflammasome inhibitor ICTA suppressed inflammasome activation, as
evidenced by a reduction in ASC polymerization, and restoration of colony forming
capacity to levels commensurate with that of WT BM cells (Figure 24R and 24S). Thus,
the reduced survival of cells harboring this MDS splicing mutation is driven by NLRP3
inflammasome-directed pyroptosis, while β-catenin activation may support propagation
of the clone.
This circuitry was also evaluated in BM cells from the conditional knock-in Sf3b1K700E mouse model, which expresses an RNA splicing subunit gene mutation found in
MDS and displays an MDS phenotype.307 Sf3b1-K700E BM cells (n=6) displayed similar
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increases in the percentage of pyroptotic versus apoptotic cells, with a significant
increase in total a-caspase-1+ cells (p=0.014) versus WT BM (n=6) (Figure 25A and
25B). Further, a-caspase-1 and a-caspase-3/7 MFI were both significantly increased in
the Sf3b1-K700E mutant BM cells (p=0.030 and p=6.92x10-3, respectively) (Figure 25C)
accompanied by increased inflammasome assembly (Figure 25D). Accordingly, NLRP3
protein expression was increased 1.9-fold in the Sf3b1-K700E cells (p=0.063) in
accordance with NLRP3 inflammasome formation (Figure 25E).
Inflammasome activation in Sf3b1-K700E mutant BM cells was confirmed by
assessment of ASC oligomerization, demonstrating marked ASC polymerization
associated with inflammasome assembly versus WT BM (p=8.4x10-3). Further, this was
dependent upon NOX-generated ROS, as (i) ASC oligomerization was significantly
reduced in Sf3b1-K700E mutant-expressing BM cells following treatment with NAC
(p=2.68x10-3) or DPI (Figure 25F-G); and (ii) the mean percentage of ROS+ cells and
ROS MFI were markedly increased in Sf3b1-K700E-expressing mutant BM cells, which
was extinguished by treatment with NAC or DPI (Figure 25H-I). Finally, nuclear
localization of β-catenin was also significantly increased in Sf3b1-K700E mutant BM
compared to WT BM (p=0.04), which was also reduced by treatment with NAC
(p=2.0x10-3) or DPI (p=1.8x10-2) (Figure 25J-K).
Notably, pharmacologic inhibition of the NLRP3 inflammasome in Sf3b1-K700E
mutant BM cells restored colony forming capacity, illustrating the importance of
inflammasome activation in the attrition of mutant cells (Figure 25L). Similar findings
were also manifest in mutant versus WT SRSF2-expressing HEK293T cells (Figure 26),
as well as in BM cells obtained from MDS murine models driven by epigenetic
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Figure 25. Sf3b1-K700E induces pyroptosis and supports self-renewal through βcatenin activation. Data are representative of BM cells harvested from wild type (WT)
(n=6) and Sf3b1-K700E mutant (n=6) mice. (A) Quantitation of the percentage of
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+

pyroptotic versus apoptotic cells. (B) Mean percentage of total a-caspase-1 , a+
+
caspase-3/7 , and annexin-V cells. (C) MFI values for a-caspase-1, a-caspase-3/7,
and annexin-V+ cells. (D) Representative micrograph (2520x magnification, 7.5 µm
scale) depicting inflammasome formation in the WT and K700E mutant cells. DAPI
(blue), a-caspase-1 (green), NLRP3 (red); merged image shows inflammasome
formation. (E) Quantitative analysis of a-caspase-1/NLRP3 confocal images. (F)
Representative density plot of inflammasome formation based on the detection of
fluorescence pulse differences in ASC. (G) Quantitation of ASC in WT, K700E and
K700E cells treated with NAC or DPI for 24 hr. (H-I) Mean percentage of (H) ROS
positive cells and (I) ROS MFI assessed by flow cytometry. (J) Representative
micrograph (2520x magnification, 7.5 µm scale) of β-catenin expression. DAPI (blue), βcatenin (red), and the merged images show nuclear localization of β-catenin. (K)
Quantitation and scoring of β-catenin confocal images based on the presence of no,
low, medium, or high nuclear β-catenin in WT, K700E and K700E cells treated with NAC
or DPI for 24 hr. (L) Colony forming capacity was assessed in WT, K700E or K700E
cells treated with increasing concentrations of ICTA (0.1-10 µM). Mean number of BFUE colonies is representative of BM cells isolated from four mice per condition, and four
replicates per mouse. Error bars: SE, *p<0.05, **p<0.01 and ***p<0.001.
regulatory gene mutations (Asxl1, Tet2)308,309 (Figure 27). To confirm that somatic gene
mutations prime HSPC for pyroptosis in MDS, we performed comparative analyses of
published gene expression profiles from human and murine SRSF2 (GSE65349) and
U2AF1 mutants (GSE30195, GSE66793) versus WT, TET2 knock-out (GSE27816) and
primary MDS (GSE19429) versus normal HSPC, demonstrating uniform up-regulation
of pyroptosis effectors consistent with transcriptional priming.309-313
Importantly, in MDS BM specimens, BM plasma concentration of S100A9
positively correlated with NLRP3 MFI, percentage and MFI of plasma ASC specks, and
with the presence of spliceosome gene mutations and variant allele frequency (VAF)
(Figure 28). Furthermore, both the percentage and MFI of plasma ASC specks were
significantly increased in MDS patients harboring somatic gene mutations (Figure 28DE). Finally, the percentage of pyroptotic erythroid precursors significantly increased in
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Figure 26. SRSF2 mutants induce pyroptosis and support self-renewal through βcatenin. HEK293T cells were transiently transfected with wild type (WT) and P95H
+
mutant SRSF2 expression plasmids. Data shown of the GFP transfected populations
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are representative of three independent experiments. (A) Representative density plot of
inflammasome formation based on the detection of fluorescence pulse differences in
ASC. (B) Quantitation of ASC positive cells. (C-G) Fold change of the mean percentage
+
+
of (C) pyroptotic cells, (D) total a-caspase-1 cells, (E) total annexin-V cells, and MFI
values for (F) a-caspase-1 and (G) annexin-V, normalized to WT transfected cells. (H-I)
Mean percentage of (H) ROS positive cells and (I) ROS MFI. (J) Representative
micrograph (1890x magnification, 10 µm scale) of β-catenin expression. DAPI (blue), βcatenin (red), and the merged images show nuclear localization of β-catenin. (K)
Quantitation and scoring of β-catenin confocal images based on the presence of no,
low, medium, or high nuclear β-catenin. Error bars: SE, *p<0.05.
parallel with splicing gene mutation VAF and with the number of somatic gene
mutations. Thus, MDS somatic gene mutations prime cells to undergo pyroptosis, which
promotes self-renewal and contributes to an inflammatory microenvironment that is
driven by NOX-derived ROS.
MDS HSPC are primed for NLRP3 inflammasome activation. Given the
increased oxidative stress in MDS, we investigated the contribution of redox-proteins in
mediating NLRP3 inflammasome activation. ROS oxidize thioredoxin (TRX) triggering
its dissociation from thioredoxin-interacting protein (TXNIP). Recent studies suggest
that liberated TXNIP serves as a redox sensitive ligand that binds NLRP3 and activates
inflammasome complex assembly.261 TXNIP gene expression was 9.6-fold increased in
lower-risk MDS BM-MNC (n=9) compared to normal donors (n=4), and increased 3.4fold in U2AF-S34F-expressing cells compared to WT U2AF1-expressing cells (Figure
29A). Further, there was increased binding of TXNIP to NLRP3 in MDS and S34Fexpressing cells, compared to normal donors and WT cells, respectively (Figure 29B
and 29C). Notably, increased NLRP3 oligomerization and activation was confirmed
through binding of NLRP3:ASC (Figure 29B and 29C). Moreover, mRNA and protein
levels of the pyrin domain-only protein (POP)-1, a key negative regulator of NLRP3
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Figure 27. Asxl1 and Tet2 deletions are sufficient to induce pyroptosis and drive
self-renewal through β-catenin activation. BM cells were isolated from Asxl1 KO,
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Tet2 KO and DKO mice and were compared to BM from wild type mice. (A)
Representative micrograph (2520x magnification, 7.5 µm scale) depicting
inflammasome formation in control and KO cells that were untreated, or treated with
NAC or DPI for 24 hr. DAPI (blue), a-caspase-1 (green), NLRP3 (red); merged images
show inflammasome formation. (B-D) Quantitative analysis of a-caspase-1/NLRP3
confocal images. Cells were pooled for analysis. (E) Representative density plot of
inflammasome formation based on the detection of fluorescence pulse differences in
ASC. (F) Quantitation of percentage of ASC positive cells. (G) Quantitation of mean cell
area. (H) Ethidium bromide dye incorporation was measured by flow cytometry at 5 min
intervals. (I) Percentage of ROS positive cells was assessed by flow cytometry. (J)
Representative micrograph (2520x magnification, 7.5 µm scale) of β-catenin
expression. DAPI (blue), β-catenin (red), and the merged images show nuclear
localization of β-catenin. (K) Quantitation and scoring of β-catenin confocal images
based on the presence of no, low, medium, or high nuclear β-catenin. Cells were pooled
for analysis. Measurements of significance were made on untreated KO cells compared
to NAC or DPI treated KO cells. Error bars: SE, *p<0.05, **p<0.01 and ***p<0.001.
inflammasome activation that functions as a dominant-negative ASC antagonist
blocking ASC oligomerization,277 was profoundly reduced in both lower-risk MDS BMMNC (n=9) and U2AF1-S34F-expressing cells (Figure 29D and 29E). To determine if
NLRP3 inflammasome activation is reinforced in MDS by reduced expression of POP-1,
U2AF1-S34F cells were transfected with POP-1 expression vectors. Significant
increases in POP-1 expression were associated with a 40% reduction in NLRP3
activation, as measured by ASC oligomerization (Figure 29F). Collectively, these
findings indicate that MDS HSPCs are primed for NLRP3 inflammasome activation.
MDS MSC and stromal-derived lineages undergo pyroptosis. It is well
established that a dynamic and complex interplay exists between hematopoietic cells
and the surrounding mesenchymal stromal cells (MSC) in the MDS bone marrow.120-122
Specifically, dysfunction in one compartment, namely hematopoietic cells or MSC,
reinforces dysfunction in the other compartment.120 Of note, co-culture of MDS-derived
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Figure 28. Somatic gene mutations and mutation variant allele fraction correlate
+
with the extent of pyroptosis in MDS. (A) The percentage of pyroptotic CD71 cells
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significantly increases with spliceosome mutation VAF. (B) There is a trend toward
+
+
+
increased a-caspase-1 CD71 cells with VAF. (C) The percentage of pyroptotic CD71
cells increases with the number of mutations. (D-E) The (D) percentage and (E) MFI of
plasma ASC specks significantly increases with the presence of a somatic gene
mutation. (F-G) The (F) percentage and (G) MFI of plasma ASC specks significantly and
positively correlate with BM plasma S100A9 concentration.
stromal cells with the F-36P AML cell line resulted in increased hematopoietic cell
death, measured by 7-aminoactinomycin D (7-AAD) staining.121 Given the inflammatory
nature of pyroptosis, with the release of DAMP signals, pro-inflammatory cytokines, and
cellular debris following lysis, we hypothesized that pyroptotic cell death of HSPC
triggers pyroptosis within MSC and stromal-derived lineages. As such, pyroptosis of
stromal cells could account for the defective ability of the MDS stroma to support
normal, effective hematopoiesis.
Foremost, we measured the extent of pyroptosis versus apoptosis in MSC and
MSC-derived lineages from lower-risk MDS (n=6) compared to normal (n=6) BM
donors. MSC were defined as CD45-CD105+, endothelial cells as CD31+ and
osteoblasts as CD34-osteocalcin(OCN)+. The mean percentage of pyroptotic MSC
(p=4.1x10-3), endothelial cells (p=0.034) and osteoblasts (p=1.0x10-3) were significantly
increased in MDS compared to normal donors (Figure 30A). While the apoptotic fraction
across the three lineages was markedly increased in MDS compared to normal, these
findings are consistent with activation of caspase-3 downstream of caspase-1 activation
during pyroptosis execution (Figure 30B). Moreover, MDS specimens displayed 13.9fold and 7.6-fold increases in the mean percentage of a-caspase-1+ MSC (p=6.6x10-5)
and endothelial cells (p=0.05) compared to normal donors (Figure 30C). Though acaspase-1+ osteoblast cells were increased 7.1-fold in MDS, this level only approached
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Figure 29. Inflammasome activation occurs via up-regulation of TXNIP and downregulation of POP-1. Data are representative of three independent experiments. (A)
qPCR analyses show markedly increased expression of TXNIP in lower-risk MDS BMMNC (n=9) compared to normal donor controls (n=4), as well as in U2AF1-S34Fexpressing cells compared to WT. (B-C) Binding of TXNIP and ASC to NLRP3 is
increased in (B) lower-risk MDS BM-MNC and (C) U2AF1-S34F cells (IP: NLRP3, IB:
NLRP3, ASC, TXNIP). (D) POP-1 gene expression is dramatically reduced in lower-risk
MDS BM-MNC (n=9) compared to normal donor controls (n=4), as well as in U2AF1S34F-expressing cells compared to WT. (E) Western blot of POP-1 and TXNIP protein
expression in lower-risk MDS BM-MNC compared to normal donors. (F) U2AF1-S34Fexpressing cells were transiently transfected with POP-1 expression vectors by
electroporation method. POP-1 expression is increased following transfection, which
corresponds with a pronounced reduction in ASC oligomerization as measured by flow
cytometry. Error bars: SE, *p<0.05.
statistical significance (Figure 30C). To a lesser extent, a-caspase-3/7+ cells were
increased across each stromal-derived lineage in MDS compared to normal (Figure
30D). Similar observations were made with respect to a-caspase-1 MFI (Figure 30E)
and a-caspase-3/7 MFI (Figure 30F). When the extent of pyroptosis versus apoptosis
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was compared across lineages in MDS, the pyroptotic cell fraction significantly
exceeded the corresponding apoptotic cell fraction (Figure 30G). Specifically, pyroptotic
MSC, endothelial cells and osteoblasts were 7.3-fold (p=4.6x10-3), 10.3-fold (p=0.03)
and 16.2-fold (p=1.1x10-4) more frequent than apoptotic cells of the same cell type
(Figure 30G). When a similar comparison was made in the fraction of a-caspase-1+
versus a-caspase-3/7+ cells of each lineage, a-caspase-1+ cells were predominant
(Figure 30H). Lastly, cell swelling, a hallmark of pyroptosis, can be measured by SSC-A
flow cytometric measurements.300 MDS-MSC had significantly larger cell area (p=0.03)
compared to normal donors (Figure 30I). While MDS endothelial cells and osteoblasts
did display a larger cell area compared to normal, these data did not reach statistical
significance. Together, these findings indicate that MDS-MSC and MSC-derived
lineages, specifically endothelial cells and osteoblasts, predominantly undergo
pyroptotic cell death.

Discussion

Heretofore, ineffective hematopoiesis in MDS has been attributed to high
fractions of proliferating BM progenitors undergoing apoptotic cell death within an
unexplained inflammatory microenvironment.196,288 Nearly two decades ago it was
reported that MDS HSPC generate IL-1β in short term cultures, which directly correlated
with the extent of cell death as measured by DNA fragmentation.99 We present evidence
that these and other biological features of MDS are explained by the activation of the
NLRP3 pattern recognition receptor by S100A9 and ROS DAMP intermediates that

114

Figure 30. Pyroptosis is manifest in MSC and stromal-derived lineages in MDS.
(A-B) The mean percentage of (A) pyroptotic and (B) apoptotic cells by mesenchymal
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lineage in lower-risk MDS (n=6) versus normal donors (n=6). (C-D) Mean percentage of
+
+
(C) total a-caspase-1 and (D) a-caspase-3/7 cells in lower-risk MDS (n=6) versus
normal donors (n=6). (E-F) Mean (E) a-caspase-1 MFI and (F) a-caspase-3/7 MFI. (G)
Comparison of the mean percentage of pyroptotic versus apoptotic cells in lower-risk
+
MDS specimens (n=6). (H) Comparison of the mean percentage of a-caspase-1 versus
+
a-caspase-3/7 cells in the same lower-risk MDS patients (n=6). (I) Flow cytometric
analysis of mean SSC-A intensity of BM-MNC by mesenchymal lineage isolated from
normal donors (n=6) or lower-risk MDS patients (n=6). Error bars: SE, *p<0.05,
**p<0.01 and ***p<0.001.
induce inflammasome assembly, β-catenin nuclear translocation and pyroptotic cell
death. Notably, pyroptosis-associated gene transcripts and inflammasome assembly
are profoundly up-regulated in MDS independent of genotype. Moreover, pyroptotic but
not apoptotic cells are markedly increased in MDS stem cells, progenitors and erythroid
precursors. Accordingly, knockdown of NLRP3 and caspase-1, but not caspase-3,
significantly reduced the pyroptotic cell fraction in MDS BM-MNC. MDS HSPCs are also
selectively primed to undergo pyroptosis, due in part to up-regulation of pattern
recognition receptors directing pyroptotic cell death, the expansion of MDSCs140 and
transcriptional priming of inflammasome components. Importantly, neutralization of
S100A9 in MDS BM plasma or pharmacologic inhibition of inflammasome assembly
suppressed pyroptosis and restored effective hematopoiesis in vitro and in the
S100A9Tg mouse model of MDS. Thus, pyroptosis, a caspase-1-dependent
inflammatory cell death, impairs HSPC survival in MDS.
S100A8/S100A9 heterodimers activate both NF-κB and NLRP3 inflammasome
assembly via an NADPH oxidase (NOX)/ROS-dependent mechanism.258,266,267,314
Intracellularly, S100A8/9 heterodimers serve as a scaffold for the membrane assembly
and activation of the NOX complex,264,265 which generates ROS via transfer of electrons
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across membranes to generate superoxide.259 As also shown here, NOX activity
regulates both priming and activation of NLRP3 inflammasomes, including the activation
of caspase-1 and IL-1β maturation.258 Moreover, transcription and nuclear localization of
β-catenin are redox- and NOX1-dependent.285,286 Although MDSC are a key paracrine
source of S100A9 in the MDS BM microenvironment,140 here we show that MDS HSPC
also express high intracellular levels of S100A9 across lineages, suggesting that
inflammasome activation may be sustained by intracrine DAMP stimulation which
following cytolysis, may be reinforced by paracrine TLR4 activation and expansion of
BM MDSC. Indeed, Schneider et al. recently reported that Rps14 haplodeficiency
induces S100A8/9 expression to direct TLR4-dependent, cell-intrinsic death of
polychromatic erythroblasts.167 Comparative transcriptome analysis also shows that
S100A8/9 is highly up-regulated in Srsf2 P95H mutant as well as Ezh2-deleted mouse
models.315,316 Additionally, our findings that catalytically-active pyroptotic ASC specks
are released from the cytosol into the extracellular space suggest that specks may
continue to reinforce bystander inflammation in the microenvironment in a non-cell
autonomous fashion.298,317 Importantly, NOX1/4 inhibition suppresses the activation of
the inflammasome and β-catenin in both MDS patient-derived BM-MNC and in cells
harboring varied classes and types of MDS founder gene mutations. Thus, S100A9
induces NOX1/4 activity to drive ROS-dependent inflammasome assembly, pyroptosis,
and β-catenin activation, explaining the proliferation and inflammatory cell death
manifest in MDS.
Another hallmark of MDS is the larger cell size of BM precursors, or
macrocytosis. A characteristic feature of NLRP3 inflammasome activation is cell
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swelling due to the activation of cation channels in the plasma membrane.214 We show
that activation of pattern recognition receptors triggers expansion in size and volume of
MDS progenitors via influx of cations by membrane channels that are activated by NOXderived ROS.217,318-320 Our findings show that MDS BM-MNC display increased influx of
the membrane impermeable, cationic dye ethidium bromide, confirming ion channel
activation. Additionally, quantitation of BM cells according to lineage and stage of
maturation confirmed a significantly larger size of MDS BM precursors versus normal
controls that increased directly with NLRP3 mean fluorescence intensity. Thus, S100A9mediated

NOX

activation

and

inflammasome-initiated

pyroptosis

explain

the

characteristic larger cell size, proliferation and inflammatory cell death manifest in MDS.
Somatic

gene

mutations

in

MDS

trigger

Rac1/NOX-dependent

ROS

generation,263,321 which we show activates both inflammasomes and Wnt/β-catenin
signaling, a pathway known to promote leukemia stem cell self-renewal. NOX-derived
ROS stabilize and activate β-catenin by oxidation and dissociation of nucleoredoxin
(NRX) from disheveled (Dvl), which in turn inactivates the β-catenin destruction
complex.287 Here we show that ROS and β-catenin nuclear localization are profoundly
increased in MDS HSPC, and that S100A9 treatment of normal BM-MNC is sufficient to
trigger NOX/ROS-dependent nuclear translocation of β-catenin and the activation of
Wnt/β-catenin target genes. Similarly, BM-MNC from S100A9Tg mice, and BM
progenitors that express varied RNA splicing gene mutations (U2AF1, SF3B1, SRSF2)
and epigenetic regulatory gene mutations (ASXL1, TET2) found in MDS similarly
undergo pyroptosis, pore formation, cell volume expansion and express high levels of
nuclear β-catenin and Wnt/β-catenin target genes, which can be suppressed by
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inhibition of the NLRP3 inflammasome or NOX1/4. Moreover, the proportion of
pyroptotic erythroid progenitors in primary MDS specimens increases with somatic gene
mutation allele burden and mutation complexity. Mechanistically, we show that the
thioredoxin-interacting protein, TXNIP, serves as a redox sensitive ligand activating the
NLRP3 inflammasome upon oxidative dissociation from thioredoxin in both MDS and
splicing gene mutant cells. Inflammasome nucleation in MDS is further reinforced by
reduced expression of the pyrin domain-only protein (POP)-1, a dominant-negative ASC
antagonist preventing NLRP3 and ASC polymerization. The forced expression of POP-1
reduced NLRP3 inflammasome activation, indicating that MDS HSPCs are primed for
NLRP3 inflammasome activation. Thus, both S100A9-induced NOX activation and MDS
gene mutations initiate pyroptosis through superoxide generation to drive β-catenin
activation and enable a proliferative advantage to the MDS clone.
Lastly, the MDS stroma is known to be impaired in its ability to support normal,
effective

hematopoiesis.

Murine

models

generated

by

MDS-related

stromal

abnormalities demonstrate that stromal defects can induce aberrances and dysplasia in
otherwise normal hematopoietic cells.122 Conversely, normal MSC co-cultured with MDS
patient-derived CD34+ HSPC adopt a phenotype characteristic of MDS-MSC.120,121
These findings illustrate the complex interplay that exists between the hematopoietic
and stromal cell compartments in MDS. Given that pro-inflammatory cytokines and
DAMP signals are released upon cytolysis in pyroptosis, we hypothesized that cell
death of hematopoietic cells can induce pyroptosis of neighboring stromal cells,
resulting in cell death or injury of stromal lineages and consequent deficient support of
hematopoiesis. Indeed, our data indicate that pyroptosis is significantly increased in
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MSC, endothelial cells and osteoblasts in MDS compared to normal donors. Similar
increases were observed in the percentage of a-caspase-1+ cells and a-caspase-1 MFI.
Moreover, the pyroptotic cell fraction significantly exceeded the corresponding apoptotic
cell fraction across stromal-derived lineages in MDS, indicating that the MDS stroma
predominantly undergoes pyroptotic cell death.
In conclusion, despite genetic heterogeneity, inflammasome activation underlies
the biological phenotype in lower-risk MDS, whereby DAMP signals and MDS gene
mutations license a common redox-sensitive inflammasome platform to drive pyroptotic
death, elaborate inflammatory cytokines, activate cation influx, and support propagation
of the MDS clone through β-catenin activation (Figure 31). These findings provide a
common platform that accounts for the biological features of MDS and suggest that
strategies targeting S100A9 neutralization or inhibition of pyroptosis signaling offer
therapeutic promise in lower-risk MDS.

Methods

MDS patient specimens. MDS patients consented on The University of South
Florida Institutional Review Board approved protocols were recruited from the Malignant
Hematology Clinic at H. Lee Moffitt Cancer Center & Research Institute, and the
Eastern Cooperative Oncology Group (ECOG) E2905 trial (NCT00843882). Pathologic
subtype of MDS was reported according to World Health Organization (WHO) criteria
and prognostic risk assigned according to the International Prognostic Scoring System

120

Figure 31. An S100A9/pyroptosis circuit provokes phenotypes manifest in MDS.
(A) S100A8/A9 binds both CD33 and TLR4, resulting in inflammasome assembly.
Ligation of S100A8/A9 to TLR4 results in NF-κB-mediated transcription and subsequent
production of pro-inflammatory cytokines such as pro-IL-1β and pro-IL-18, along with
inflammasome components. (B) Through interaction with Rac2 and p67phox,
S100A8/A9 promotes activation of NOX, which results in a dual function. First, NOX
proteins generate ROS, which serve to activate NLRs and inflammasome assembly.
Second, NOX-derived ROS oxidize NRX, leading to its dissociation from Dvl. Once
dissociated, Dvl suppress the β-catenin destruction complex (GSKβ/CK1/APC/Axin),
resulting in stabilization of β-catenin. This allows β-catenin to enter the nucleus and
induce transcription of TCF/LEF controlled genes, including Cyclin-D1 and c-Myc, which
are essential to self-renewal. (C) Transient receptor potential melastatin 2 (TRPM2), a
calcium-permeable cation channel in hematopoietic cells, is activated by NOX-derived
214
ROS via oxidation of a single channel methionine residue, Met . Upon activation,
TRPM2 causes an influx of calcium leading to mitochondrial depolarization and further
release of ROS, which activate the inflammasome complex. (D) Formation of the
inflammasome complex occurs as a consequence of ROS activation and DAMP
signaling. Once activated, inflammasomes mediate conversion of pro-caspase-1 to its
mature and catalytically active form. Active caspase-1 cleaves pro-IL-1β and pro-IL-18
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to their mature forms. (E) Pyroptosis ensues with loss of membrane integrity resulting in
release of pro-inflammatory cytokines and other intracellular contents into the
extracellular milieu. (F) MDS-related gene mutations activate NF-κB and NLRP3 via
NOX-generated ROS.
(IPSS). Patients were segregated as lower- (low, intermediate-1) and higher-risk
(intermediate-2, high) MDS.
Mice. S100A9Tg mice have been described.140 Wild type FVB/NJ mice were
purchased from Jackson Laboratories (Bar Harbor, Maine). Bone marrow (BM) cells
were isolated from tibias and femurs of male and female mice.
Reagents and cells. Parental TF-1 cells and TF-1 cells engineered to express
mutant U2AF1 were cultured in RPMI-1640 supplemented with 10% FBS and 2 ng/mL
recombinant human GM-CSF. Normal, heparinized BM aspirates were purchased from
Lonza Walkersville or AllCells, LLC. Normal and MDS BM mononuclear cells (BMMNC) were isolated from heparinized BM aspirates using Ficoll-Hypaque Plus gradient
centrifugation (GE Healthcare). Recombinant human S100A9 and the CD33/Siglec 3
chimeric fusion protein were generated as described.140 NAC and DPI were purchased
from Sigma. Active caspase-1 and caspase-3/7 were detected using FAM-FLICA®
Caspase-1 and Caspase-3/7 activity kits, (ImmunoChemistry Technologies). NLRP3
antibodies were purchased from Abcam (ab4207) or AdipoGen (AG-20B-0014), and βcatenin antibodies from BD Biosciences (610154). Caspase-1 antibodies (#3866) were
purchased from Cell Signaling Technology, Inc. IL-1β antibodies (AF-201-NA) were
acquired from R&D Systems, Inc.
Immunofluorescence confocal microscopy. MDS BM-MNC, normal donor
BM-MNC and mouse BM cells were stained with 30x FAM-FLICA® Caspase-1 solution
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at a ratio of 1:30 for 2 hr at 37°C. Cells were washed and cytospins were generated
using a 5 min centrifugation at 450 rpm. Slides were fixed at 37°C for 10 min using BD
Cytofix Fixation Buffer (BD Biosciences), and then washed with PBS. Cells were
permeabilized with 0.1% Triton X-100/2% BSA in PBS for 15 min at room temperature.
After washing with PBS, cells were blocked using 2% BSA in PBS for 30 min at room
temperature and washed again. Cells were incubated with the appropriate primary
antibody overnight (1:400 for NLRP3, 1:20 for β-catenin) at 4°C. The next day, cells
were washed with PBS and incubated with the appropriate secondary antibodies
(1:500) for 1 hr at room temperature. After washing, cells were covered with ProLong
Gold Antifade Reagent with DAPI prior to the addition of a coverslip (Life Technologies).
Co-localization of a-caspase-1 with NLRP3 inflammasomes was assessed using
a Leica TCS SP5 AOBS Laser Scanning Confocal microscope (Leica Microsystems).
Analysis of images was performed with Definiens Developer 2.0 (Definiens AG), which
distinguishes cells based on brightness and size thresholds, followed by a watershed
segmentation algorithm. Intensity values and Pearson’s correlation coefficient were
extracted from the segmented cells. For β-catenin image analysis, confocal images
were imported into Definiens Tissue Studio v3.0, 64 Dual in .tif format. Cells were
separated from background using the RGB thresholds. Nuclei were identified by setting
thresholds in the DAPI channel. β-catenin intensity in the nucleus and cytoplasm was
established by setting thresholds to low, medium and high in the red channel on a scale
of 0-255.
Flow cytometry analyses. For human samples, treated and untreated BM-MNC
were incubated overnight in IMDM, supplemented with 10% autologous BM plasma.
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Cells were then harvested, washed twice in PBS, and stained with LIVE/DEAD Violet
fluorescent reactive dye (Life Technologies) and Zombie NIR Viability dye (BioLegend)
according to the manufacturer’s protocols. Cells were resuspended in 1x PBS with 2%
BSA, and incubated at room temperature for 15 min to block non-specific binding. After
washing, cells were stained with 30x FAM-FLICA® Caspase-1 and Caspase-3/7
solution at a ratio of 1:30 for 2 hr at 37°C. For flow cytometry analyses of phenotypically
distinct hematopoietic lineages, human cells were washed and stained for cell surface
receptors using CD38:PE-CF594, CD33:BV711, CD34:APC (BD Biosciences, 562288,
563171, 555824, respectively), and CD71:PE-Cyanine7 (eBioscience, 25-0719-42). For
analyses of phenotypically distinct stromal cell lineages, human cells were washed and
stained for cell surface receptors using CD105:BUV395, CD31:FITC, CD34:BUV395
(BD Biosciences, 563803, 553372, 563778, respectively) and osteocalcin:Alexa Fluor
488 (R&D Systems, IC1419G). Mouse cells were washed and stained for cell surface
receptors using Lineage Cocktail:V450, CD117:BUV395, and Ly-6A/E:BV786 (BD
Biosciences, 561301, 564011, 563991, respectively). All antibodies were diluted 1:20,
and cells were stained for 30 min at 4°C. Cells were washed, resuspended in 1x binding
buffer, and stained with Annexin-V:PE or Annexin-V:V500 at a dilution of 1:20 for 15 min
at room temperature (BD Biosciences, 556421) for hematopoietic and stromal cell
lineage panels, respectively. 1x binding buffer was added to a final volume of 400 µL.
ASC staining was carried out as described.298 Briefly, cell pellets were
resuspended in 1 mL of prewarmed BD Permeabilization Buffer III, and incubated on ice
for 30 min. Cells were washed 2x with staining buffer. Following washing, cells were
stained with rabbit-anti-ASC primary antibodies at a 1:1500 dilution and incubated for 90
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min (Santa Cruz, sc-22514-R). Cells were washed, stained with secondary antibodies at
a dilution of 1:1500, and incubated for 45 min. Cells were washed, and sample
acquisitions were carried out using a BD LSR II flow cytometer and FACSDiva software.
For ASC speck detection, 400 µg of protein in BM plasma from normal donors
and MDS patients was stained with rabbit-anti-ASC primary antibodies at a 1:1500
dilution and incubated for 90 min. Secondary antibodies were added at a dilution of
1:1500 and incubated for 45 min. Sample acquisitions were carried out using a BD
FACSCalibur flow cytometer. Threshold for FSC and SSC were set to zero to allow
detection of specks.
Sample acquisitions were carried out using a BD LSR II flow cytometer and
FACSDiva software (BD Biosciences). Calibration was carried out prior to each
experiment using Rainbow Mid-Range Fluorescent Particles (BD Biosciences). To
establish compensation settings, ArC Amine Reactive Compensation Beads were used
for viability staining (Life Technologies), and BD CompBead Plus Anti-Mouse Ig
κ/Negative Control (BSA) Compensation Plus Particles and Anti-Rat and Anti-Hamster
Ig κ/Negative Control Compensation Particles Set were used for surface receptor
conjugates for human and murine studies, respectively (BD Biosciences). Data were
analyzed using FlowJo 9.7.5 software (FlowJo, LLC). Gating strategies for evaluating
the extent of pyroptosis versus apoptosis in normal/MDS specimens and WT/S100A9Tg
mice are illustrated in Figure 32.
Lentiviral infection of primary mononuclear cells. Lentiviral constructs were
purchased from Origene. NLRP3 (TL30582b), Caspase-1 (TL305640), Caspase-3
(TL305638b) and scrambled (TR30021) HuSHTM shRNA plasmids were amplified by
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Figure 32. Flow cytometry gating strategies for evaluating the extent of
pyroptosis versus apoptosis in normal/MDS specimens and WT/S100A9Tg mice.
The gating strategies depicted take place after gating for cell lineage was carried out.
(A) For normal donors and MDS specimens, the gates for annexin-V, a-caspase-1 and
a-caspase-3/7 positivity were identified using fluorescence minus one (FMO) controls.
The annexin-V positive cells were then stratified by a-caspase-1 and a-caspase-3/7
positivity. Using the gates identified for a-caspase-1 and a-caspase-3 positivity, a
quadrant plot was made. Apoptotic cells were defined as annexin-V+/a-caspase-1-/acaspase-3/7+ and pyroptotic cells annexin-V+/a-caspase-1+/a-caspase-3/7+. (B)
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Representative density plots from a normal BM donor versus an MDS specimen.
Annexin-V positive cells from the stem cell (CD34+CD38-), progenitor (CD34+CD38+),
immature myeloid (CD33+) and erythroid (CD71+) populations were stratified according
to a-caspase-1 and a-caspase-3/7 positivity, allowing for the characterization of the
extent of pyroptotic versus apoptotic cell death. (C) For WT/S100A9Tg mice analyses,
the gates for annexin-V, a-caspase-1 and a-caspase-3/7 positivity were identified using
FMO controls and a quadrant plot stratifying the annexin-V positive cells according to acaspase-1 and a-caspase-3/7 expression was created as described in (A). (D)
Representative density plot from a WT versus a S100A9Tg sample. The plot depicts the
extent of pyroptosis versus apoptosis in the LSK positive HSPC population.
transforming One Shot® Top10 competent cells (Life Technologies) according to
manufacturer’s protocol. Single colonies were expanded and plasmid DNA prepared
using the Qiagen QIAprep® Mini Prep Kit. HEK293T cells were transfected by
incubating 2600 ng of shRNA plasmid, 30 µL Lipofectamine® 2000 (Invitrogen) and 26
µL MISSIONTM Lentiviral Packaging Mix (Sigma) in 500 µL of Opti-MEM®I (Life
Technologies) for 15 min at room temperature. This mixture was then added to 70%
confluent HEK293T cells with 4 mL Opti-MEM®I medium without serum in a 100 mm
dish. After 6 hr, 6 mL of DMEM with 10% FBS (Mediatech) was added. After 16 hr,
medium was changed and 10 mL fresh DMEM was added. Virus was collected at 48
and 72 hr using 0.45 µm filters. The titer was at least 5 x 105 IFU/mL and virus was
stored at 4 °C.
For primary cell infections with caspase-1 and caspase-3 lentivirus, 2.5x106 cells
were plated in a 100 mm dish with 1.25 mL virus, 1.25 mL opti-MEM®I and 8 µg/mL
polybrene. Cells were incubated overnight, then 5 mL of fresh IMDM with 10% FBS
(Mediatech) was added. RNA was isolated 72 hr after infection using Qiagen RNeasy
Isolation Kit. mRNA levels were analyzed by qPCR using GAPDH mRNA levels as a
control. For primary cell infections with NLRP3 lentivirus, 2x106 cells were plated in a 24
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well plate with 500 µL fresh virus, 500 µL Opti-MEM®I and 8 µg/mL polybrene. The
plate was spun at 2,200 rpm for 90 min. After 1 hr, 5 mL of fresh IMDM was added.
Knockdown efficiency of NLRP3 protein was determined by flow cytometry. For both
infection protocols, 10% v/v of autologous BM plasma was added to the cells at 72 hr.
Cells were stained with annexin-V, 7-AAD, and FAM-FLICA® Caspase-1 and analyzed
using a BD FACSCalibur flow cytometer 24 hr after plasma was added.
Enzyme-linked immunosorbent assays (ELISA). Human S100A9 DuoSet
ELISA kit was purchased from R&D Systems and HMGB1 ELISA kit was purchased
from MYBioSource. ELISA assays were performed according to manufacturer’s
protocol.
Intracellular S100A9 flow cytometry. BM-MNC were incubated overnight in
IMDM medium with 10% autologous BM plasma. Cells were then harvested, washed
twice in 1x PBS, fixed with BD Cytofix Fixation Buffer at 37°C for 10 min, and stored at 80°C until staining. For staining, cells were warmed to 37°C, spun down, and washed
twice with staining buffer. Cells were suspended in 1 mL of pre-warmed BD
Permeabilization Buffer III, incubated on ice for 30 min, washed twice with staining
buffer and stained with antibodies at a 1:20 dilution for 30 min at 4°C (S100A9:FITC
[BioLegend]; CD38:PE-CF594; CD33:BV711; CD34:APC [BD Biosciences]; and
CD71:PE-Cyanine7 [eBioscience]). Cells were washed and resuspended in 400 µL
staining buffer. Sample acquisitions were performed using a BD LSR II flow cytometer
and FACSDiva software (BD Biosciences).
Pore formation assay. MDS and normal donor BM-MNC were incubated in 10%
autologous BM plasma at 37°C overnight. Cells were then washed and suspended in 1
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mL of PBS with 12.5 µg/mL ethidium bromide (Fisher Scientific). Sample acquisitions
were acquired using a BD FACSCalibur flow cytometer at 5 min intervals.
Real-time quantitative PCR. RNA was isolated from BM-MNC using the
RNeasy Mini Kit (Qiagen). cDNA was produced using the iScript cDNA Synthesis Kit
(Bio-Rad). Sequences for primers can be found in Table 4. GAPDH mRNA was used for
transcript normalization. cDNA was amplified using the iQ SYBR Green Supermix and
the CFX96 Real-Time PCR Detection System (Bio-Rad). PCR conditions were as
follows: 10 min at 95°C, followed by 40 cycles of amplification (15 seconds at 95°C and
1 min at 60 °C). Relative gene expression was calculated using the -2ΔΔCt method.
Table 4. Primer sequences used for real-time quantitative PCR.

Colony formation assays. For MDS assays, 4 replicates of 3.5x105 BMMNC/mL were resuspended in 10% autologous BM plasma and plated in MethoCult
methylcellulose medium (Stemcell Technologies) supplemented with 1% v/v penicillinstreptomycin and 3 units/mL erythropoietin (Epo). CD33-IgG and MCC950 were added
directly to the medium prior to plating. BFU-E, CFU-GM and CFU-GEMM colonies were
scored using an inverted light microscope 14 days after plating. For assays of TF-1
cells expressing mutant U2AF1, 4 replicates of 3x104 cells/mL were plated in medium
supplemented with 1% v/v penicillin-streptomycin and increasing concentrations of
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ICTA. Colonies were counted 7 days after plating. For colony assays of primary Sf3b1K700E mouse BM cells, BM cells were isolated from 4 mice per condition and 4
replicates of 3.5x105 BM cells/mL were plated in MethoCult with increasing
concentrations of ICTA. Colonies were scored 14 days after plating.
ROS detection. ROS levels were determined using CellROX® Deep Red
Reagent using the manufacturer’s protocol (Life Technologies).
ICTA mouse treatment studies. ICTA was synthesized by the Drug Discovery
Core Facility at H. Lee Moffitt Cancer Center & Research Institute. Six month old
S100A9Tg (n=5) were dosed every other day with 50 mg/kg ICTA by oral gavage, for a
total of eight weeks.
SRSF2 transfection of HEK293T cells. HEK293T cells were transfected by
incubating 4 µg of SRSF2 expression plasmid with 10 µL Lipofectamine® 2000 in 100
µL of Opti-MEM®I for 20 min at room temperature. This mixture was added to 70%
confluent HEK293T cells with 2 mL Opti-MEM®I medium without serum in a 6 well
plate. Cells were incubated at 37°C for 4 hr in a humidified chamber, then medium was
replaced with 2 mL of DMEM with 10% FBS. Cells were treated with NAC and DPI 24 hr
later, and subsequent analyses were carried out 48 hr following transfection.
Immunoblotting. U2AF1-S34F-expressing TF-1 cells were treated for 24 hr as
indicated and harvested. Normal and lower-risk MDS BM-MNC were thawed and
pelleted. Samples were lysed in 1x RIPA buffer (250 µM NaOV4, 2 µg/mL aprotinin, 2
µg/mL leupeptin, 0.2 µg/mL pepstatin A and 500 µM PMSF), and proteins were resolved
by SDS-PAGE and transferred to PVDF membranes. Membranes were blocked for 30
min in 5% dry milk PBS-T solution (1x PBS, Tween®20), and incubated overnight with
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the indicated antibody. For caspase-1 detection, the membrane and indicated antibody
were incubated in TBS-T solution (1x TBS, 5% w/v BSA, 0.1% Tween®20). The next
day, membranes were washed and secondary antibodies were incubated for 3 hr.
Membranes were developed using ECL or ECL+ according to manufacturer’s protocol
(Thermo Scientific).
Immunoprecipitation. Following lysis, 200 µg of protein were incubated with 2
µg of the indicated antibody on ice for 2 hr. 50 µL of Protein A Agarose beads (EMD
Millipore) were added to each sample, and bead-lysate slurries were incubated
overnight at 4°C on a rotator. The next day, samples were washed with 500 µL of lysis
buffer three times. Beads were dissociated at 95°C for 5 min following addition of
sample

buffer.

Proteins

were

separated

by

SDS-PAGE

and

analyzed

by

immunoblotting.
ASC crosslinking. For normal and MDS BM-MNC, 10x106 cells were incubated
overnight in autologous plasma. Cells were harvested, washed twice with 1x PBS and
lysed with 100 µL of 1x RIPA buffer containing 1 tablet of Complete PhosStop (Roche
Diagnostics, Indianapolis, IN) for 10 min on ice. Samples were spun down at 5,000 rpm
for 10 min at 4°C, and cell lysates were removed and saved. Cell pellets were washed
twice with 1x PBS, spun at 5,000 rpm for 10 min at 4 °C for each wash, and cells were
resuspended in 100 µL of 1x PBS.

Disuccinimidyl suberate (2 mM) (DSS,

ThermoScientific) was then added, samples were incubated on a rotator for 30 min at
room temperature, and then spun down at 5,000 rpm for 10 min at 4°C. The
supernatant was removed and saved. 20 µL of sample buffer was added to the saved
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lysate and supernatant samples, and the crosslinked pellet was resuspended in 30 µL.
Samples were boiled at 99°C for 5 min and proteins resolved by SDS-PAGE.
Next-generation sequencing and mutation identification. DNA was extracted
from 40 total PB and BM samples. Target amplification of DNA for each sample was
performed using the GeneRead DNAseq Panel PCR Kit V2 (Qiagen). Target regions of
26 common genes and genotype fingerprint regions were enriched using the Human
Colorectal Cancer Panel according to manufacturer instructions. Samples were
barcoded using NEXTflex-96™ DNA Barcodes (Bioo Scientific) and pooled in equal
amounts before running on an Illumina MiSeq 2000. Sequence reads were aligned to
the human genome using the GeneRead Targeted Exon Enrichment Panel Data
Analysis (Qiagen). Sample data with synonymous variants, noncoding variants and
variants present in databases of normal genomes (i.e., ESP6500) were discarded.
Remaining variants were filtered to contain more than 50x coverage and variant
frequencies greater than 0.2. Of these variants, those that were present in COSMIC, or
those not present in COSMIC but having SIFT scores ≤0.05 and Polyphen scores
≥0.909, were considered candidate somatic mutations. Clinical and mutational patient
characteristics are summarized in Table 5.
POP-1 overexpression. PYDC1 expression (RC211240) and empty control
(PS100001) vectors were purchased from Origene Technologies, Inc. 5 µg of plasmid
was added to 6 million cells suspended in 100 µL electroporation solution (Ingenio®
Solution, Mirus Bio LLC.) and electroporated using Amaxa Nucleofector® program T-20
(Lonza Cologne AG, Germany). Cells were resuspended in 30 mL of appropriate
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Table 5. Clinical and genotypic characteristics of sequenced patients. Bone
marrow (BM) or peripheral blood (PB) samples were obtained for DNA extraction and
sequencing. Patients were characterized according to WHO diagnostic classifications:
(i) refractory anemia with ring sideroblasts (RARS); (ii) refractory anemia (RA); (iii)
refractory cytopenia with multilineage dysplasia (RCMD); and (iv) refractory anemia with
excess blasts (RAEB). Risk stratification was determined by IPSS classification: 0, low;
1, intermediate-1; 2, intermediate-2; 3, high risk. For each patient, genes without
mutations are blank, and those harboring mutations are identified by a plus (+). Data
that was unavailable is listed as NA.
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growth medium.

Expression and functional assays were performed 48 hr after

transfection.
Statistical analyses. Data are expressed as means ± standard error. Statistical
analyses were carried out in Microsoft Excel using student’s t-test. *P values <0.05,
**p<0.01, and ***p<0.001 were considered to be statistically significant. Correlations
were performed using chi-squared test for non-continuous variables and logistic
regression for continuous variables. Comparisons of all pyroptotic parameters and
somatic gene mutation variant allele frequency (VAF) were performed using chi-squared
test for binary variables and Mann-Whitney and Kruskal-Wallis tests for continuous
variables. These analyses were performed using SPSS software v22 (SPSS, Inc.).
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CHAPTER 3
Pyroptosis of Erythroid Progenitors Accounts for the Erythroid Defect
Characteristic of the 5q- Syndrome
Introduction
Identified in 1974, the 5q- syndrome represents a distinct subtype of
myelodysplastic syndromes (MDS) characterized by a clonal, interstitial deletion of the
long arm of chromosome 5 [del(5q)].35 Patients with del(5q) MDS generally present with
a progressive, macrocytic and hypoplastic anemia with normal or elevated platelet count
and

dysplastic,

oligonuclear

megakaryocytes,150

suggesting

that

the

major

hematopoietic defect lies within the erythroid compartment. Accordingly, anemia
remains the principal therapeutic challenge for patients with del(5q) MDS, as
approximately 93% of patients will become transfusion-dependent in the course of their
disease.151 Lenalidomide, a second-generation immunomodulatory drug (IMiD), is FDAapproved for del(5q) MDS and represents the standard of care for this subset of
patients for over a decade.45 Although approximately 83% of lenalidomide-treated
patients respond quickly and become transfusion-independent, 50% of these will
develop resistance within two or three years,322 illustrating the need for novel
therapeutic agents.
The commonly deleted region (CDR) in del(5q) MDS encompasses a gene-rich
area on chromosome 5, spanning approximately 1.5-megabases or 40 genes.154 Using
array-based transcriptome analyses together with gene sequencing, haploinsufficiency
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of select 5q- genes has been implicated in disease pathobiology, as no mutations have
been described in the other allele to date.155 Subsequent studies have confirmed that
haploinsufficient loss of ribosomal protein S14 (RPS14), casein kinases 1A1
(CSNK1A1), TRAF-interacting protein with forkhead-associated domain B (TIFAB),
diaphanous related formin 1 (DIAPH1, also known as mDia1) and the microRNAs
(miR)-145

and

-146a

contribute

to

disease

biology.117,160,169,171,173

Notably,

haploinsufficent loss of these key target genes in murine models results in marrowrelated changes characteristic of MDS, but more importantly, a severe and progressive
anemia, confirming that the hemizygous loss of these genes contributes to the erythroid
defect observed in MDS.
Mechanistically, these murine models implicate activation of p53 (RPS14), βcatenin (CSNK1A1) and the TLR4/TRAF6/NF-κB signaling axis (miR-145/miR-146a,
TIFAB, DIAPH1) in the pathobiology of del(5q) MDS. Although these individual
mechanisms are well supported, a unifying mechanism by which loss of a diverse set of
genes allows for del(5q) MDS development remains unclear. Recently, we reported that
danger associated molecular pattern (DAMP) signals, like S100A9, and a diverse set of
somatic gene mutations (including U2AF1, SRSF2, SF3B1, ASXL1 and TET2) activate
the redox-sensitive NLRP3 inflammasome pathway in non-del(5q) MDS.199 NLRP3
inflammasome activation drives pyroptotic cell death and activation of β-catenin,
effectively accounting for the central hallmarks of non-del(5q) disease, specifically
significant cell death in the context of proliferation. Given that haploinsufficiency of a
diverse set of genes results in del(5q) MDS, we hypothesized that activation of the
NLRP3 inflammasome in these patients may function as a unifying pathobiologic
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mechanism, akin to that observed in non-del(5q) disease. To this end, we investigated
the role of NLRP3 inflammasome activation in two distinct murine models of del(5q)
MDS, namely in the context of Rps14 haploinsufficiency and concurrent loss of mDia1
and microRNA (miR)-146a, as well in a preliminary cohort of del(5q) patient specimens.

Results

Rps14 haploinsufficiency induces NLRP3 inflammasome activation in
erythroid progenitors but not HSPC. NLRP3 inflammasome activation was assessed
in a murine model of Rps14 haploinsufficiency, whereby Rps14 is conditionally reduced
to haploinsufficent levels in hematopoietic cells, specifically.167 Whole bone marrow
(BM) cells were isolated from Rps14 and wild type (WT) littermates. Using confocal
fluorescence microscopy, NLRP3 activation was measured by the co-localization of
cleaved or active (a)-caspase-1 and NLRP3 (Figure 33A). BM cells from Rps14 mice
evidenced robust formation of NLRP3 inflammasome complexes, warranting further
investigation of NLRP3-mediated signaling events.
For one, NLRP3 activation results in pyroptosis, a caspase-1-dependent, proinflammatory cell death. Typical cell death markers, like annexin-V and propidium iodide
(PI), cannot distinguish apoptosis from pyroptosis. Instead, these types of programmed
cell death are reliably distinguishable by flow cytometry using the markers annexin-V, acaspase-1 and a-caspase-3.199 Specifically, apoptotic cells are defined as a-caspase-1/a-caspase-3/7+/annexin-V+

and

pyroptotic

cells

as

a-caspase-1+/a-caspase-

3/7+/annexin-V+. We first investigated pyroptosis of the hematopoietic stem and
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Figure 33. Rps14 haploinsufficiency induces NLRP3 inflammasome activation in
erythroid progenitors but not HSPC. Data are representative of BM cells harvested
from WT (n=5) and Rps14 haploinsufficient (n=7) mice. (A) Representative confocal
fluorescence micrograph (2520x magnification) of active (a)-caspase-1 and NLRP3
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expression in Rps14 haploinsufficient BM cells versus WT controls. DAPI (blue), acaspase-1 (green), NLRP3 (red); merged images show inflammasome formation. (B-C)
+
The mean percentage of (B) pyroptotic and (C) a-caspase-1 cells in ungated, lineage
+
+
negative (Lin ) and LSK (Lin Sca-1 c-Kit ) positive hematopoietic stem and progenitor
(HSPC) cells. (D) Representative scatter plots of RI-RIV erythroid progenitor BM cells
isolated from WT and Rps14 haploinsufficient mice. Erythroid populations are gated
according to expression of CD71 and Ter119. (E) Quantitation of inflammasome
activation based on ASC oligomerization in BM RI-RIV erythroid progenitors from WT
+
and Rps14 haploinsufficient mice. (F) Fold reduction in the mean percentage of ASC RI
and RIV erythroblasts following treatment of Rps14 BM cells with DPI [2 µM] and ICTA
[20 µM] for 24 hours in vitro. Error bars: SE, *p<0.05 and **p<0.01.
progenitor cell (HSPC) population in the Rps14 haploinsufficient versus the WT bone
marrow, as pyroptotic cell death of this population is characteristic of non-del(5q)
MDS.199 HSPC are identifiable in mice as LSK (Lin-Sca-1+c-Kit+) positive. Notably, the
mean percentage of pyroptotic (Figure 33B) and a-caspase-1+ (Figure 33C) HSPC did
not differ in Rps14 haploinsufficient and WT mice.
Since this model is characterized by a progressive anemia,167 we next
investigated NLRP3 inflammasome activation in erythroid progenitors from four monthold mice. Maturation of murine erythroid precursors is readily assayed by flow cytometry
through the differential expression of the markers CD71 and Ter119, which are also
referred to as transferrin receptor protein 1 (TfR1) and lymphocyte antigen 76 (Ly76),
respectively.167 Four distinct erythroid populations can be characterized from least to
most

mature:

RI,

basophilic/early

chromatophilic

(CD71+Ter119+);

RII,

polychromatophilic (CD71intermediateTer119+); RIII, orthochromatophilic (CD71lowTer119+);
RIV, enucleated erythrocytes (CD71-Ter119+). Compared to WT controls, Rps14
haploinsufficient mice demonstrated dramatic reductions in erythroid populations,
particularly the RIII and RIV subsets (Figure 33D).
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Notably, assessment of NLRP3 inflammasome oligomerization and activation
can be measured by flow cytometric changes in fluorescence pulse height and area
measurements of the inflammasome adaptor protein ASC.297 ASC functions to recruit
pro-caspase-1 to the site of the inflammasome, whereby its incorporation and
oligomerization forms mature complexes, effectively serving as a surrogate marker of
NLRP3 activation.297 The percentage of ASC+ RI and RII erythroblasts was significantly
increased in Rps14 haploinsufficient BM compared to WT controls (Figure 33E),
suggesting that NLRP3 inflammasome activation is manifest in early stage
erythropoiesis. As NLRP3 is redox-sensitive and is activated in response to NADPH
oxidase (NOX)-derived ROS, we next tested whether inhibition of NOX using
diphenyleneiodonium (DPI) or inhibition of NLRP3 using the icariin derivative ICTA can
reduce NLRP3 activation in the context of Rps14 haploinsufficiency. Indeed, treatment
with DPI or ICTA resulted in approximately 15-30% reduction in the proportion of ASC+
RI and RII erythroblasts, respectively (Figure 33F).
Rps14 haploinsufficient erythroid precursors predominantly undergo
pyroptosis. Next, we aimed to investigate the extent of pyroptosis versus apoptosis in
the context of Rps14 haploinsufficieny within erythroid subsets. The mean percentage
of pyroptotic RI-RIII erythroblasts was significantly increased in the Rps14
haploinsufficient mice compared to normal controls (Figure 34A), whereas no significant
differences were detected in the corresponding apoptotic cell fraction (Figure 34B).
Accordingly, the mean percentage of a-caspase-1+ cells (Figure 34C) and a-caspase-1
mean fluorescent intensity (MFI) (Figure 34D) were significantly increased in Rps14 RIRIII erythroblasts compared to WT controls. Though a-caspase-3/7 MFI was
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Figure 34. Rps14 haploinsufficient erythroid progenitors predominantly undergo
pyroptotic cell death. Data are representative of BM cells harvested from WT (n=5)
and Rps14 haploinsufficient (n=7) mice. (A-C) The mean percentage of (A) pyroptotic,
+
(B) apoptotic and (C) a-caspase-1 RI-RIV erythroid progenitors in Rps14
haploinsufficient BM cells compared to WT controls. (D-E) Mean fluorescence intensity
(MFI) of (D) a-caspase-1 and (E) a-caspase-3/7 in RI-RIV erythroblasts in Rps14
haploinsufficient BM cells compared to WT controls. (F) Comparison of the mean
percentage of a-caspase-1 versus a-caspase-3/7 MFI in the RI-RIV populations in
Rps14 haploinsufficient mice. (G) Colony forming capacity was assessed in BM cells
isolated from WT versus Rps14 haploinsufficient mice. The mean number of erythroid
and granulocyte-macrophage (CFU-GM) colonies are represented. (H-I) Fold change of
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(H) CFU-GM and (I) erythroid colony forming capacity in Rps14 haploinsufficient BM
cells treated with increased concentrations of the NLRP3 inhibitor ICTA [2-20 µM]. Error
bars: SE, * p<0.05, **p<0.01 and ***p<0.001.
significantly increased in Rps14 BM RI-RIII compared to normal (Figure 34E), these
data are not surprising as caspase-3 is activated downstream of caspase-1 during
pyroptosis. More importantly, comparison of a-caspase-1 and a-caspase-3/7 MFI in
Rps14 haploinsufficient RI-RIV erythroblasts confirms that caspase-1 activation
significantly exceeds caspase-3/7 activation in each erythroid population (RI-RIV)
(Figure 34F). Together, these data demonstrate that attrition of erythroid progenitors in
Rps14 haploinsufficient BM is mediated primarily by pyroptotic cell death.
Lastly, the erythroid defect in the Rps14 haploinsufficient mice was corroborated
in colony formation assays, whereby a significant reduction in erythroid colony forming
capacity was evidenced in the Rps14 mice compared to WT controls (Figure 34G). No
difference was observed in granulocyte/monocyte (CFU-GM) colony forming capacity
(CFC) between the two groups (Figure 34G). Notably, while treatment of Rps14 BM
cells with ICTA had no effect on granulocyte-macrophage CFC (Figure 34H), ICTA
treatment significantly increased erythroid CFC in a concentration-dependent manner
(Figure 34I). These findings indicate that NLRP3 inhibition can rescue erythropoiesis in
the context of Rps14 haploinsufficiency, a mechanism distinct from the cytotoxic effect
of lenalidomide in del(5q) MDS.
ROS and β-catenin activation are significantly increased in Rps14
haploinsufficient erythroid progenitors. Somatic gene mutations are known to
increase levels of reactive oxygen species (ROS), which like DAMP signals, can direct
activation of β-catenin.302-305 In non-del(5q) MDS, we demonstrated that NOX-derived
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ROS activate the redox-sensitive NLRP3 inflammasome, triggering not only pyroptosis,
but also activation of β-catenin.199 We hypothesized that the loss of genetic material
through chromosome 5 deletion in del(5q) MDS would additionally trigger increased
ROS production and consequent nuclear localization of β-catenin. The percentage of
ROS+ cells (Figure 35A) and ROS MFI (Figure 35B) were significantly increased in the
BM of Rps14 mice compared to controls. Investigation of the RI-RIV erythroid lineage
populations illustrated that the early RI erythroblasts in the Rps14 haploinsufficient mice
had a significant increase in the percentage of ROS+ cells (Figure 35C) and ROS MFI
(Figure 35D) versus normal controls. No significant differences were observed in the
RII-RIV populations. Notably, treatment of Rps14 haploinsufficient BM cells with DPI or
ICTA resulted in a dramatic reduction in the percentage of ROS+ cells (Figure 35E) and
ROS MFI (Figure 35F), demonstrating that inhibition of NOX or NLRP3 can reduce
ROS. Lastly, nuclear localization of β-catenin, representative of its transcriptionally
active form, was assessed using confocal fluorescence microscopy in BM cells
harvested from WT mice, Rps14 haploinsufficient mice or Rps14 cells treated with DPI.
Whereas Rps14 haploinsufficient cells evidenced significant nuclear localization of βcatenin, nuclear expression was negligible in WT littermates (Figure 35G). Importantly,
treatment of Rps14 cells with DPI reduced active β-catenin to levels similar to WT
controls (Figure 35G). These data demonstrate that ROS and β-catenin activation are
increased in the context of Rps14 haploinsufficiency in a NOX- and NLRP3-dependent
manner.
Concurrent loss of mDia1 and miR-146a results in pyroptotic cell death of
erythroid precursors. Next, we investigated an alternative murine model of del(5q)
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Figure 35. ROS and β-catenin activation are markedly increased in erythroid
progenitors in the context of Rps14 haploinsufficiency. Data are representative of
BM cells harvested from WT (n=5) and Rps14 haploinsufficient (n=7) mice. (A-B) Mean
(A) percentage and (B) MFI of ROS in ungated WT and Rps14 haploinsufficient BM
cells. (C-D) Mean (C) percentage and (D) MFI of ROS in RI-RIV erythroid progenitors
from WT and Rps14 haploinsufficient BM cells. (E-F) Mean (E) percentage and (F) MFI
of ROS in RI-RIV erythroid progenitors from Rps14 haploinsufficient BM cells treated for
24 hours with DPI [2 µM] and ICTA [20 µM]. (G) Representative micrograph (2520x
magnification) of β-catenin expression in BM cells from WT, Rps14 haploinsufficient or
Rps14 cells treated with DPI [2 µM] for 24 hours. DAPI (blue), β-catenin (red); merged
images show nuclear β-catenin localization. Error bars: SE, *p<0.05 and **p<0.01.
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MDS, namely the concurrent loss of both mDia1 and miR-146a, two genes located
within or near the CDR and haplodeficient in del(5q) MDS. Loss of these 5q- genes
results in hypersensitivity to the TLR4/TRAF6/NF-κB signaling axis, which is
deregulated in both non-del(5q) and del(5q) MDS.117,174 More specifically, mDia1 has
known roles in innate immune cell activation.174-176 Loss of mDia1 results in a significant
increase of the TLR4 co-receptor CD14 on granulocytes, sensitizing cells to TLR4
ligands such as LPS and resulting in aberrant innate immune activation.174 Furthermore,
as miR-146a targets TNF receptor-associated factor 6 (TRAF6) for degradation,
haploinsufficiency in del(5q) MDS results in increased expression of this TLR4 signaling
intermediate.117 Increased expression of TRAF6 drives abnormal activation of NF-κB,
reduced blood cell counts and bone marrow failure.117 Together, the dual loss of mDia1
and miR-146a represents an applicable model of del(5q) disease.
First, following isolation of BM cells from double wild-type (DWT) and double
knockout (DKO) mice, NLRP3 inflammasome formation was assessed via ASC
oligomerization in RI-RIV erythroid progenitors by flow cytometry. The percentage of
ASC+ cells was increased in ungated BM cells from DKO mice compared to DWT, but
more importantly in the RI and RII erythroblast populations (Figure 36A), suggesting an
aberrant activation of the NLRP3 inflammasome in early erythropoiesis. Accordingly,
pyroptotic cell death was dramatically increased in the RI-RIV erythroid populations in
the DKO mice compared to DWT controls (Figure 36B). The extent of apoptosis was not
different between the DWT and DKO RI-RIV populations (Figure 36C). Indeed, when
the percentage of pyroptotic versus apoptotic RI-RIV DKO cells was compared, the
pyroptotic fraction significantly exceeded the corresponding apoptotic cell fraction
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Figure 36. Concurrent loss of mDia1 and miR-146a results in pyroptotic cell death
of erythroid progenitors. Data are representative of BM cells harvested from DWT
(n=3) and DKO (n=5) mice. (A) Quantitation of inflammasome activation based on ASC
oligomerization in ungated BM cells and RI-RIV erythroid progenitors from DWT and
DKO mice. (B-C) The mean percentage of (B) pyroptotic and (C) apoptotic ungated BM
cells and RI-RIV erythroid progenitors from DWT and DKO mice. (D) Comparison of the
mean percentage of pyroptotic versus apoptotic ungated BM and RI-RIV cells isolated
+
from DKO mice. (E-F) Mean (E) percentage of a-caspase-1 cells and (F) a-caspase-1
MFI in ungated BM and RI-RIV cells from DWT and DKO mice. (G-H) Mean (G)
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percentage of a-caspase-3/7 cells and (H) a-caspase-3/7 MFI in ungated BM and RIRIV cells from DWT and DKO mice. Error bars: SE and *p<0.05.
(Figure 36D). These data suggest that DKO mice predominantly undergo a pyroptotic,
not apoptotic, cell death. In support of these findings, the percentage of a-caspase-1+
cells (Figure 36E) and a-caspase-1 MFI (Figure 36F) were profoundly increased in RI
DKO erythroblasts compared to DWT controls. While the percentage of a-caspase-3/7+
cells (Figure 36G) and a-caspase-3/7 MFI (Figure 36H) were additionally increased in
the RI DKO cells, this likely occurs downstream of caspase-1 activation in accordance
with execution of the pyroptotic program. Taken together, these data illustrate that early
erythroid progenitors from DKO mice undergo pyroptotic cell death, with marked
activation of caspase-1.
ROS and β-catenin activation are significantly increased in mDia1/miR-146a
double knockout mice. We hypothesized that dual loss of mDia1 and miR-146a would
increase ROS generation with activation of β-catenin. Accordingly, the mean
percentage of ROS+ cells (Figure 37A) and ROS MFI (Figure 37B) were significantly
increased in ungated BM cells from DKO mice compared to DWT controls. ROS were
also significantly increased across the RI-RIV erythroid populations in the DKO mice
compared to controls (Figure 37A and 37B), indicating that deletion of these genes
increases ROS production in the DKO mice. Moreover, nuclear localization of β-catenin
was significantly increased in the BM of DKO mice compared to DWT controls (Figure
37C). Therefore, these data corroborate findings of NLRP3 inflammasome-induced
ROS generation and β-catenin activation following the loss of central 5q- genes.
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Figure 37. ROS and β-catenin activation are significantly increased with dual loss
of mDia1 and miR-146a. Data are representative of BM cells harvested from DWT
(n=3) and DKO (n=5) mice. (A-B) Mean (A) percentage and (B) MFI of ROS in ungated
BM cells and RI-RIV erythroid progenitors isolated from DWT and DKO mice. (C)
Representative micrograph (2520x magnification) of β-catenin expression in BM cells
from DWT and DKO mice. DAPI (blue), β-catenin (red) and merged images show
nuclear β-catenin localization. Error bars: SE and *p<0.05.
NLRP3 inflammasome inhibition restores effective erythropoiesis in del(5q)
MDS. NLRP3 inflammasome formation and activation was markedly increased in a
preliminary cohort of del(5q) MDS patient BM-MNC specimens (n=2) compared to
normal controls (n=6) (Figure 38A). Importantly, short-term treatment of del(5q) BMMNC with 10 µM ICTA significantly reduced inflammasome activation, as well as protein
expression of both a-caspase-1 and NLRP3 (Figure 38A). To determine if NLRP3
inflammasome inhibition could improve hematopoiesis, colony forming capacity was
assessed after plating del(5q) MDS BM-MNC in autologous BM plasma and increasing
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Figure 38. NLRP3 inflammasome inhibition restores effective erythropoiesis in
patients with del(5q) MDS. (A) Representative confocal fluorescence micrograph
(2520x magnification) of active (a)-caspase-1 and NLRP3 expression in normal BMMNC (n=6) compared to del(5q) MDS BM-MNC (n=2) untreated or treated with 10 µM
ICTA for 24 hours. DAPI (blue), a-caspase-1 (green), NLRP3 (red); merged images
show inflammasome formation. (B) Colony forming capacity was assessed in BM-MNC
from a del(5q) MDS specimen treated with increasing concentrations of ICTA. Error
bars: SE, *p<0.05, **p<0.01 and ***p<0.001.
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concentrations of ICTA. Whereas ICTA treatment had no effect on granulocytemacrophage (GM) CFC, ICTA treatment significantly increased erythroid CFC in a
concentration-dependent manner (Figure 38B). These data are consistent with findings
observed in the Rps14 haploinsufficiency model (Figure 33H and 33I), and indicate that
inflammasome inhibition restores effective erythropoiesis in primary MDS specimens.

Discussion

We recently reported that central hallmarks of the non-del(5q) MDS phenotype,
including cell death in the context of proliferation, can be attributed to aberrant activation
of the NLRP3 inflammasome complex.199 This complex functions to drive caspase-1dependent pyroptotic cell death of hematopoietic stem and progenitor cells (HSPC) and
the simultaneous activation of β-catenin, which can augment cell proliferation and
survival. In this way, activation of β-catenin supports propagation and proliferation of the
MDS clone. Of note, both recurrent somatic gene mutations and over-expressed DAMP
proteins, like S100A9, trigger activation of the redox-sensitive NLRP3 inflammasome
pathway.199 Most important, neutralization of S100A9 and inhibition of the NLRP3
inflammasome complex was able to augment normal hematopoiesis in non-del(5q)
MDS patients, suggesting novel strategies for therapeutic intervention.199
To date, the ineffective erythropoiesis characteristic of del(5q) MDS, resulting in
severe and progressive hypoplastic anemia, has been attributed to cooperative
haploinsufficiency of a number of genes encoded in the deleted portion of chromosome
5q, including, but not limited to, RPS14, DIAPH1 (mDia1) and miR-146a.117,160,169,171,173
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We hypothesized that the widespread loss of genetic material on chromosome 5q in
del(5q)

MDS

would

share

a

similar

pathobiological

mechanism

of

NLRP3

inflammasome activation as is observed in non-del(5q) disease. Accordingly, this
hypothesis was corroborated in two distinct murine models of del(5q) MDS, namely in
the context of Rps14 haploinsufficiency and the dual loss of mDia1 and miR-146a, as
well as in primary del(5q) MDS specimens. While NLRP3 inflammasome activation and
pyroptotic cell death of hematopoietic stem and progenitor cells (HSPC) was not
observed in these models, this was not surprising. We anticipated that defects in
hematopoiesis would largely be restricted to the erythroid compartment, as the 5qsyndrome is characterized by severe macrocytic anemia. Indeed, in both models, the
early erythroid progenitor populations, identified by CD71 and Ter119 staining as the RI
and RII subsets, demonstrated significant NLRP3 inflammasome formation with
caspase-1 activation. These populations predominantly underwent pyroptosis, rather
than apoptotic cell death. Additionally, NLRP3 inflammasome activation was robustly
increased in primary del(5q) specimens. ICTA-mediated inflammasome inhibition not
only reduced inflammasome activation and protein expression of a-caspase-1 and
NLRP3, but significantly improved erythroid colony forming capacity. Taken together,
our findings suggest that the aberrant activation of NLRP3 in early erythroid progenitors
prevents their maturation to mature, enucleated erythrocytes, effectively driving the
anemia that is clinically manifest in MDS.
Moreover, the two murine models demonstrated that ROS are significantly
increased in the early RI and RII erythroblast populations. ROS, which are increased
with somatic gene mutation and in the context of gene loss, function to activate the
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NLRP3 inflammasome, triggering pyroptosis. Additionally, ROS can increase nuclear
localization of β-catenin, which occurs through an NADPH oxidase (NOX)-dependent
mechanism. In each model, ROS were dramatically reduced in the RI and RII erythroid
progenitor populations following NOX or NLRP3 pharmacological inhibition. Active βcatenin, which was increased in BM cells harboring genetic loss compared to WT
controls, was significantly reduced following NOX inhibition. These data support the
hypothesis that the del(5q) clone is propagated through activation of β-catenin, which
occurs through a NOX-dependent mechanism.
Murine models of del(5q) MDS have described mechanisms of pathobiology,
including implication of p53 activation, β-catenin and TLR4 signaling. Here, our findings
illustrate a common mechanism of pathobiology that is shared in non-del(5q) and
del(5q) MDS, specifically activation of the NLRP3 inflammasome complex. Our data
indicate that loss of central 5q- genes, irrespective of the gene in question, triggers
NLRP3 activation and leads to pyroptosis and β-catenin activation. These data unify
previous mechanisms of del(5q) pathobiology, as reduced expression of each gene is
linked to activation of the NLRP3 inflammasome complex. Foremost, RPS14
haploinsufficiency results in the erythroid-specific accumulation of the tumor suppressor
protein p53, contributing to erythroid progenitor cell death and the development of
anemia.163 These data were corroborated in an Rps14 haploinsufficent murine model of
MDS, which additionally demonstrated that the danger associated molecular pattern
(DAMP)

proteins

S100a8

and

S100a9

were

significantly

up-regulated

in

haploinsufficient erythroid progenitors.167 S100A9 is also increased intracellularly in BMMNC and in the plasma of non-del(5q) MDS patients, which we demonstrated triggers
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NLRP3 inflammasome activation, pyroptosis and nuclear localization of β-catenin.199
Also, ribosomal stress not only activates p53 but also the NLRP3 inflammasome.323
Moreover, hypersensitivity to TLR4 signaling in del(5q) MDS results in aberrant
activation of NF-κB, which is known to drive transcriptional expression of NLRP3. In this
way, loss of mDia1 and miR-146a, which augment TLR4 signaling and responsiveness,
would additionally increase NLRP3 expression. ROS generation resulting from genetic
loss would serve as a secondary signal for NLRP3 activation, triggering aberrant
inflammasome activation. Lastly, loss of casein kinase 1 alpha 1 (CSNK1A1), a model
not studied in this manuscript, results in increased β-catenin activation in del(5q) MDS,
as CK1α is a central regulator of the β-catenin destruction complex and thereby of βcatenin nuclear translocation.169 Here, we not only show that β-catenin activation is
increased in murine models of del(5q) disease other than CK1α haploinsufficiency, but
also that activation occurs by an NOX-dependent mechanism. More specifically,
induction of NOX-derived ROS additionally triggers β-catenin activation with concurrent
activation of NLRP3. Together, biological events resulting from Rps14, mDia1 and miR146a haploinsufficiency can mechanistically be explained by NLRP3 inflammasome
activation.
Finally, identification of the NLRP3 inflammasome complex as a driver of the
del(5q) MDS phenotype allows for novel avenues for therapeutic intervention. This
pathway is likely activated irrespective of the degree of genetic loss (size of the 5q
chromosomal deletion), and therefore represents a very attractive therapeutic target
with translational potential.
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Methods
MDS patient specimens. MDS patients were consented on IRB approved
protocols and recruited from the Eastern Cooperative Oncology Group (ECOG) E2905
trial (NCT00843882).
Mice. Rps14 haploinsufficient and WT BM cells, and tibias and femurs from
mDia1/miR-146a DWT and DKO mice were generously provided by Drs. Benjamin
Ebert and Rebekka Kramann-Schneider and Dr. Peng Ji, respectively.
Reagents and cells. DPI was purchased from Sigma. ICTA was synthesized by
the Chemical Biology Core Facility located at H. Lee Moffitt Cancer Center and
Research Institute. Active caspase-1 and caspase-3/7 were detected using FAMFLICATM Caspase-1 (#98), FLICA-660 Caspase-1 (#9122), FLICA-660 Caspase-3 & 7
(#9125) and SR-FLICATM Caspase-3 & 7 (#932) assay kits (ImmunoChemistry
Technologies). NLRP3 antibodies were purchased from Abcam (ab4207) and β-catenin
antibodies from BD Biosciences (610154).
Immunofluorescence confocal microscopy. Following isolation, BM cells were
stained with 30x FAM-FLICA® Caspase-1 solution for 2 hr at 37°C at a ratio of 1:30,
washed and cytospun at 450 rpm for 5 min. Slides were fixed using BD Cytofix Fixation
Buffer (BD Biosciences) at 37°C for 10 min, and then washed with PBS. Cells were
permeabilized with 0.1% Triton X-100/2% BSA in PBS for 15 min at room temperature,
washed and then blocked using 2% BSA in PBS for 30 min at room temperature.
Following washing, cells were incubated with the appropriate primary antibody overnight
(1:400 for NLRP3, 1:20 for β-catenin) at 4°C. After 24 hr, cells were washed with PBS
and incubated with the appropriate secondary antibodies (1:500) for 1 hr at room
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temperature. Slides were washed and covered with ProLong Gold Antifade Reagent
with DAPI and a coverslip (Life Technologies).
Cell death flow cytometry assay. Rps14 haploinsufficient and WT BM cells
were resuspended in 1x PBS and stained with 30x FAM-FLICATM Caspase-1 and
FLICA-660 Caspase-3 & 7 reagents at a 1:30 dilution for 30 min at 37°C. mDia1/miR146a double KO and DWT cells were stained following a similar protocol, but rather with
FLICA-660 Caspase-1 and SR-FLICATM Caspase-3 & 7 reagents. Cells were washed
with 1x PBS. For RI-RIV erythroid progenitor staining, cells were stained for surface
receptors using CD71:BV510 (563112) and Ter119:BUV395 (563827) at a 1:20 dilution
for 30 min at 4°C (BD Biosciences). For HSPC staining, cells were stained for surface
receptors using lineage cocktail:V450 (561301), CD117:BUV395 (564011) and Ly6A/E:BV786

(563991)

under

the

same

surface

receptor

staining

protocol

aforementioned (BD Biosciences). Following washing, cells were resuspended in 1x
binding buffer. For Rps14 and mDia1/miR-146a DKO experiments, cells were stained
with annexin-V:PE (559763) and annexin-V:BV421 (563973), respectively, at a 1:20
dilution for 15 min at room temperature (BD Biosciences). The final volume was brought
to 400 µL with 1x binding buffer. Sample acquisitions were made on a BD LSR II flow
cytometer using FACSDiva software. To establish compensation settings, anti-Rat and
Anti-Hamster Ig κ/Negative Control Compensation Particles Set was used (BD
Biosciences). Data were analyzed using FlowJo 9.7.5 software (FlowJo, LLC).
ROS detection. ROS were detected using CellROX® Deep Red Reagent
according to the manufacturer’s protocol (Life Technologies).
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ASC oligomerization. Cell pellets were permeabilized by resuspending in 1 mL
of prewarmed BD Permeabilization Buffer III and incubating on ice for 30 min (BD
Biosciences). Cells were washed twice with staining buffer, resuspended in 1x PBS and
stained with rabbit anti-ASC primary antibodies at a 1:1500 dilution (Santa Cruz, sc22514-R). Cells were incubated for 90 min at 37°C, and then washed. Cells were
resuspended in staining buffer, stained for surface receptors and concurrently stained
with secondary anti-rabbit antibodies at a 1:1500 dilution for 30 min at 4°C. Sample
acquisitions were carried out using a BD LSR II flow cytometer and FACSDiva software.
Colony formation assays. 4 replicates of 3.5x105 BM cells/mL per mouse were
plated in MethoCult methylcellulose medium with recombinant cytokines (Stemcell
Technologies) supplemented with 1% v/v penicillin-streptomycin and increasing
concentrations of ICTA, as indicated. Erythroid and CFU-GM colonies were manually
scored fourteen days after plating using an inverted light microscope.
Statistical analyses. All data are reported as means ± standard error. Microsoft
Excel was used to carry out statistical analyses, specifically student’s t-test. *P values
<0.05, **p<0.01, and ***p<0.001 were considered to be statistically significant.
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CHAPTER 4
NLRP3 Inflammasome-Derived ASC Specks are a Diagnostic Biomarker for
Myelodysplastic Syndromes (MDS)
Introduction
Pyroptosis, or caspase-1-dependent cell death, is mediated by the formation of
NLRP3 inflammasome complexes, which function as redox-sensitive, cytosolic sensors
of danger signals.227 Upon stimulation, NLRP3 undergoes a conformational change
fostering homotypic pyrin domain interaction with the adaptor protein ASC [apoptosisassociated speck-like protein containing a caspase activation and recruitment domain
(CARD)], triggering ASC nucleation and polymerization to create large, cytoplasmic
filaments.239 Exposure of the ASCCARD on the filament surface serves as a docking
platform for recruitment of pro-caspase-1 monomers that are activated by proximityinduced autocatalysis to initiate proteolytic processing of pro-caspase-1. The ASC
speck formed by ASC filament clusters creates abundant caspase-1 activation sites,
thereby acting as an inflammasome signal amplification mechanism.239,324
ASC specks, or aggregated clusters of ASC filaments, are approximately one
micron in diameter in size and are released into the extracellular milieu following
cytolysis and execution of pyroptosis.298 Released ASC specks retain catalytic activity,
whereby they continue to recruit and mature pro-caspase-1 and its substrate IL-1β.298
Notably, neighboring cells may phagocytose released ASC specks, which subsequently
function as a scaffold for ASC polymerization and nucleation in the recipient cell.298 In
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this way, ASC specks function as danger signals which propagate inflammation not only
in the extracellular space, but additionally in cells of the surrounding stroma.298
Myelodysplastic

syndromes

(MDS)

are

characterized

by

ineffective

hematopoiesis resulting from caspase-1-dependent, pyroptotic cell death.199 All too
frequently, the pathologic diagnosis of MDS is not straightforward owing in part to the
vast disease heterogeneity, quality of bone marrow aspirates for cytological examination
and

reliance

on

morphologic

assessment,

which

is

vulnerable

to

observer

discrepancies.42,92,325 Additionally, a substantial number of hematologic conditions share
features of MDS, particularly overlap syndromes like chronic myelomonocytic leukemia
(CMML). As such, MDS is perceived to have a high diagnostic error rate, typically
between 30-40%, highlighting the potential value and impact of an MDS-specific
biomarker.
Importantly, co-localization of NLRP3 and active (a)-caspase-1 by confocal
fluorescence microscopy confirmed selective activation of the NLRP3 inflammasome in
MDS compared to other bone marrow malignancies.199 As ASC specks are readily
quantified by flow cytometry,298 we hypothesized that bone marrow (BM) or peripheral
blood (PB) plasma-derived ASC specks may serve as a biologically rational biomarker
for the diagnosis of MDS.

Results

ASC specks are significantly increased in MDS. For flow cytometric analyses,
the gate for ASC specks was determined using the secondary only control (Figure 39A).
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Figure 39. The percentage of plasma ASC specks increases with protein
concentration. (A) Representative histogram of ASC speck staining, which is gated
according to the secondary only antibody control. (B-C) Increasing BM and PB plasma
protein concentrations were assessed for the mean percentage of (B) BM and (C) PB
159

plasma-derived ASC specks. (D-E) Representative confocal fluorescence micrograph
(4725x and 4725x magnification, respectively) of ASC speck expression in (D) THP-1
and (E) U937 cells that were untreated, or treated with 100 ng/mL LPS, 5 mM ATP and
5 µM nigericin or 5 µg/mL rhS100A9 for 24 hours. DAPI (blue), ASC (green) and
merged images show ASC specks.
The percentage of BM and PB plasma-derived ASC specks increased linearly with
protein concentration, confirming assay specificity (Figure 39B and 39C). Next, the
ability of the ASC antibody employed to detect ASC specks was further validated using
confocal fluorescence microscopy in THP-1 parental, NLRP3 knockout (KO) THP-1 and
U937 cells. THP-1, NLRP3 KO and U937 cells were treated with 100 ng/mL LPS, 5 mM
ATP and 5 µM nigericin or 5 µg/mL recombinant human S100A9 (rhS100A9) for 24
hours, which is known to induce NLRP3 inflammasome activation.199 In all three cell
lines, LPS/ATP/nigericin and rhS100A9 treatment induced expression of ASC as a
result of priming (Figure 39D and 39E). Whereas the formation of ASC specks,
evidenced by the detection of punctate ASC staining, was induced in THP-1 parental
and U937 cells, specks did not form in NLRP3 KO cells, confirming NLRP3-dependence
(Figure 39D and 39E).
To further assess ASC speck expression, we measured the percentage of ASC
specks in a preliminary cohort of normal donors (n=3) and MDS patients (n=6). ASC
specks were significantly increased (p=0.015) in MDS BM plasma compared to normal
donors (Figure 40A), prompting validation of speck expression by confocal microscopy.
Cellular expression of ASC specks in MDS compared to healthy donors confirmed that
MDS BM-mononuclear cells (BM-MNC) display both increased ASC protein expression,
consistent with inflammasome priming, and greater punctate staining, confirming ASC
speck formation (Figure 40B). Furthermore, to assess ASC speck expression in MDS,
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Figure 40. ASC specks are significantly increased in MDS and may have
prognostic value. (A) The percentage of ASC specks in BM plasma samples is
significantly greater in MDS specimens (n=6) than normal donors (n=3) (p=0.015). (B)
Representative confocal fluorescence micrograph (2520x magnification) of ASC speck
expression in BM-MNC from normal donors and lower-risk MDS patients. DAPI (blue),
ASC (green), merged images and white arrows show and point to ASC specks,
respectively. (C) The percentage of ASC specks in matched PB and BM plasma
-4
samples (n=38) is significantly greater in PB plasma (p=3.5x10 ). (D) The percentage of
PB plasma-derived ASC specks was investigated in normal, healthy donors (n=40) and
patients of lower-risk (n=180), higher-risk (n=69) and del(5q) (n=24) MDS. Error bars:
SE, *p<0.05 and ***p<0.001.
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we first measured the percentage of ASC specks in the BM of matched PB and BM
plasma samples (n=38). The percentage of PB plasma-derived ASC specks in MDS
significantly exceeded the percentage of BM plasma-derived specks (p=3.5x10-4)
(Figure 40C). Given that PB samples are more readily accessible, and if sensitive and
specific, could serve as a diagnostic screen determining the need for a BM aspirate and
biopsy, further investigation of PB plasma was prioritized. The percentage of PB
plasma-derived ASC specks was significantly increased in lower-risk (n=180) and
higher-risk (n=69) MDS compared to normal, healthy donors (n=40, p=2.8x10-32 and
2.4x10-3, respectively), whereas no significant difference was observed between normal
donors and patients with deletion 5q [del(5q)] MDS (n=24) (Figure 40D). Given that
del(5q) MDS is characterized by erythroid hypoplasia arising from p53 activation, these
findings are not surprising, and perhaps suggest that molecular genetic testing on PB
may be complimentary, and further enhance specificity. Importantly, the percentage of
ASC specks was significantly increased in lower-risk compared to higher-risk MDS
(p=5.6x10-14) (Figure 40D), which is consistent with our previous report illustrating that
lower-risk MDS, but not higher-risk disease, is characterized by excessive NLRP3
inflammasome activation and pyroptotic cell death.199 Together, these data suggest that
PB plasma-derived ASC specks may have diagnostic utility and serve as a surrogate
marker reflecting the extent of pyroptosis in hematopoietic cells and prognostic risk.
The percentage of PB plasma-derived ASC specks is a diagnostic
biomarker for MDS. To determine the utility of PB plasma-derived ASC specks as a
specific MDS diagnostic biomarker, ASC speck percentage was determined in plasma
from patients with varied hematologic malignancies. As hyperglycemia stimulates
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NLRP3 inflammasome assembly and activation, we measured plasma glucose levels by
colorimetric assay to adjust for this potentially confounding variable and to optimize the
assay. The data provided in Table 6 summarize the number and types of samples
investigated, the mean percentage of ASC specks normalized to plasma glucose
concentration and corrected for volume, and the statistical significance comparison of
each respective sample group compared to normal, healthy donors (n=40) and MDS
patients (n=294). The glucose-adjusted speck percentage in lower-risk MDS remained
significantly elevated versus normal donors (p=3.7x10-6) (Figure 41). Although the
corrected percentage of ASC specks was significantly greater in higher-risk MDS
compared to normal donors (p=6.7x10-6), the glucose-adjusted speck percentage in
lower-risk patients significantly exceeded the percentage in higher-risk samples
(p=7.6x10-5). Compared to normal, healthy donors (n=40), ASC specks were
significantly greater in patients with LR-MDS (p=3.7x10-6), HR-MDS (p=6.7x10-6),
secondary acute myeloid leukemia (AML, p=9.9x10-3), essential thrombocythemia (ET,
p=0.04), multiple myeloma (MM, p=0.01) and large granular lymphocytic leukemia (LGL,
p=0.02) (Figure 41). Importantly, MDS samples displayed significantly greater corrected
percentage of PB plasma-derived ASC specks compared to each hematologic
malignancy investigated, including de novo AML (p=6.5x10-4), secondary AML
(p=4.3x10-4),

chronic

myelomonocytic

leukemia

(CMML,

p=1.6x10-6),

chronic

lymphocytic leukemia (CLL, p=1.6x10-6), chronic myeloid leukemia (CML, p=2.1x10-6),
acute lymphoblastic leukemia (ALL, p=2.1x10-6), ET (p=1.4x10-4), polycythemia vera
(PV, p=7.9x10-5), MM (p=3.9x10-5) and LGL (p=5.1x10-5) (Figure 41).
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Table 6. Mean percentage of PB plasma-derived ASC speck values across sample
cohorts. The mean percentage of ASC specks is normalized to plasma glucose
concentration and corrected for volume. Statistical significance was determined by
comparing normal, healthy donors (n=40) and MDS specimens (n=294) to each
respective sample group. (ns, not significant)

Notably, the NLRP3 inflammasome is activated in adipose-based macrophages
in type 2 diabetes (T2D).326 In a cohort of T2D patients without cancer, the glucoseadjusted speck percentage was significantly lower than levels detected in MDS
specimens (p=1.8x10-6) (Figure 41). Although ASC specks were about 2-fold greater in
T2D patients compared to normal, healthy donors, the change was not significant.
Therefore, although NLRP3 inflammasome assembly may not be MDS-specific, these
data together indicate that NLRP3 inflammasome-driven pyroptosis and release of ASC
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Figure 41. The percentage of glucose-adjusted, PB plasma-derived ASC specks is
specific for MDS. Glucose-adjusted ASC speck percentage in normal donors (n=40),
lower-risk MDS (n=180), higher-risk MDS (n=69), all MDS (n=249), del(5q) MDS (n=24),
de novo acute myeloid leukemia (AML, n=16), secondary AML (n=26), chronic
myelomonocytic leukemia (CMML, n=20), chronic lymphocytic leukemia (CLL, n=50),
chronic myeloid leukemia (CML, n=52), acute lymphoblastic leukemia (ALL, n=7),
essential thrombocythemia (ET, n=20), polycythemia vera (PV, n=20), multiple myeloma
(myeloma, n=20), large granular lymphocytic leukemia (LGL, n=19) and type 2 diabetes
(T2D, n=25). A cutoff of 0.039 was selected to minimize total misclassification error. At
this cutoff point, the biomarker achieves 95% sensitivity and 82% specificity in
classifying MDS from normal donors. In an external validation cohort (MDS, n=196), the
biomarker achieved 96% sensitivity at the 0.039 cutoff point. Error bars: SE, **p<0.01
and ***p<0.001.
specks is specific for MDS in steady state, in the absence of infection. Moreover, these
findings suggest that the corrected percentage of PB plasma-derived ASC specks may
be a useful biomarker for the diagnosis of MDS.
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Furthermore, statistical analyses were performed to determine a rational cutoff
point for the diagnostic biomarker. Specifically, sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV) were used to evaluate accuracy. A
cutoff of 0.039 was selected to minimize total misclassification error, namely the sum of
the false positive and false negative rate. With this cutoff, the PPV and NPV are 96%,
and 76%, respectively, and the biomarker achieves 95% sensitivity and 82% specificity
in classifying MDS from normal donors, other BM malignancies and T2D. These
parameters were validated in an independent dataset (n=196) in which the biomarker
achieved 96% sensitivity at the 0.039 cutoff point, confirming the high sensitivity of the
biomarker (Figure 41).
Specks may serve as a biomarker index of ineffective hematopoiesis. We
hypothesized that ASC specks reflect the magnitude of medullary pyroptosis and
therefore may additionally serve as a PB biomarker of response to treatment in lowerrisk MDS patients. To this end, we interrogated the glucose-adjusted percentage of
ASC specks in the PB plasma of lenalidomide-treated, responding and non-responding
patients at the time of screening and week 16. Among responders, 4 and 8 patients had
del(5q) and non-del(5q) MDS, respectively. The corrected percentage of ASC specks
decreased a mean of 63% (range 60-69%) at week 16 in the del(5q) patients, indicative
of a significant reduction (p=7.2x10-5) (Figure 42A). Additionally, ASC specks decreased
a mean of 21% (range 3-77%) at week 16 in the non-del(5q) responders (Figure 42B),
findings that are consistent with prior clinical studies showing that suppression of the
del(5q) clone with lenalidomide treatment more robustly restores effective erythropoiesis
as measured by maximum rise in hemoglobin and response duration.61,159,327
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Figure 42. PB plasma-derived ASC specks are a response biomarker to
lenalidomide treatment. (A-B) Mean corrected ASC speck percentage at the time of
screening and week 16 in lenalidomide-treated, (A) del(5q) MDS (n=4) responding
patients and (B) non-del(5q) MDS (n=8) responding patients. (C) Mean corrected ASC
speck percentage at the time of screening and week 16 in lenalidomide-treated, nondel(5q) MDS (n=24) non-responding patients. Error bars: SE, ***p<0.01.
Conversely, the percentage of specks increased 2.4-fold at week 16 in non-responding
patients (Figure 42C). Importantly, these findings were corroborated in two independent
datasets of lenalidomide-treated, lower-risk MDS patients (Figure 43). Specifically, the
corrected percentage of ASC specks decreased in responding patients and increased in
non-responders over the course of treatment. The corrected percentage of ASC specks
did not predict for treatment response to erythropoietin stimulating agents (ESAs) in LR-
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MDS patients or to hypomethylating agents (HMAs) in HR-MDS patients (Figure 44).
These data suggest that specks may serve as a biomarker index of ineffective
hematopoiesis and perhaps of early response to immunomodulatory drug therapy.

Discussion

Recently, we reported that NLRP3 inflammasome-driven pyroptotic cell death is
a hallmark of lower-risk MDS, driven by somatic gene mutations and danger associated
molecular pattern (DAMP) signals, such as S100A9.199 Pyroptosis culminates in
cytolysis, with release of pro-inflammatory cytokines, DAMP signals and ASC specks,
which together exacerbate inflammation in bystander cells. ASC specks, themselves an
extracellular DAMP signal, are only one micron in diameter but retain catalytic activity,
evidenced by their ability to catalyze maturation of pro-caspase-1 and pro-IL-1β within
the microenvironment.298 Since specks are only secreted upon cytolysis, they function
as a surrogate marker of the magnitude of hematopoietic pyroptotic cell death. Given
that pyroptosis is a hallmark of lower-risk MDS, we hypothesized that ASC specks may
be a biologically rationale biomarker for the diagnosis of MDS.
To this end, we optimized a flow cytometry assay for the detection of extracellular
ASC specks in BM and PB plasma. To start, the percentage of ASC specks increased
linearly in both BM and PB plasma with increasing concentrations of protein. The ability
of the primary ASC antibody employed to detect ASC specks was corroborated by
confocal fluorescence microscopy, whereby expression of ASC and specks increased in
THP-1 and U937 cells treated with either rhS100A9 or LPS/ATP/nigericin. Notably, the
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Figure 43. PB plasma-derived ASC specks are a response biomarker to
lenalidomide treatment in two independent data sets. (A-B) Mean corrected ASC
speck percentage pre- and post-lenalidomide treatment in MDS (A) responding (n=3)
and (B) non-responding (n=7) patients from the University of Florence. (C-D) Mean
corrected ASC speck percentage pre- and post-lenalidomide treatment in MDS (C)
responding (n=28) and (D) non-responding (n=42) patients from the Groupe
Francophone des Myélodysplasies (GFM) cooperative group.328 Error bars: SE.
formation of ASC specks is NLRP3-dependent, as specks failed to nucleate in the
context of NLRP3 deficiency.
Furthermore, comparison of matched PB and BM plasma samples from MDS
patients illustrated that the percentage of ASC specks is significantly greater in the PB
plasma. Notably, ASC specks have a prion-like phenotype, whereby they are resistant
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Figure 44. PB plasma-derived ASC specks remain unchanged after response to
ESA or HMA therapy. (A-B) Mean corrected ASC speck percentage pre- and post-ESA
treatment in LR-MDS (A) responding (n=10) and (B) non-responding (n=18) patients.
(C-D) Mean corrected ASC speck percentage pre- and post-HMA treatment in HR-MDS
(C) responding (n=15) and (D) non-responding (n=3) patients. Error bars: SE.
to proteolytic degradation and persist long after cell death.298 It is possible that while
specks may be cleared quickly in the BM by resident macrophages, they persist within
the PB because of poorer clearance and prion-like proteolytic resistance. Indeed,
mouse models show that specks remain in tissues for up to 96 hours following injection,
indicating that inflammasome-initiated pyroptosis may have prolonged effects on the
microenvironment.298 This would reconcile the observation of greater expression of
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specks within MDS PB plasma compared to BM plasma. In order to optimize the
diagnostic assay, plasma glucose levels were measured by colorimetric assay to adjust
for the confounding effects of hyperglycemia, which is a known stimulus of NLRP3
inflammasome activation. Consequently, the biomarker was defined as the percentage
of ASC specks normalized to plasma glucose concentration corrected for volume. The
glucose-adjusted speck percentage was significantly greater in both lower- and higherrisk MDS compared to normal donors. This increase in speck expression in MDS
compared to normal donors was confirmed by confocal microscopy, whereby MDS BMMNC demonstrated increased number of ASC specks. Importantly, speck expression
was greater in lower-risk versus higher-risk MDS, suggesting possible utility for
prognostic discrimination that might be enhanced when coupled with PB molecular
genetic studies. Not surprisingly, expression of ASC specks did not differ between
normal donors and patients with del(5q) MDS, which is characterized by erythroid
hypoplasia (Chapter 3). As such, release of ASC specks would be expected to be lower
in del(5q) MDS.
Moreover, investigation of ASC speck expression in a panel of other hematologic
malignancies, including other myeloid and lymphoid leukemias, myeloproliferative
neoplasms and overlap syndromes, like CMML, illustrated that specks are MDSspecific. Using statistical approaches, a cutoff point of 0.039 was identified to maximize
sensitivity and specificity of the biomarker, which were 95% and 82%, respectively.
Importantly, the biomarker achieved 96% sensitivity at the 0.039 cutoff point in an
independent, external dataset, confirming high biomarker sensitivity. ASC specks
additionally have utility as a measurement of the magnitude of pyroptotic cell death and
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therefore response to treatment with lenalidomide. In responding patients, the glucosecorrected percentage of ASC specks was significantly reduced post-treatment whereas
specks remained unchanged or even increased in non-responders. These findings were
corroborated in two independent datasets. Changes in the corrected percentage of ASC
specks, however, was not observed upon treatment response to ESA or HMA therapy in
LR- and HR-MDS, respectively, suggesting utility as a response biomarker may be
limited to immunomodulating agent therapy.
Lastly, ASC specks are readily quantified by flow cytometry. Using BM
morphology alone, the error rate of MDS diagnosis is high, approximately 30-40%,
which can be attributed to a number of confounding variables.325,329 Additionally,
diagnoses rely heavily of morphological assessments of dysplasia, which are known to
be vulnerable to observer error. The identification of a diagnostic assay that is
independent of morphology is invaluable from a diagnostic perspective. Therefore, PB
plasma-derived ASC specks represent the first diagnostic biomarker for MDS and may
additionally be useful in monitoring incipient treatment responses in lower-risk patients.

Methods

Patient specimens. Normal plasma samples were obtained from peripheral
blood samples purchased through Florida Blood Services. CMML plasma samples were
generously provided by Dr. Eric Padron, and CML and CLL samples from Dr. Javier
Pinilla-Ibarz. Plasma samples from other hematologic malignancies and type 2 diabetes
patients were obtained from consented patients on a protocol approved by the
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University of South Florida Institutional Review Board (Pro00026210). MDS patient
plasma samples and BM-MNC were obtained from patients consented on the Eastern
Cooperative Oncology Group (ECOG) E2905 trial (NCT00843882), and additionally
provided by Drs. Valeria Santini and Erico Masala of University of Florence and Pierre
Fenaux and Olivier Kosmider of the Groupe Francophone des Myélodysplasies (GFM)
cooperative group. MDS patients were stratified according to the International
Prognostic Scoring System (IPSS). Patients of low and intermediate-1 risk and
intermediate-2 and high risk were considered to have lower-risk and higher-risk disease,
respectively.
Reagents and cells. THP-1 and U937 cells were acquired from ATCC and
maintained in RPMI-1640 supplemented with 10% FBS and 1% penicillin/streptomycin
solution. Lipopolysaccharide (LPS), ATP and nigericin were purchased from SigmaAldrich. Normal BM cells were purchased from AllCells, LLC.
ASC speck staining. Plasma protein was quantified using BCA Protein Assay
Kit (ThermoFisher Scientific). 300 µg of plasma from each donor was aliquoted into flow
tubes and stained with anti-ASC primary antibodies (sc-22514-R, Santa Cruz) at a
1:1500 dilution for 1 hour at 37°C, followed by secondary antibody staining at a 1:1500
dilution for 30 minutes at 37°C. Samples were acquired using a BD FACSCalibur flow
cytometer and threshold settings for forward scatter (FSC) and side scatter (SSC) were
set to zero to allow for speck detection. Data were analyzed using FlowJo 9.7.5
software (FlowJo, LLC).
Immunofluorescence confocal microscopy. For cell line studies, THP-1 and
U937 cells were plated and treated for 24 hours at 37°C concurrently with 100 ng/mL
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LPS and 5 mM ATP or 5 µg/mL rhS100A9. After that, 5 µM nigericin was added to the
LPS/ATP-treated cells for 1 hour at 37°C. Subsequently, cells were collected from all
treatment groups and washed. Cytospins of cell lines and normal and MDS BM-MNC
were generated by centrifugation for 5 min at 450 rpm, and fixed using BD Cytofix
Fixation Buffer (BD Biosciences) for 10 min at 37°C. Slides were washed with 1x PBS,
permeabilized with 0.1% Triton X-100/2% BSA in 1x PBS for 15 min at room
temperature. Slides were washed again and blocked for 30 min at room temperature
using 2% BSA in 1x PBS. After washing, slides were incubated with anti-ASC (sc22514-R, Santa Cruz) primary antibodies at a 1:20 dilution at 4°C overnight. Slides were
washed again in 1x PBS and incubated with goat anti-rabbit Alexa Fluor 488 secondary
antibodies at a 1:250 dilution for 1 hour at room temperature. Slides were washed and
ProLong Gold Antifade Reagent with DAPI (Life Technologies) and a coverslip were
added. Images were taken using a Leica TCS SP8 AOBS Laser Scanning Confocal
microscope (Leica Microsystems).
Enzyme-linked

immunosorbent

assays

(ELISA).

Plasma

glucose

concentration was measured using Glucose Colorimetric Assay Kit according to the
manufacturer’s protocol (#10009582, Cayman Chemical).
Statistical analyses. Data are expressed as means ± standard error.
Measurements of statistical significance using student’s t-test were made in Microsoft
Excel. *P values <0.05, **p<0.01, and ***p<0.001 were considered to be statistically
significant. Additional statistical analyses were carried out by the study statistician. The
sample numbers used provided greater than 90% power to detect significant differences
between diseases. The diagnostic biomarker was defined as the percentage of PB
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plasma-derived ASC specks adjusted for glucose. Sensitivity, specificity, positive
predictive value (PPV) and negative predictive value (NPV) were used to evaluate
classification accuracy of the biomarker at varied cutoff points.
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CHAPTER 5
Discussion

Implications

MDS-Specific Implications. Over the next few decades, the incidence of MDS
and other age-related disorders is projected to dramatically increase, owing to the
greying of populations in developed countries.47 Irrespective of prognostic risk, the only
curative treatment for MDS is allogeneic stem cell transplantation (alloSCT).48,49
Unfortunately, most patients are not eligible for alloSCT given their advanced age and
the frequent presence of comorbid conditions. While three therapies have received
FDA-approved designation for MDS, no novel therapies have been approved in over a
decade. As patients become refractory to current treatment standards, care largely
becomes empirical. For these reasons, there is a heightened necessity for novel
therapeutic approaches that can directly and specifically target pathways central to
disease pathobiology.
To date, despite the presence of vast genetic heterogeneity, lower-risk MDS
pathobiology has been characterized by the proliferation of HSPC counter-balanced by
programmed cell death mediated by pro-inflammatory cytokines.196,288 More specifically,
cell death was attributed to apoptosis, a non-inflammatory mode of cell death. Despite
this, the literature strongly supports the role of innate immune activation in the
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pathobiology of MDS, evidenced by pro-inflammatory cytokine, chemokine and growth
factor profiles, PRR expression and signaling, MDSC and the inflamed BM
microenvironment.93,122,140 Indeed, a history of infection and autoimmune disease has
been linked to MDS predisposition, suggesting that immune dysfunction precedes MDS
development.25 These findings support an apparent cell death paradox in MDS,
whereby a non-inflammatory mechanism of cell death, namely apoptosis, has been
implicated in the context of widespread inflammation. Notably, a pro-inflammatory cell
death mechanism called pyroptosis, which is dependent on caspase-1 activation, was
first characterized in microbial infection.212 Pyroptosis is mediated by the formation of
inflammasome complexes, or cytosolic, heptameric oligomers of NOD-like receptors, or
NLRs, that function to detect both host- and microorganism-derived danger signals.
Among the five inflammasome-forming proteins, NLRP3 is the best characterized.
Here, we demonstrate that key hallmarks of MDS pathobiology can be attributed
to aberrant activation of the NLRP3 inflammasome, which directs pyroptotic cell death,
pro-inflammatory cytokine elaboration, cation influx and propagation of the MDS clone
through β-catenin activation. Pyroptosis better accounts for characteristic features of
MDS that have historically been ascribed to apoptosis, including inflammatory cell death
in the context of HSPC proliferation. Importantly, NLRP3 inflammasome activation
occurs irrespective of molecular phenotype, elucidating for the first time, a mechanism
by which diverse genetic heterogeneity converges to yield a shared MDS phenotype.
These data also provide a common circuit responsible for MDS pathobiology, as NLRP3
inflammasome-initiated pyroptosis and β-catenin activation are hallmarks of both nondel(5q) and del(5q) disease. As such, the causal role of NLRP3 inflammasome
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activation in the pathobiology of MDS identifies biologically rational and novel avenues
for therapeutic intervention, including neutralization of S100A9 and inhibition of the
NLRP3 inflammasome. Given that these approaches directly target underlying aspects
of disease biology, it is likely that they would have significant clinical benefit across
MDS subtypes, and if applied early in the diagnosis of lower-risk MDS, could potentially
be disease-modifying. In the context of del(5q) MDS, the therapeutic potential of NLRP3
inflammasome inhibition was demonstrated in this manuscript, and occurs by a
mechanism distinct from that of lenalidomide, the standard of care for this disease
subset. Accordingly, NLRP3 inflammasome inhibition may represent an innovative
approach for treating del(5q) patients that have developed resistance to lenalidomide.
Furthermore, we have described the first diagnostic biomarker for MDS, namely
the glucose-adjusted percentage of PB plasma-derived ASC specks. Given the
magnitude of pyroptosis in lower-risk MDS, ASC specks provide an index of the extent
of pyroptotic cell death and as such, serve as a biologically rational biomarker for the
diagnosis of MDS. The biomarker is both sensitive and specific, and can accurately
distinguish MDS from normal donors, various other BM malignancies and T2D. Since
the biomarker is measured independent of cytological and morphological examination, it
can be employed to complement current diagnostic methods and reduce diagnostic
error, which is reported in approximately 30-40% of cases. The biomarker may also
predict early treatment response to immunomodulatory drug therapy in lower-risk
patients, illustrating additional potential clinical utility.
Implications Related to Other Inflammatory Conditions and Diseases of
Major Health Concern. Activation of the NLRP3 inflammasome is tightly regulated,
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evidenced by a two-step mechanism of activation and by the number of endogenous
negative regulators that function to dampen inflammasome-driven responses.
Deregulation of the inflammasome complex has been implicated in a vast number of
diseases, including heritable and acquired inflammatory conditions and other
autoimmune diseases that have an inflammatory pathobiology.330,331 Therefore,
increased understanding of the nuances governing NLRP3 inflammasome signaling and
regulation could lead to novel therapeutic agents that abrogate pathway activation. To
this end, our findings with respect to the role of NLRP3 inflammasome activation in
MDS pathobiology, as well as novel strategies aimed at inflammasome inhibition, can
widely impact healthcare and effectively generate new treatment approaches for a
number of malignancies, and metabolic and immune disorders. These conditions are
generally summarized in Figure 45.
Inflammasomopathies. Appropriately named, inflammasomopathies represent
the group of disorders resulting from autosomal dominant mutations in NLRP3, which
render the inflammasome constitutively active.254,332 Of the 90 disease-associated
mutations that have been reported, the majority reside within the nucleotide binding
domain (NBD) of NLRP3. It has been hypothesized that these mutations disrupt binding
ability of an unknown negative regulator or possibly the intrinsic ability of NLRP3 to selfregulate.254 Interestingly, while no mutations in NLRP3 have been described in MDS to
date, NLRP3 single nucleotide polymorphisms (SNPs) are significantly enriched in
patients with a history of autoimmune disorders.333 Further, prior to nomenclature
changes, NLRP3 was previously referred to a cryopyrin. As such, these disorders are
also referred to as cryopyrin-associated periodic syndromes (CAPS), or
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Figure 45. NLRP3 inflammasome activation is a pathobiological driver of many
inflammatory conditions and diseases of major health concern. Aberrant activation
of the NLRP3 inflammasome in the brain is a pathobiologic driver of Alzheimer’s
disease, Parkinson’s disease and multiple sclerosis; in the lungs: fibrosing disorders; in
the heart: cardiovascular disease; in the pancreas: type 2 diabetes mellitus; in the bone
marrow and joints: MDS, gout and pseudogout, respectively. NLRP3 inflammasome
activation also contributes pathobiologically to inflammasomopathies and ischemiareperfusion injury.
cryopyrinopathies. The inflammasomopathies share a spectrum of clinical phenotypes,
ranging from less to most severe, specifically familial cold autoinflammatory syndrome
(FCAS), Muckle-Wells syndrome (MWS) and chronic infantile neurological cutaneous
articular syndrome (CINCA), respectively.254
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Notably, disease severity directly correlates with IL-1β production, and as such,
therapeutic interventions have been aimed at IL-1 receptor inhibition, IL-1β
neutralization and caspase-1 inhibition. For example, anakinra is an IL-1 receptor
antagonist that significantly reduces both IL-1β transcriptional priming and secretion of
the mature cytokine.334 Although it is not FDA approved for the treatment of
inflammasomopathies, anakinra is commonly used as an off-label treatment in these
disorders.335 Because of its short half-life, patients require daily injections of anakinra
which results in significant pain and discomfort. Of note, anakinra is FDA approved for
the treatment of rheumatoid arthritis and is being investigated in other indications,
including renal disease and dermatitis. Furthermore, neutralization of IL-1β is achieved
by rilonacept, a chimeric protein generated by the fusion of the IL-1 receptor binding
region to the Fc portion of human IgG1.336 Rilonacept received FDA approval in 2008 for
inflammasomopathy treatment. The benefit of rilonacept over anakinra therapy, namely
weekly injections versus daily, is offset by the fact that rilonacept is significantly greater
in cost than anakinra.335 The last of the IL-1β neutralization strategies is canakinumab, a
human IL-1β monoclonal antibody.335 With a significantly longer half-life, patients
receive only one injection every eight weeks.335 Canakinumab received FDA approval
for inflammasomopathies in 2009, and has since been explored in other indications,
including rheumatoid arthritis, gout and type 2 diabetes mellitus. Finally, VX-765 is a
selective inhibitor of caspase-1, which significantly reduces secretion of both IL-1β and
IL-18.337 Despite this, VX-765 has yet to be tested clinically for the treatment of
inflammasomopathies. Taken together, while these therapies have had success, with
some even gaining FDA approval, patients still acquire resistance, indicating the need
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for novel, more effective treatment approaches. Such efforts have been aimed further
upstream at the level of the NLRP3 inflammasome, as no NLRP3-specific inhibitors
exist to date.
Type 2 diabetes mellitus. Type 2 diabetes mellitus (T2D) represents a major,
global health concern and is generally characterized by peripheral insulin resistance
arising from the impaired ability of pancreatic beta cells to produce and secrete
insulin.332 The literature strongly supports an aberrant role of innate immune activation
in T2D. More specifically, IL-1β and NLRP3 inflammasome activation have been
identified as pathobiological drivers of the disease. Notably, the incidence of T2D is
increased among patients with MDS,8 suggesting that increased understanding of
NLPR3 inflammasome activation in MDS can increase understanding of T2D biology,
and that novel therapeutic approaches can be utilized in both diseases.
To start, hyperglycemia induces innate immune signaling within pancreatic islets,
up-regulating TLR2 and TLR4 gene and protein expression, NF-κB activation, and both
MyD88-dependent and -independent signaling pathways.338 This is accompanied by
glucose-driven increases in IL-1β transcriptional priming and secretion, caspase-1
activity and pancreatic beta cell death.339,340 Indeed, IL-1β functions in a positive
feedback loop, whereby hyperglycemia induces maturation of IL-1β by beta cells, which
upon secretion triggers cell death of islet cells and increased glucose concentrations.332
These effects are mitigated by the in vitro treatment of islet cells with an IL-1 receptor
antagonist.340 In a randomized clinical trial, IL-1 receptor antagonism significantly
improved glycemic control and beta cell insulin secretory function, illustrating the
importance of IL-1β in disease pathobiology.341 However, insulin sensitivity was not
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changed among the control and treatment arms, indicating the need for more effective
treatment approaches. Similar findings were observed in a murine model of T2D and in
Il1b knockout mice.342,343
Importantly, increased NLRP3 inflammasome activation in pancreatic beta cells
and fat-based macrophages, active caspase-1 and IL-1β correlate not only with
increased risk of developing diabetes, but also disease severity.331 Nlrp3 knockout mice
display insulin sensitivity, enhanced insulin signaling and significant reductions in proinflammatory cytokines,344 implicating NLRP3 inflammasome activation in disease
pathobiology. Pancreatic beta cells basally express NLRP3, ASC, caspase-1 and IL-1β,
but levels are profoundly increased upon high glucose exposure.261 Notably,
hyperglycemia also induces islet cell expression of thioredoxin-interacting protein
(TXNIP),339 a redox protein known to directly bind to NLRP3, inducing a conformational
change that results in inflammasome assembly and activation.261 Txnip-/- mice evidence
reduced inflammasome activation, IL-1β secretion and cell death.261 Similarly, siRNAdirected silencing of TXNIP in human adipocytes significantly reduced levels of IL-1β
and mitigated the negative effects of hyperglycemia.339 Mechanistically, TXNIP directly
and indirectly suppresses glucose uptake while additionally inducing NLRP3
inflammasome activation, leading to IL-1β generation and cell death of insulin-producing
beta cells.330 TXNIP serves as a key regulator of glucose homeostasis by directing
degradation

of

the

plasma

membrane

glucose

transporter

GLUT1

through

internalization of clathrin-coated pits, whereas nuclear-localized TXNIP suppresses
GLUT1 gene transcription.345 As such, therapies aimed at NLRP3 inflammasome
inhibition would likely impart significant clinical benefit to patients with T2D.
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Cardiovascular disease. Cardiovascular disease is the leading cause of death
worldwide. The literature strongly supports a causal role for inflammation, ROS and
NLRP3 inflammasome activation in the pathobiology of various cardiovascular
diseases, including hypertension and atherosclerosis. Intronic, tandem repeat
polymorphisms in NLRP3 are associated with increased systolic blood pressure and
increased risk of developing hypertension compared to individuals with wild-type
NLRP3.346 Interestingly, hypertension positively correlates with the development of
T2D,254 implicating an aberrant role of NLRP3 in both diseases. In a rat model of
hypertension, aortic cells from hypertensive animals significantly up-regulated NADPH
oxidase (NOX) activity compared to littermate controls.347 NOX-derived ROS contribute
to abnormal vascular structure and functionality, perpetuating disease severity.348
Nearly three decades ago, it was reported that inflammation is a central mediator
of atherosclerosis, and today, inflammation is regarded as a causal factor in the
formation and progression of atherosclerotic plaques.254 During atherosclerosis,
cholesterol monohydrate crystals accumulate within lysosomes of macrophages
following phagocytosis, as well as within lesions in the extracellular space.349 The
accumulation of cholesterol crystals leads to hardening of the arterial walls as well as
narrowing of arterial vessels, which together increase risk of heart attack and stroke.330
Until recently, the cause of chronic inflammation in the pathobiology of atherosclerosis
was unknown but has since been attributed to the NLRP3 inflammasome. As plaques
develop, monocytes are recruited to the site of the lesion whereby they differentiate into
macrophages.350 The macrophages phagocytose the cholesterol crystals that are
abundant in the lesions, resulting in lysosomal damage.350,351 Subsequently, through a
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cathepsin B-dependent mechanism, the NLRP3 inflammasome becomes activated,
generating and secreting mature IL-1β in a caspase-1-dependent manner.350,351 In this
way, the cholesterol crystals function as DAMPs triggering aberrant activation of the
inflammasome complex. Notably, in a transplant model of disease, mice deficient in
Nlrp3 and Il1 had reduced inflammation, smaller lesions and were more resistant to the
development of atherosclerosis.351 Similarly, siRNA-mediated silencing of NLRP3
mitigated release of IL-1β in response to cholesterol crystals.350 Perhaps not
surprisingly, levels of IL-1β correlate with disease severity.352 These data together
indicate a central role for inflammasome activation in disease pathobiology, and suggest
that inflammasome inhibitors may have therapeutic efficacy in cardiovascular disease.
Multiple sclerosis. Although the pathobiology of multiple sclerosis (MS) is
complex and still under investigation, the literature supports an aberrant role for NLRP3
inflammasome activation. Generally, MS is a devastating autoimmune disease
characterized by demyelination resulting from myelin-specific CD4+ T cells that
penetrate

the

central

nervous

system

(CNS)

to

injure

oligodendrocytes.330

Phenotypically, the CNS loses significant functionality, resulting in widespread
challenges that are physical, mental and even psychiatric in nature.330 No cure for MS
exists to date, illustrating the imperative need for new treatment approaches.
Experimental autoimmune encephalomyelitis (EAE) is a commonly used murine
model of MS, whereby immunization of mice with myelin oligodendrocyte glycoprotein
(MOG) results in the expansion of MOG-reactive T cells.330 An aberrant role of caspase1 activation in MS pathobiology was described nearly a decade before NLRP3 was
implicated. EAE induced transcriptional priming of caspase-1, expression of which
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positively correlated with disease severity.353 Moreover, increased levels of active
caspase-1 also correlated with circulating levels of pro-inflammatory cytokines, including
IL-1β,353 suggesting that caspase-1 plays a central role in cytokine generation in MS.
Finally, mice lacking caspase-1 had significant reductions in EAE severity, with marked
loss of MOG-specific Th1 cells.353 Furthermore, a model of EAE in the context of Nlrp3
loss elegantly supports these findings and the crucial role of the NLRP3
inflammasome/caspase-1 axis in MS. Loss of Nlrp3 resulted in a significant reduction in
disease severity and course, substantial reductions in inflammatory cell infiltration,
reduced myelin destruction and diminished response capacity of Th1 and Th17 CD4+
cells.354 IFN-γ and IL-17 are pro-inflammatory cytokines secreted by Th1 and Th17 cells,
respectively, and these CD4+ T cell populations have well-documented roles in the
pathobiology of autoimmunity. Also, in a model of EAE in the context of Il1 knockout,
IFN-γ and IL-17 production were significantly reduced in the T cell compartment, which
was associated with an improved phenotype.355 Interestingly, Th17 cells are profoundly
increased in LR-MDS patients,97 consistent with an autoimmune reaction. Taken
together, these data suggest that akin to LR-MDS, therapies targeting the NLRP3
inflammasome may have clinical utility in treating MS.
Alzheimer’s

disease.

Alzheimer’s

disease

(AD)

is

a

devastating

neurodegenerative disease whereby progressive dementia occurs as a result of
neuronal cell death, specifically of microglial cells.270 Mechanistically, the pathogenesis
of AD has been linked to the accumulation of amyloid β, a fibrillar peptide, within senile
plaques in the cerebrum.270,330 Nearly three decades ago, it was determined that
expression of IL-1β was significantly increased in senile plaques,356 and recent reports
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have indicated that active caspase-1 expression is increased in patients with AD,357
suggesting a pathobiological role for NLRP3 inflammasome activation. Accordingly,
microglial cells were shown to be recruited to senile plaques, whereby they become
activated by and phagocytose amyloid β.358 Once phagocytosed, amyloid β damages
lysosomes, resulting in release of cathepsin B,270 a known secondary trigger for NLRP3
inflammasome activation. Consequently, the NLRP3 inflammasome becomes activated,
triggering autocatalytic cleavage of caspase-1 and subsequent generation and release
of IL-1β. Notably, genetic deletion of Asc, Casp1 or Il1b prevented microglial activation,
indicating the importance of the NLRP3 inflammasome axis in the pathobiology of
AD.270 These findings were corroborated and strongly supported by experiments
performed in Nlrp3-/- mice crossed with APP/PS1 transgenic mice, a common model of
AD characterized by amyloid β plaque deposition.357 In this context, deposition of
amyloid β was significantly reduced, as was senile plaque size and activation of
microglia.357 Together, these data suggest that inhibition of the NLRP3 inflammasome
signaling pathway would likely afford therapeutic benefit in AD.
Parkinson’s disease. Parkinson’s disease (PD) is a neurodegenerative disease
characterized by aberrant cell death of dopaminergic neurons within the susbtantia
nigra of the midbrain, resulting in severe motor impairments.330,359 Within the
dopaminergic neurons, Lewy bodies form, which are aggregated inclusions within the
cell that contain significant amounts of the fibrillar protein alpha-synuclein (α-Syn).359
The α-Syn fibers that form in PD are similar to the amyloid β fibers that form in AD.330
Although unknown for a time, the marked inflammation characteristic of PD has since
been attributed to an aberrant role of NLRP3 inflammasome activation. Mechanistically,
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dopaminergic cells release α-Syn into the extracellular space, which is subsequently
phagocytosed by microglial cells.359 Upon phagocytosis, and by a mechanism similar to
amyloid β-induced NLRP3 inflammasome activation in AD, the α-Syn induces lysosomal
damage, triggering the release of cathepsin B that serves as a secondary activation
trigger

for

NLRP3

inflammasome

complex

assembly.359

Consequently,

the

inflammasome generates active caspase-1 and IL-1β, which is secreted and propagates
inflammation. Notably, the phagocytosis event also triggers activation of NOX, resulting
in ROS generation that additionally may activate the inflammasome complex.359 Once
released, inflammatory cytokines and ROS damage the surrounding dopaminergic cells,
triggering cell death. The detrimental effects of NLRP3 inflammasome-driven IL-1β
production were demonstrated in a murine model, whereby mice were dosed daily with
IL-1β. Compared to controls, IL-1β-treated mice phenocopied human PD just after three
weeks of treatment, with significant cell death of dopaminergic neurons, increased
microglial cell activation and inflammatory cell infiltrate, and severe akinesia.360 Finally,
the aberrant role of NLRP3 inflammasome activation in PD was demonstrated in an
alternative model. Nlrp3-/- mice treated with the neurotoxin 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP), a known inducer of the PD phenotype, were protected from
overt development of PD compared to littermate controls.361 These data indicate that
abrogating NLRP3 inflammasome signaling or neutralization of IL-1β may have clinical
utility in PD.
Gout and pseudogout. Gout and pseudogout represent two common
arthropathies, or rheumatic diseases, which are characterized by the abnormal
deposition of crystals, specifically monosodium urate (MSU) and calcium pyrophosphate
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dehydrate (CPPD), respectively, in the intra- and periarticular spaces within joints.332
Phenotypically, these areas are acute and chronically inflamed, resulting in severe pain
and swelling.331,332 Though MSU and CPPD have had a longstanding and welldescribed role in the pathobiology of gout and pseudogout, respectively, the precise
mechanism underlying crystal-induced inflammation was just recently elucidated. Both
MSU and CPPD induce NLRP3 inflammasome activation, triggering activation of
caspase-1 and subsequent maturation and release of IL-1β and IL-18.362 Indeed,
crystal-induced generation of IL-1β is abrogated in macrophages that lack ASC, CASP1
or NLRP3, indicating the importance of the NLRP3 inflammasome signaling cascade in
the disease pathobiology. These data are supported by an in vivo model of disease,
whereby mice deficient in Nlrp3 had improved phenotypes and reduced infiltration of
inflammatory cells, particularly neutrophils, which are associated with severe joint
pain.362 Finally, a small pilot study of anakinra, an IL-1 receptor antagonist, was
performed in ten patients with gout refractory to standard anti-inflammatory therapies.363
Though responses varied among patients, 90% demonstrated resolution of arthritic
symptoms in just three days after treatment was initiated, with no adverse effects
reported among the cohort.363 While randomized trials would be required to confirm
effectiveness, abrogation of the NLRP3 inflammasome axis is an attractive therapeutic
approach in gout and pseudogout.
Fibrosing disorders. Prolonged exposure to environmental irritants is a known
etiological factor of MDS, the pathobiology of which is intricately linked to NLRP3
inflammasome activation. Notably, fibrosing disorders represent a heterogeneous group
of diseases that include idiopathic pulmonary fibrosis (IPF), silicosis and asbestosis.
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These disorders are progressive and fatal, with no effective therapeutic strategies
identified to date. However, they have been linked to aberrant inflammation, specifically
resulting from NLRP3 inflammasome activation.
Silicosis and asbestosis develop after prolonged and chronic exposure to silica
and asbestos, respectively, evidenced by increased production of pro-inflammatory
cytokines, including IL-1β, by alveolar macrophages isolated from individuals reporting
greater than ten years of exposure, versus controls with less than ten years.269 Notably,
in a British study, those harboring a polymorphism in the receptor IL-1RA were at 10.2fold greater risk of developing a fibrosing disorder, implicating a role of aberrant IL-1β
production in these conditions.364 From a mechanistic standpoint, once inhaled, silica
and asbestos deposit in the lung alveoli, whereby they undergo clearance by resident
macrophages through phagocytosis.269 Subsequently, phagocytosis of these crystalline
irritants results in NOX-dependent ROS generation and lysosomal destabilization, both
of which trigger NLRP3 inflammasome activation.269,365,366 The inflammasome then
activates caspase-1, triggering maturation and release of IL-1β, which instigates
inflammation and lung injury mediated by the activation of fibroblasts. The importance of
the NOX/ROS/NLRP3 inflammasome-dependent pathway in pathobiology was
confirmed by a number of in vitro and in vivo observations. For one, Nlrp3-/- mice have
reduced fibrosis, immune cell infiltrate and cytokine production when challenged by a
model of asbestos inhalation.366 Also, shRNA-directed silencing of p22phox, a central
subunit of the NOX complex, in the THP-1 monocytic cell line resulted in significant
reductions in IL-1β secretion.366 Finally, thioredoxin (TRX) is a key redox protein that
regulates NLRP3 inflammasome activation by binding to TRX-interacting protein
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(TXNIP) under basal conditions.260 In high ROS conditions, TRX undergoes oxidation,
which liberates TXNIP and allows it to bind to NLRP3, leading to inflammasome
assembly and activation.261 Silencing of TRX in THP-1 cells resulted in a significant
increase in mature IL-1β production, implicating a redox-dependent mechanism of
inflammasome activation.366
Lastly, IPF represents a particularly devastating condition whereby progressive
lung injury, resulting in scarring and fibrosis, leads to respiratory failure and death. No
effective therapies have been identified to date, indicating the need for increased
understanding of disease pathobiology. Acute pulmonary injury is commonly
investigated in a murine model whereby mice are treated with the cytotoxic agent
bleomycin, which induces a phenotype akin to human IPF with increased inflammation,
cytokine and chemokine production, and fibrosis.367 Notably, mice deficient in Il1ra were
protected from bleomycin-induced lung injury, while those treated with recombinant
murine IL-1b were phenotypically similar to mice subjected to bleomycin treatment.367
Use of anakinra significantly decreased inflammation following bleomycin treatment,367
confirming the pathobiological role of IL-1β generation in IPF. Importantly, IL-1β
production in response to bleomycin-induced injury required the NLRP3 inflammasome
adaptor protein ASC, implicating a role for inflammasome activation.367 More than likely,
unknown DAMP signals trigger NLRP3 inflammasome activation in IPF, resulting in
caspase-1 activation and release of IL-1β, leading to activation of fibroblasts that
exacerbate lung injury. These data warrant investigation of inflammasome inhibitors in
fibrosing disorders, which may represent the first effective, targeted therapeutic
approach in these conditions.

191

Ischemia-reperfusion injury. Ischemia-reperfusion injury (IRI) describes the
condition of tissue or organ damage resulting from loss of blood flow to the area, which
culminates in significant injury and cell death that is exacerbated following the
restoration of flow to the area, which increases immune cell infiltration, ROS and
inflammation.331 IRI is known to occur following a number of conditions, including
serious trauma, stroke and transplantation surgery.331 The inflammatory response
generated as a consequence results in significant organ damage, morbidity and even
mortality, as dysfunction in one organ can trigger a systemic immune reaction that
damages other organs.331 Presently, no therapies exist for the prevention or treatment
of IRI, indicating a clear therapeutic need.
Renal, hepatic and myocardial IRI occur commonly, and the sterile inflammation
resulting from each type of injury occurs as a consequence of NLRP3 inflammasomedriven inflammation. In murine models of renal IRI, loss of Nlrp3 was associated with
significant reduction in pro-inflammatory cytokine generation, specifically IL-1β and IL18, immune cell infiltration and preservation of renal function.368 Similarly, mice pretreated with shRNAs targeting Nlrp3 were protected from hepatic injury following
ischemia induction.369 Active caspase-1, IL-1β and IL-18 generation and NF-κB activity
were all significantly reduced with Nlrp3 downregulation.369 Both pharmacologic
inhibition of the IL-1 receptor as well as gene delivery of IL-1 receptor antagonist to the
liver protected mice from IRI and increased survival following injury.370,371 Lastly, loss of
Casp1 and Asc protected mice from myocardial injury following IRI, with significant
reductions in IL-1β production, immune cell infiltration and fibrosis.372 Neutralization of
IL-18 or IL-1β in murine models of myocardial IRI resulted in improved outcomes, with
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reduced injury, inflammation and increased survival.373 In a small pilot study of 10
patients, treatment with the IL-1 receptor antagonist anakinra improved cardiac
remodeling following IRI without adverse effects,374 warranting further investigation in
randomized clinical trials.
From a generalized mechanistic overview, IRI results in the increased expression
of ROS and DAMP signals, triggering NLRP3 inflammasome-dependent activation of
caspase-1 and maturation of inflammatory cytokines IL-1β and IL-18. The inflammatory
response results in the recruitment of other immune cell infiltrate, which exacerbates
inflammation, tissue damage and injury. Taken together, these data suggest that
inhibition of the NLRP3 inflammasome may prevent IRI and adverse outcomes arising
from organ injury.

Future Directions

NLRP1 Inflammasome Activation. Masters et al. reported the first evidence of
pyroptosis in the hematopoietic system whereby infection-induced cytopenia occurred
as a consequence of NLRP1 inflammasome activation.231 Specifically, an activating
point mutation in Nlrp1a (Q59P) results in aberrant Nlrp1 inflammasome-driven
caspase-1 activation, leading to a lethal inflammatory phenotype characterized by
severe cytopenia, abnormal myeloid lineage maturation and HSPC death.231 These data
suggest that ineffective hematopoiesis can be attributable to activation of the NLRP1
inflammasome in certain contexts. Given these findings, along with the casual role of
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NLRP3 inflammasome activation in MDS pathobiology, we investigated the role of
NLRP1 inflammasome activation in MDS.
We found that NLRP1 transcript expression is significantly increased in BM-MNC
from MDS patients (n=10) compared to normal donors (n=6), approximately 23.2-fold
(Figure 46A). Formation of active NLRP1 inflammasome complexes was confirmed by
confocal fluorescence microscopy (Figure 46B), whereby BM-MNC from LR- and HRMDS specimens display significantly increased a-caspase-1 (MFI 21.1-fold increase in
LR [p=7.9x10-4] and 23.8-fold in HR [p=0.081]) and co-localization with NLRP1 (MFI
34.3-fold increase in LR [p=6.4x10-3] and 23.2-fold in HR [p=0.15]) protein expression
versus normal donors (Figure 46C). These findings indicate that NLRP1 inflammasome
formation is significantly increased in MDS BM-MNC.
Moreover, given that S100A9 is a primary initiator of NLRP3 inflammasome
activation and pyroptosis in LR-MDS, we investigated the ability of S100A9 to initiate
assembly of NLRP1 inflammasome complexes. Treatment of the U937 monocytic cell
line with 5 µg/mL rhS100A9 (Figure 47A) resulted in a significant increase in NLRP1
inflammasome formation (1.2-fold, p=1.1x10-11), with corresponding increases in protein
expression of a-caspase-1 (2.0-fold, p=3.0x10-5) and NLRP1 (1.2-fold, p=1.6x10-3)
compared to untreated controls (Figure 47B). Importantly, treatment of normal BM-MNC
with rhS100A9 significantly increased NLRP1 inflammasome formation and activation
(5.6-fold, p=3.9x10-5), evidenced by co-localization of a-caspase-1 and NLRP1 (Figure
47C and 47D). While rhS100A9 treatment did induce protein expression of a-caspase-1
(1.4-fold, p=0.02) and NLRP1 (126.1-fold, p=2.3x10-3), as well as maturation of active
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Figure 46. NLRP1 inflammasome formation and activation is significantly
increased in MDS BM-MNC. (A) qPCR analysis of NLRP1 gene expression in BMMNC isolated from MDS patient specimens (n=10 total; n=5 lower-risk and n=5 higherrisk disease) compared to normal BM-MNC (n=6). (B) Representative confocal
fluorescence micrograph (2520x magnification, 7.5 µm scale) of a-caspase-1 and
NLRP1 expression in MDS versus normal BM-MNC. DAPI (blue), a-caspase-1 (green),
NLRP1 (red); merged images show inflammasome formation. (C) Quantitative analysis
of confocal images of BM-MNC isolated from MDS patients [LR (n=7), HR (n=3)] and
normal donors (n=6). Error bars: SE, **p<0.01 and ***p<0.001.
NLRP1 inflammasome complexes, this occurred to a lesser extent than that observed in
MDS specimens (Figure 47D). Together, these data indicate that S100A9 also initiates
NLRP1 inflammasome activation in MDS.
Moving forward, it would be interesting and worthwhile to continue investigations
into the role of NLRP1 inflammasome activation in MDS, given that both NLRP3 and
NLRP1 inflammasomes are active. As activation of both complexes culminate in
pyroptosis, it would be important to identify the contribution of NLRP1 inflammasome
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Figure 47. S100A9 induces NLRP1 inflammasome formation in U937 cells and
normal BM-MNC. (A) Representative micrograph (2520x magnification, 7.5 µm scale)
depicting inflammasome formation in U937 cells untreated or treated with 5 µg/mL
rhS100A9 for 24 hours. DAPI (blue), a-caspase-1 (green), NLRP1 (red); merged images
show inflammasome formation. (B) Quantitative analysis of confocal images from (A).
(C) Representative micrograph (2520x magnification, 7.5 µm scale) depicting
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inflammasome formation in normal, untreated BM-MNC or normal BM-MNC treated with
5 µg/mL rhS100A9 for 24 hours. DAPI (blue), a-caspase-1 (green), NLRP1 (red);
merged images show inflammasome formation. (D) Quantitative analysis of confocal
images of BM-MNC from normal donors (n=6), normal BM-MNC treated with rhS100A9
(n=2) and MDS patients (n=10). Error bars: SE, *p<0.05, **p<0.01 and ***p<0.001.
activation to MDS pathobiology. To start, preliminary investigations can be carried out in
the THP-1 NLRP3 knockout cell line, which would provide biological assessment of the
contribution of NLRP1 inflammasome activation following inflammasome-specific
stimuli. Following treatment of these cells with rhS100A9 or other stimuli, we can assess
NLRP1 inflammasome formation, caspase-1 activation and generation of IL-1β.
Moreover, as ICTA is an NLRP3 inflammasome inhibitor, it would be interesting to
determine whether treatment of the NLRP3 KO cells additionally inhibits formation and
activation of NLRP1 inflammasome complexes. Lastly, colony formation assays
performed in THP-1 NLRP3 KO cells with and without CRISPR/Cas9-mediated deletion
of NLRP1 would confirm whether the NLRP1 inflammasome imparts negative effects on
colony forming capacity.
To determine if NLRP1 inflammasome activation contributes to pyroptosis and
ineffective hematopoiesis, colony formation assays can be performed on MDS BM-MNC
following CRISPR/Cas9-mediated deletion of NLRP1 and/or NLRP3. Genetic ablation of
NLRP3 would be expected to increase colony forming capacity, and deletion of NLRP1
may also. It is likely that the combination would have additive effects on improving
hematopoiesis. It would also be worthwhile to treat LR-MDS BM-MNC with ICTA as well
as S100A9Tg BM cells, and assess changes in NLRP1 inflammasome activation. In the
event that NLRP1 plays a non-redundant role in pathobiology, novel pharmacologic
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inhibitors of inflammasome complexes would need to abrogate both NLRP1 and NLRP3
inflammasome formation to truly afford clinical benefit.
ER Stress/Inflammasome Signaling Axis. The function of the endoplasmic
reticulum (ER) is intricately linked to cellular redox status. We reported a role for
NAPDH oxidase (NOX) 1/4-specific activation in LR-MDS, whereby somatic gene
mutations and DAMP signals, particularly S100A9, activate these NOX-specific isoforms
to generate ROS that initiate NLRP3 inflammasome and β-catenin activation.199
Notably, NOX4 is associated both with the plasma membrane and is the only ER
membrane resident NOX isoform. NOX4-dependent ROS production is a key upstream
signal directing the ER stress response.375 Within the ER, three transmembrane
proteins function as sensors of ER unfolded proteins, namely inositol-requiring enzyme
1α (IRE1α), protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) and
activating transcription factor 6 (ATF6).376 Accumulation of unfolded proteins within the
ER triggers activation of these sensors, resulting in downstream signaling aimed to
restore cellular homeostasis or alternatively, in the absence of remediation, initiate cell
death.376 Interestingly, TLR2 and TLR4 signaling activates IRE1α, which augments
innate

immune

signal

response,377

which

are

significantly

up-regulated

and

hyperactivated in LR-MDS. Furthermore, expression of the redox protein TXNIP is
induced and stabilized upon IRE1α activation, whereby IRE1α marks a number of
microRNAs (miRs) for degradation, including miR-17, which negatively regulates TXNIP
activity.378,379 During basal conditions, TXNIP resides within the nucleus. However,
during oxidative stress, it shuttles to the site of mitochondria whereby it directly binds
mitochondrial-associated NLRP3,380 mediating NLRP3 activation. NLRP3 then activates
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caspase-2 and Bid, which propagate mitochondrial damage, leading to the release of
mitochondrial-derived

ROS

(mtROS)

and

mitochondrial

DNA

(mtDNA).381,382

Consequently, mtROS and mtDNA function as triggers of NLRP3 inflammasome
assembly, resulting in inflammasome activation, maturation of caspase-1 and IL-1β
production.378 Pharmacologic inhibition of IRE1α or TXNIP silencing were shown to
block mature IL-1β release,378,382 indicating the importance of ER stress-dependent
activation of the NLRP3 inflammasome complex. The interaction between the ER,
mitochondria and the NLRP3 inflammasome is outlined in Figure 48.
We have shown that MDS BM-MNC are under oxidative stress, that TXNIP gene
and protein expressions are increased and others demonstrated that mitochondrial
dysfunction is common.199,203 Therefore, it would be informative and worthwhile to
investigate the ER stress/NLRP3 inflammasome axis in MDS. These investigations
would further our understanding of the mechanisms governing NLRP3 inflammasome
assembly, and may additionally identify novel therapeutic strategies. Finally, NLRP1 is
up-regulated during ER stress through an IRE1α-dependent mechanism,383 which
raises the notion that perhaps increased NLRP1 expression and activation in MDS is a
consequence of ER stress. Elucidating the relationship between NLRP1 activation and
the ER stress pathway, as well as potential interaction between NLRP1 and NLRP3 in
MDS represents a promising line of investigation.
5’ Adenosine Monophosphate (AMP)-Activated Protein Kinase. AMPactivated protein kinase (AMPK) is a central energy sensor and regulator of metabolism,
with known anti-inflammatory actions.342 Functional loss of AMPK activity has been
associated with a growing number of inflammatory and metabolic conditions.384 AMPK

199

Figure 48. ER stress triggers NLRP3 activation, leading to mitochondrial
dysfunction and activation of the NLRP3 inflammasome complex. (A) ER stress
results in activation of one or more of the ER stress sensors, including IRE1α. (B) Once
active, IRE1α triggers the degradation of miR-17, a negative regulator of the redox
protein TXNIP, which increases TXNIP expression and function. (C) Under basal
conditions, TXNIP resides within the nucleus but shuttles to mitochondria under
conditions of oxidative stress. Here, it directly binds and activates NLRP3, which
catalyzes maturation of caspase-2 to its proteolytically active form. (D) Active caspase-2
drives mitochondrial damage, which leads to the release of mitochondrial ROS (mtROS)
and DNA (mtDNA) into the cytosol. (E) Both mtROS and mtDNA function as secondary
signals for NLRP3 inflammasome activation, resulting in activation of caspase-1,
release of IL-1β and IL-18 and pyroptosis.
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and NLRP3 inflammasome activation are negatively related, as loss of AMPK activity
increases inflammasome-driven inflammation.384 More specifically, this occurs through a
NOX-dependent mechanism. Wang et al. demonstrated that reduced AMPK activity
increases expression of NOX1 and NOX4, including other key subunits required for
NOX function.385 This was associated with reduced NOX-dependent ROS generation
and NF-κB activation, which was attenuated by pharmacological activation of AMPK or
over-expression of a constitutively active form of AMPK, illustrating that AMPK
negatively regulates NOX and ROS.385 Notably, metformin, a drug used in the treatment
of type 2 diabetes mellitus, activates AMPK and reduces NLRP3 inflammasome
activation, significantly reducing the release of both IL-1β and IL-18.384 These findings
are supported by AMPK-mediated phosphorylation of TXNIP during conditions of stress,
which results in degradation of the redox protein.345
Given the pathobiological role of the NLRP3 inflammasome in MDS, it is highly
plausible that AMPK activation is suppressed. As both NOX-derived ROS and TXNIP
mediate NLRP3 inflammasome activation in LR-MDS, and AMPK negatively regulates
the function of these proteins, activation of AMPK activity represents a worthwhile
strategy for investigation in MDS. Moreover, reductions in AMPK activity result in
mitochondrial dysfunction with augmented release of mtROS and mtDNA.342 Evidence
of aberrant mitophagy has been documented in LR-MDS,105,210 suggesting that reduced
AMPK activity may be culpable. To start, AMPK activation could be assessed in LRMDS BM-MNC specimens, S100A9Tg BM cells and in the mutant cell lines and models
of gene mutation (Chapter 2). If AMPK activation were indeed reduced in MDS, then
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identification of a potent and specific activator could inhibit NLRP3 inflammasomedriven signaling and pyroptosis.
Moreover, AMPK activation suppresses transcriptional reprogramming of somatic
cells to a stem cell-like phenotype, characterized by increased expression of
transcription factors like Oct4, Sox2 and c-Myc.386 Interestingly, metformin treatment is
capable of inhibiting somatic reprogramming, effectively creating a barrier to
stemness.386 Given that MDS progression is associated with increased stem cell
survival, self-renewal and propagation, it is likely that AMPK activation may prevent
propagation of the MDS clone and disease progression to leukemia.

Conclusion

Identification of the NLRP3 inflammasome complex as a driver of the MDS
phenotype, both in non-del(5q) and del(5q) disease, has the capacity to transform the
present understanding of the pathobiology of MDS. More importantly, the findings
described in this manuscript indicate that strategies intended to neutralize S100A9 or
inhibit NLRP3 inflammasome assembly offer therapeutic potential in these disorders. In
del(5q) MDS, our preliminary investigations indicate that NLRP3 inflammasome
inhibition can promote effective erythropoiesis without selective clonal suppression.
These data support the investigation of inflammasome inhibitors in patients that are
refractory to lenalidomide, the current standard of care. Moreover, we have identified
the first diagnostic biomarker of MDS, or the percentage of glucose-adjusted PB
plasma-derived ASC specks. Specks are not only readily quantified by flow cytometry,
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but also provide an independent parameter of morphology, which is invaluable from a
diagnostic perspective. The implementation of speck quantitation at the time of
diagnosis has the capacity to minimize diagnostic error. In implicating NLRP3
inflammasome activation in MDS pathobiology, we have opened new avenues for
exploration. Specifically, pathways related to NLRP1 inflammasome activation, ER
stress and AMPK activity have yet to be explored in MDS. Increased understanding of
NLRP3 inflammasome signaling and regulation will surely lead to the identification of
novel targets with potential clinical translation, not only in MDS but also diseases with
aberrant inflammasome activation such as Alzheimer’s disease, Parkinson’s disease,
type 2 diabetes mellitus, inflammatory bowel and rheumatologic disorders, among
others.
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